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Abstract
ABSTRACT
This thesis describes the investigation of the effect of endothelin-1 (ET-1) on gene 
expression and protein phosphorylation states in two different fibroblast cell lines using 
proteomics tools.
Protein synthesis was monitored during the first 4 hours following stimulation of human
*2 e
lung fibroblasts with ET-1 using pulsed S methionine labelling. Out of the total 
proteome visible on 2D gel electrophoresis 22 proteins that are differentially expressed 
were identified using MALDI-TOF peptide fingerprinting methodology. Changes in 
protein expression were temporally distinct and proteins could be classified into several 
different groups according to their similar kinetic behaviour possibly implying 
functional correlations between them.
The presence of ET receptors in NRK-49F (normal rat kidney fibroblast) cells was 
confirmed by calcium imaging and radioactive labelled specific ET ligand binding 
studies.
Changes in the phosphorylation states of proteins as well as the kinetics of these 
changes were assessed in NRK-49F cells following brief stimulation with ET-1. For 
these studies the enriched phosphoproteome was used. Enrichment was achieved by an 
immobilized metal affinity chromatography methodology developed in our laboratory. 
Individual proteins were detected with immunostaining or mass spectrometry. ET-1 
stimulation was associated with phosphorylation of multiple proteins including: the 
members of ERK1/2 and p38 MAPK pathways and small GTP-ase pathway; an enzyme 
regulating calcium levels; a transcription factor; and a number of cytoskeletal,
3
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chaperone and metabolic proteins. Nearly all of the identified proteins were represented 
in multiple phosporylated forms that individually showed different kinetic behaviour 
during the examined period of time. The multiplicity of phosphorylations in the 
identified proteins has an impact on their function. The results widen the current 
knowledge about ET-1 signalling in NRK fibroblasts and provide a framework for 
further studies.
From the list of the detected phosphoproteins the phosphorylation of RhoGDI was 
analyzed further. By using SILAC methodology and mass spectrometry a RhoGDI 
peptide phosphorylated after ET-1 stimulation was detected and phosphorylation sites 
were mapped. This finding gives an insight into the role RhoGDI phosphorylation may 
have in regulating the activity of some small GTPases as downstream effectors of ET-1 
signalling.
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Chapter 1
CHAPTER 1. INTRODUCTION 
1.1 Background
First reports of endothelin (ET) were noted in the late 1980s, when a new 
vasoconstricting agent was detected in the culture medium of human endothelial cells 
(Hickey et al., 1985; Gillespie et a l ,  1986; O’Brien et al., 1987). Yanagisawa 
sequenced the vasoconstricting peptide and named it ET, later endothelin-1 (ET-1) 
(Yanagisawa et a l ,  1988). With the discovery of homologous human (ET-2 and ET-3) 
and mouse (Vasointestinal contractor (VIC), also known as "mouse ET-2") peptides, the 
ET family was formed (Inoue et al., 1989; Saida and Mitsui, 1991).
Until recently ET was the most powerful known endogenous vasoconstrictor (Ames et 
a l  1999). In addition ET has many other important physiological roles: in promoting 
development and differentiation (Kurihara et al., 1994), in regulating cardiovascular and 
renal homeostasis (Webb et a l ,  1998), as a neurotransmitter in the brain (Damon, 1998) 
and as a growth factor (Bagnato et al., 1997). It has also been suggested that ET is a 
mediator in various diseases including: cardiovascular and renal disorders, respiratory 
diseases and cancer (Goldie, 1999). ET exerts its physiological effects by binding to ET 
receptors and thereby inducing various signalling cascades within a cell. The examples 
mentioned above show that ET and ET receptors have a critical role in multiple 
biological processes and gaining a detailed understanding of the mechanisms of their 
signal transduction pathways is of great importance.
18
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1.2 Endothelins
1.2.1 ET and tissue/cell distribution
Endothelins, including ET-1, ET-2, ET-3 and VIC, belong to a family of disulfide 
bonded 21-amino acid peptides (2.5kDa) that have a multitude of physiological 
activities and are produced by a variety of cells and tissues (Rubanyi and Polokoff,
1994). The ET family has a strong structural resemblance (67% sequence similarity) to 
cardiotoxic snake venoms (sarafotoxins) which were discovered in the Israeli burrowing 
asp (Atractaspis engadensis) (Sokolovsky, 1992). This similarity indicates that 
endothelins and sarafotoxins may have similar biological effects.
Each ET isoform is encoded by a separate gene, and is synthesised initially as a long 
peptide precursor known as "pre-proendothelin" which is 200 amino acids in length 
(Yanagisawa et a l , 1988) (Fig. 1-1). These are then processed to predominantly "pro- 
endothelin" which is subsequently converted into ET by the activity of an endothelin- 
converting enzyme (ECE), a membrane bound metalloendopeptidase (Xu et a l , 1994).
ET-1 was first discovered in a medium of cultured endothelial cells which have proven 
to be the major source of ET-1 in vivo (Yanagisawa et al., 1988). Other cell types 
known to produce ET-1 in humans include: vascular smooth muscle cells, epithelial 
cells, keratinocytes, macrophages, neurons and some cancer cell lines (Rubanyi and 
Polokoff, 1994).
19
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The expression of ET-2 and ET-3 was demonstrated in human endometrium, placenta 
and neurons. In addition to this ET-2 was found to be expressed in human renal 
adenocarcinoma (Tokito et al., 1991).
The gene expression of VIC was reported in mouse intestine, uterus, ovary, stomach, 
lung, testis, cerebrum and cerebellum and to a small extent in kidney and heart (Uchide 
et al., 2000).
1.2.2 Functional characteristics of ET
Once released endothelins can bind to ET-receptors either on the same cell (autocrine 
effect) or cells in the immediate vicinity (paracrine effect). In normal physiological 
conditions levels of ET in plasma are picomolar and these levels are unable to induce a 
biological response by activating ET-receptors (Pollock, 1998). However, in various 
pathophysiological states levels of circulating ET and the number of ET-receptors is
2 0
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significantly elevated (Daggassan et al., 1996; Serneri et al., 2000; Bruno et al., 2000; 
Bruno et al., 2002).
Experiments with transgenic animals helped to discover some of the functions that 
endothelins have in vivo. These include the first reports describing knockouts of the 
ET-1 gene (Kurihara et al., 1994) which highlighted the importance of ET in 
development. ET-1 -/- homozygous mice showed morphological abnormalities in 
craniofacial organs and increased mortality. Moreover, heterozygous (ET-1 +/-) mice 
showed a mild rise in blood pressure when compared to wild type mice. In addition, ET 
-/- mice showed an impaired growth of the thyroid gland and thymus (Kurihara et al.,
1995).
Experiments with ET-2 knockouts have not yet been published, but it was mentioned at 
the 5th International conference on ET that these mice are apparently normal at birth but 
are later characterized by severe growth retardation (Webb et al., 1998). Mice with 
targeted disruption of the ET-3 gene developed a spotted coat colour and a megacolon 
(Baynash et al., 1994).
Levels of expression of ET isoforms vary in different stages of life (embryo, neonatal 
and adult) and in different tissues (Uchide et al., 2002). The expression levels of ET-1 
and VIC genes in mice are increased in lungs and intestines just after birth. As the 
lungs and intestines undergo the biggest changes of all organs functionally after birth 
(commencement of respiration and absorbtion of nutrients) the authors suggest that 
endothelins may play a role in the adaptation to extra-uterine life.
21
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1.3 ET receptors
Endothelins exert their biological effects by binding to and activating ET receptors A 
and/or B (ETaR and ETbR) (Takasuka et al., 1992; Sakurai et al., 1992), which belong 
to a superfamily of G-protein coupled receptors (GPCR). A third receptor (ETc) was 
found in the African homy clawed amphibious toad {Xenopus laevis) (Karne et al., 
1993).
Pharmacological studies implicated the existence of different subtypes of ETa and ETb 
receptors. Differential sensitivity to BQ-123, an ETA receptor antagonist, enabled the 
subclassification of ETA receptors into ETA1 (BQ-123 sensitive) and ETA2 (BQ-123 
resistant) (Endoh et al., 1998). Two ETb receptor subtypes were found in rats (Gellai et 
al., 1996). The ETbI localized in vascular endothelium mediated vasodilatation, whilst 
the ETb2 localized in vascular smooth muscles mediated vasoconstriction.
Recent reports form Gregan et al. (2004 a, b) showed that ET receptors can form 
constitutive homo- and heterodimers. On the structural level ET receptors also show a 
diversity of modifications (Roos et al., 1998; Stannard et al., 2003 a). Stannard et al. 
(2003 a) suggested the existence of a number of receptor species that differ in the 
number and position of phosphorylations and palmitoylations. These examples show 
how ET receptor heterogeneity can affect the complexity of ET signalling.
Structurally ET receptors share similar features with other GPCRs:
• amino-terminal region located on the extracellular surface of the plasma 
membrane;
• 7 TM helices interconnected with 3 extracellular and 3 intracellular loops; and
22
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• a lipid modified cytoplasmatic C terminus that forms the fourth intracellular 
loop.
ETaR and ETbR have different binding affinity for ET isopeptides (Sakurai et al., 
1992). ETaR can bind ET-1 and ET-2 (ET-l>ET-2), but not ET-3 at physiological 
concentrations. ETbR, on the other hand has similar binding affinity for all three 
isoforms of ET. This makes ET-3 the only endogenous ligand able to distinguish 
between ET receptor subtypes. ETc receptor predominantly binds ET-3.
It has been shown that both ETA and ETb receptors are widely distributed throughout 
various cells and tissues in vascular endothelium, smooth muscles and also in other 
nonvascular structures within the heart, lung, kidney and nervous system (Rubanyi and 
Polokoff, 1994). ETa receptor expression is co-localized with the expression of ET-1 
and ETb receptor expression is co-localized with the expression of ET-3 in various 
tissues (MacCumber et al., 1989).
Gene inactivation studies of ET receptors have demonstrated that they are equally 
important in embryonic development as their ligands, endothelins (Clouthier et al., 
1998; Hosoda et al., 1994). In knockout mice where both receptors were targeted only 
double homozygous knockouts (ETa-/- ETb-/-) showed 100% lethality (Yanagisawa et 
al., 1998). Other knockouts displayed variable percentages of lethality, suggesting that 
perhaps not all ET-ETR mediated signals are essential for development.
Research of ET-ETR signalling has provided various peptide and non-peptide agonists 
and receptor subtype specific antagonists that have proved to be useful in delineating 
the mechanisms of ET receptor activation. Apart from endogenous agonists
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(endothelins), sarafotoxins have also been used (S6c as ETbR selective agonist) as well 
as other synthetic agonists (Davenport, 2002). Radioactively labelled endothelins are 
commonly used for the characterization and localization of ET binding sites. Although 
the major application of these reagents is in basic research, some of them are also of 
clinical interest (Benigni and Remuzzi, 1999).
1.4 Physiological effects of ET
The biological actions of ET can be observed on three distinct hierarchical levels which 
are mutually interconnected:
• the general effect of ET on tissues and organs;
• the effect on a single cell; and
• intracellular effect -  signalling pathways.
1.4.1 On the tissue/organ level
As mentioned earlier ET has many diverse physiological effects. ET acts on different 
tissues and organs maintaining a balance between health and disease. As yet it is still 
not certain what the primary role or purpose is of such a potent and versatile 
biologically active substance. Its resemblance to a snake venom makes the study of 
ET’s physiological mechanisms even more interesting.
The main role of ET appears to be in regulating the homeostasis of vascular tissues. 
This includes the control of blood volume, pressure, flow and viscosity (Serneri et al., 
1995; Abassi et al., 1998; Stepp et al., 2001) and implicates the action of ET on diverse 
organ systems: cardiovascular, renal, pulmonary and others. In addition to regulating
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normal organ function, it has been observed that many disorders linked to vascular 
systems are immediately followed by elevated levels of circulating endothelin:
• Cardiovascular disorders: acute myocardial infarction, congestive heart failure, 
angina pectoris, arterial hypertension, atherosclerosis (Toyo-oka et al., 1991; 
Wei et al., 1994; Hocher et al., 1997);
• Diabetes: complications in diabetes (Sarman et al., 1998);
• Pulmonary disorders: pulmonary hypertension, asthma (Dupuis et al., 1998; 
Hay, 1999); and
• Renal disorders: chronic renal failure (Kohan et al., 1997).
These disorders are often found to respond well to treatment with bosentan, a non- 
selective ET receptor antagonist (Roux et al., 1999).
Another important role of ET is in development, as demonstrated by research which 
uses gene targeting: knockouts and mutations of ET and ET receptor genes. These 
experiments showed that the ET-1/ETaR axis is essential for the development of 
cranial/cardiac neural crest-derived structures whilst ET-3/ETbR signalling has a role in 
enteric nervous system and melanocyte development and differentiation (Kurihara et 
al., 1994; Baynash et al., 1994; Clouthier et al., 1998; Hosoda et al., 1994).
ET peptides and their receptors have been localized in the human brain suggesting the 
possibility of ET’s action as a neurotransmitter (Ambar et al., 1988; Naidoo et al., 
2004). Additionally, ET can modulate the neurotransmission in other tissues (Luciano 
et al., 1998; Yoneyama et al., 1995; Wong-Dusting et al., 1989).
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Angiogenesis is the process of formation of new blood vessels and in adults it occurs in 
wound healing and the regeneration of tissues, but it is also a critical event for the 
progression of tumours. In recent years research has emphasized the role of ET in 
angiogenesis with implications both in the processes of normal tissue vascularization 
and in tumour-induced neovascularization (Goligorsky et al., 1999; Cruz et al., 2001; 
Josko et al., 2001; Bagnato and Spinella, 2003).
Endothelins perform other biological actions (intestinal tract movement, menstrual 
cycle control, release of bioactive substances) and are also associated with many 
different diseases (liver disorders, septic shock, rejection of transplants and cancer) 
(Matsumoto et al., 1994; Nelson et al., 1995; Watschinger et al., 1996).
1.4.2 On the cellular level
All physiological effects of ET are carried out essentially on the level of a single cell, 
and this is then aggregated to result in a bigger tissue effect, as described in the section 
above. The outcome of the stimulation of cells with ET can result in a number of cell 
responses: cell contraction, cell growth, cell proliferation, cell transformation, cell 
migration and the regulation of apoptosis. Depending on the cell type and location, 
these effects in combination or alone give rise to tissue specific response.
ET is one of the most prominent vasoconstrictors found to date and it carries out this 
role by acting on vascular smooth muscles cells (VSMC). However, it has also been 
shown that ET is able to contract nonexcitable cells such as mesangial cells and 
fibroblasts (Simonson and Dunn, 1990; Fireman et al., 2001; Shi-Wen et al ., 2004).
26
Chapter 1
The proliferative function of ET was also noticed on a variety of cells and is important 
in ET-controlled development and differentiation, angiogenesis, wound healing, 
transplantation, progression of some ET related diseases and cancer (Lahav et al., 1996; 
Alberts et al., 1994; Bagnato and Spinella, 2003).
Cell proliferation together with the other cellular effects of ET all contribute to the 
importance of endothelins in tumour progression. (Kusuhara et al., 1992; Salani et al., 
2000; Del Bufalo et al., 2002). In addition, there is evidence for both pro- and anti- 
apoptotic roles of ET in different cells mediated via different receptors and intracellular 
mechanisms. In human melanoma cells and in rat aortic smooth muscle cells ETb 
mediated the apoptotic ET-1 signal (Cattaruzza et al., 2000; Okazawa et al., 1998) 
whilst the same receptor mediated survival in rat endothelial cells (Shichiri et al., 1997). 
On the other hand in fibroblasts ETaR mediated anti-apoptotic effects of ET-1 (Shichiri 
et al., 1998). In a previous study from our group proteins that regulate the cell cycle 
were identified as downstream targets of ET-1 in human lung fibroblasts (Stannard et 
al., 2003 b).
Collectively, these reports show that ET uses many different ways, frequently 
overlapping, to perform its function. For most of the physiological effects it is still not 
clear what the critical step is in limiting the outcome of the ET induced cellular 
behaviour. The fact that there are three isotypes of ET and at least two receptor 
subtypes explains to a certain extent the diversity of ET induced physiological 
responses.
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1.5 Signal transduction pathways of ET receptors
The biological effects of endothelins are initiated by the binding of these peptides to ET 
receptors and the subsequent activation of a cascade of cell signalling events. The 
network comprising endothelins, ET receptors and their signalling pathways is often 
termed the ET axis (Nelson et al., 2003).
The ET axis can be further subdivided into the ET-1/ETaR axis and the ET-3/ETbR 
axis, because ET-3 binds only to the ETb receptor under physiological conditions 
(Clouthier et a l ,  1998). The mechanisms of signal transduction of the two subtypes of 
ET receptors (ETa and ETb) have not yet been fully documented. In the sections which 
follow the key components of ET intracellular signalling will be described.
1.5.1 G proteins
Commonly ET signalling pathways begin with the binding of the ligand to the 
heptahelical receptor. The binding of the ligand to the receptor changes the receptor’s 
conformation and as a consequence the receptor associates with distinct classes of 
heterotrimeric guanine nucleotide regulatory proteins (G proteins). G proteins in their 
inactive form are stably associated in a heterotrimer comprising three subunits: a- 
subunit (that has a guanine nucleotide binding site and a GTPase activity) and (3 and y  
subunits (that form a tight dimer) (Hamm, 1998). G proteins have been classified into 
four groups based on the similarity of the amino acid sequences of their a-subunits: Gs, 
Gi/o, Gq/n and G12/13 (Neer, 1995). It has been shown that ET receptors can couple to 
several types of G a protein subunits: Gq, Gn, Gs and Gi (Aramori et al., 1992; 
Takigawa et al., 1995). The exact type to which the ET receptor will couple depends on
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what set of G protein subunits the particular cell expresses. After the activation of the G 
proteins, their a  subunits exchange the bound nucleotide GDP to GTP. This reaction 
causes the heterotrimer to become less stable and to dissociate into an a-subunit and a 
Py-dimer. Both molecules can then propagate the signal further down the cascade onto 
a variety of effectors (Neer, 1995).
Possible signalling pathways mediated by ET are illustrated in Fig. 1-2. The possible 
effector molecules of G a and Gpy in ET signalling include: PLCP, adenylate cyclase, 
PLD, PLA2, guanylate cyclase and tyrosine kinases (Douglas and Ohlstein, 1997). The 
activation of these enzymes triggers the production or the inhibition of production of a 
number of second messengers such as cAMP, DAG, IP 3 , cGMP, P IP 3 and phosphatidic 
acid.
EG FR
MEKI cAMP
Nucleus Regulation of 
gene expression
F ig u re  1-2 A  sim p lified  diagram  o f  possib le signa lling  pa thw ays m edia ted  by E T -1 .
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1.5.2 Calcium signalling
The rise of calcium (Ca2+) concentration in cells stimulated with ET is a principal early 
response that mediates the intracellular actions of this GPCR peptide-agonist. The
'J,  9 4 -
mechanism that elevates cytosol Ca involves its release from Ca -storing organelles
9 4 -or the influx of extracellular Ca via a receptor-operated channel or a voltage 
dependent channel (Somlyo and Somlyo, 1994). In short, ET-ETR interaction triggers 
the Gotq or Gjpy activation of phospholipase C (PLC), the membrane located enzyme 
that mediates the breakdown of phosphatidylinositol 4,5-bisphosphate (PIP2) into two 
second messenger molecules: insoitol-1,4,5 triphosphate (IP3) and 1,2-diacylglycerol 
(DAG) (Pollock et al., 1995). IP3 binds to specific Ca2+ sensitive IP3 receptors in the 
membrane of the endoplasmic reticulum (ER) and thereby initiates Ca2+ release, whilst 
DAG is believed to mediate the activation of protein kinase C (PKC) (Fig. 1-2).
The ET-1 triggered release of Ca2+ from ER can result also from the activation of 
another type of ion channel (similar to the IP3 receptor), the ryanodine receptor (Kai et 
al., 1989; Wagner-Mann et al., 1991). The ET evoked increase in Ca2+ is biphasic in 
that an initial rapid phase is followed by a sustained signal (Rodland et al., 1991; 
Somlyo and Somlyo, 1994). The IP3 induced rise in Ca2+ represents the first phase.
9 ,
This Ca release triggers other events that can lead to cell membrane depolarization 
and an influx of extracellular calcium. Channels that can mediate the entrance of 
extracellular Ca2+ in ET stimulated cells are: voltage-dependent Ca2+ channels (VDCC) 
(L-type Ca2+ channels) (Goto et al., 1989); receptor operated Ca2+ channels (ROC) 
(Iwamuro et al., 1999; Simpson et al., 1990; Shetty et al., 1994); and store-operated 
channels (SOC) (Iwamuro et al., 1999). Membrane ion channels other than Ca2+ 
channels may also be activated during ET-signalling namely Ca2+ dependent potassium
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channel (KCa) (Gordienko et al., 1994) and Ca2+ activated Cl' channel (Takenaka et al., 
1992).
The rise in cytosol calcium ions makes it possible for them to bind to various Ca2+-  
modulating proteins and propagate the signal. Probably the most well-known Ca2+- 
binding protein is calmodulin (CaM), which regulates many different enzymes and 
proteins. Many proteins regulated by Ca -CaM also take part in ET signalling 
including: Ca2+-calmodulin-dependent protein kinases, myosin light-chain kinase 
(MLCK), caldesmon, calcineurin (protein phosphatase 2B (PP2B)), adenylyl cyclase, 
Ca2+-ATPase and nitric oxide synthase (NOS) (Zhu et al., 2000; Adam et al., 1990; 
Yokomori et al., 2003). Additionally, PKC, PLC, PLA2 and PLD by themselves are 
Ca2+-binding proteins and are important transducers of ET signalling (Schramek et al., 
1994; Liu et al., 1992).
1.5.3 PKC signalling
The activation of PKC by ET is a well recognized event. Nevertheless, the role of this 
Ser/Thr kinase in ET signalling is complex. PKC is a mediator in ET-induced cell 
contractions as well as ET-induced mitogenesis (Pollock et al., 1995; Rybin et al., 
1999). The mammalian PKC family of proteins can be classified into three sub-families 
based on sequence similarity and the type of molecule the enzymes require for their 
activation: the conventional PKC (cPKC), the novel PKC (nPKC) and the atypical PKC 
(aPKC). cPKCs (which include the isoforms: a, pi, pH and y) are activated by 
phospholipid, DAG and Ca2+. The nPKCs (8 , e, r\ and 0) do not require Ca2+ but 
require phospholipids and DAG, whilst the aPKC (k, 1,  ^ and p) are activated by 
phospholipids only (Toker, 1998).
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ET-1 can activate the following PKC isoforms: a(R ybin et a l ,  1999), 5 (Obara et 
a l ,  1999), r\ (Robin et al., 2004; Eude et a l ,  2000) and PKC^ (Kanashiro et a l ,  2000). 
The isoform expression is cell specific and this probably contributes to a particular 
cell/tissue response to ET (Ohno et a l ,  1987). PKC is regarded as a broad specificity 
Ser/Thr kinase (with some differences in substrate recognition between the subclasses 
of PKC) that can phosphorylate Ser and Thr in the vicinity of Arg in the consensus 
sequence RxxS/TxxRx (a common sequence in many proteins) (Nishikawa et a l ,  
1997.). Despite the broad specificity of PKC isoforms, it seems that they have 
specialized roles in the cell because in addition to specific cell/tissue distribution, PKC 
isoforms seem to localize differentially in cellular compartments upon stimulation 
(Goodnight e t a l ,  1995).
1.5.4 MAPK signalling
ET can also activate gene expression and cell proliferation by adopting the mitogen 
activated protein kinase (MAPK) signalling pathway (Simonson et a l ,  1992; Cazaubon 
et a l ,  1993). This pathway was generally linked to the receptor tyrosine kinase 
signalling but recent accumulating data have revealed the involvement of G protein- 
coupled receptors in mitogenic signalling (van Biesen et a l ,  1996; Gutkind, 1998). It 
has been well documented that ET-1 has a role as a comitogen, requiring low 
concentrations of some other growth stimulating factors to produce a full mitogenic 
response (Yang et a l ,  1999; Hafizi et a l,  1999).
MAPK pathways typically follow a track of phosphorylation events (phosphorelay) 
during which three kinases are sequentially activated (Fig. 1-3): the extracellular signal 
first reaches the MKK kinase (MAPK kinase kinase) which then transfers the signal to
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the MKK (MAPK kinase) by virtue of phosphorylating Ser/Thr residues (Johnson and 
Lapadat, 2002). Activated MKKs also have dual specificity whereby they catalyse the 
phosphorylation of Thr and Tyr residues on specific MAPK. MAPKs are a family of 
kinases that also phosphorylate various substrates including: other protein kinases, 
transcription factors, phospholipases and cytoskeletal proteins.
U pstream  kinases 
MEK-1 M A PKK7 M APKK4 M APKK6
I \ /  \  /
ERK 1/2 JN K  p38
F ig u re  1-3 A  s im p lifie d  d iagram  o f  M A P K  m o d u le .
Five members of the MAPK family have been described in mammals: extracellular 
signal-regulated kinase (ERK1/2), the c-Jun NH2-terminal kinases (JNK), p38MAPK, 
ERK3/4 and ERK5 (Widmann et al., 1999). The last two subgroups are not well 
characterized. These groups of MAPKs can be functionally separated by the diverse 
signals to which they respond and therefore activate distinct patterns of gene expression. 
The ERK group is involved in the signals prompting cells to respond through growth 
and differentiation (Gudermann et al., 2000). The JNKs are activated by environmental 
stress signals and have a role in the regulation of cell survival and apoptosis (Touriner et 
al., 2000). p38MAPK is also a stress activated protein kinase and has been shown to 
participate in inflammation, cell growth, differentiation, cell cycle and apoptosis (Ono 
and Han, 2000).
/ " :  ‘\  
M APKKK
M APKK
M APK J
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It was first believed that ET activates predominantly the ERK pathway, using both Gi 
and Gq proteins (Hilal-Dandan et al., 1997; Abdel-Latif et al., 2000). Recent data 
showed that ET could also induce the JNK and the p38MAPK pathway (Bogoyevitch et 
al., 1995; Clerk et al., 1998). The signal following the activation of GPCRs to MAPKs 
is delineated for ERK and JNK but not for p38 MAPK. ET-1 could therefore stimulate 
the pathways mediated by all three MAPKs even in the same cell suggesting that the 
signal mediated by ET is far more complex than previously anticipated and that it 
possibly involves interaction and crosstalks between different signalling routes.
Several pathways through which ET might join in the MAPK signalling pathway can be 
hypothesised. One possibility is the activation of the Ras protein via the py subunit of 
the Gi protein which has been shown to be involved in some GPCR-mediated nuclear 
signalling like the Angiotensin II (Yamazaki et al., 1999). On the other hand, the Gq 
protein can couple to the MAPK pathways both independently and dependently of PKC 
(Caverzasio et al., 2000). Since Gq is most frequently associated with ET-1 stimulation 
of MAPK signalling, it is very likely that this is the route of choice that ET undertakes 
in most cell types where it induces proliferative effects.
Additionally, ET-1 could switch to the ERK pathway by two other mechanisms: the 
recruitment of p-arrestin to the ETA receptor and the transactivation of EGFR (Imamura 
et al., 2001; Daub et al., 1996). ET receptors are internalised within 20 mins of their 
stimulation (Cramer et al., 1997). In the process of preparation for internalisation the 
receptor is initially desensitised by phosphorylation (see section 1.5.7 Termination of 
signalling). The Gpy subunit associated with the receptor mobilizes GRKs (G protein- 
coupled receptor kinases) which phosphorylate the ligand occupied receptor thus 
enabling the binding of arrestins to the receptor. Arrestins can act as docking sites for
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the protein kinase Src which in turn can activate a pathway leading to ERK. It is still 
not clear how the signal from Src continues, but one possibility is that it phosphorylates 
the She adaptor protein, which then binds to the Grb2/Sos complex with the signal then 
proceeding in the usual way (Lutrell et al., 1999; Hall et al., 1999) (Fig. 1-2).
Another relatively recent discovery is that some GPCRs are able to induce a release of a 
growth-factor homologue from the membrane that binds to its corresponding growth- 
factor receptor and activates it. This process is termed transactivation. ET-1 was 
shown to transactivate EGFR by releasing an EGF-like growth factor, heparin-binding 
EGF (HB-EGF) (Daub et al., 1996). It is thought that GPCRs activate a membrane 
metalloproteinase that cleaves the membrane-bound proHB-EGF, releasing HB-EGF 
that binds to EGFR and activates the EGF signalling pathway (Prenzel et al., 1999) (Fig 
1-2).
1.5.5 Tyr kinase signalling
ET-1 stimulation of cells increases the tyrosine phosphorylation of a number of proteins 
(Force et al., 1991; Zachary et al., 1992). The tyrosine kinases reported to be involved 
in ET signalling are Src, focal adhesion kinase (FAK) and the Janus kinases (JAK), all 
of which may play an important role in ET’s mitogenic activity.
Src is a nonreceptor tyrosine kinase, activated by ET-1 (Miyamoto et al., 2003). The 
activation of Src requires the presence of a tyrosine phosphatase to dephosphorylate 
Tyr527, which acts as an inhibitory modification by binding to and masking the kinase 
domain of Src (Cooper and Howel, 1993). The identity of the phosphatase allowing Src 
activation is still not known. Upon Src activation there are several domains through
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which Src can establish its interactions with other proteins: SH2 domain binds Tyr- 
phosphorylated proteins, SH3 domain binds proline-rich motifs and the phosphorylated 
Tyr residues on Src itself can associate with other SH2-containing proteins (Cohen et 
al., 1995). This allows Src to form multiprotein complexes accommodating various 
signalling proteins.
FAK is tyrosine phosphorylated upon ET-1 stimulation (Zachary et al., 1992). 
Accumulating data suggest that FAK is the substrate of Src, as they both associate with 
one another and are both co-localized in focal adhesions (Calalb et al., 1995; Polte and 
Hanks, 1997; Shen and Guan, 2001). ET-1 stimulation leads to FAK-Src complex 
formation (Salazar and Rozengurt, 1999). This complex can then serve as a docking 
site for She, which when phosphorylated binds growth factor receptor binding protein-2 
(Grb2) and Son of sevenless (Sos). Finally, the formed complex can initiate the Ras- 
ERK pathway (Schlaepfer et al., 1999). ET-1 also stimulates the tyrosine 
phosphorylation of paxillin, a cytoskeletal protein and substrate of FAK which is found 
in complex with FAK in focal adhesions (Zachary et al., 1993).
Src and FAK are important tyrosine kinases in the processes of cytoskeletal 
reorganizations and the formation of actin stress fibres and focal adhesions although 
their precise role is not clear. These events are often triggered by growth factors and are 
mediated by Rho GTPase (Ridley and Hall, 1992). Focal adhesions are the sites at the 
cell surface where the cell cytoskeleton forms an attachment to the extracellular matrix 
(Petit and Thiery, 2000). They form at the sites of plasma membrane where bundles of 
actin stress fibres terminate. Focal adhesions modulate cell shape and motility and play 
a role in anchorage dependent cell growth (Ilic et al., 1995; Frisch et al., 1996; 
Schlaepfer et al., 1999).
36
Chapter 1
The JAK/STAT (Signal transducers and activators of transcription) pathway, first 
discovered in interferon regulation of gene expression, can also be activated by Gq- 
coupled receptors (Angiotensin II) (Marrero et al., 1995). JAK tyrosine kinases 
associate with the activated receptor and then cross-phosphorylate one another which 
switches them to an active form. They can then phosphorylate STATs. Additionally 
they can phosphorylate the receptor itself enabling in this way the binding of different 
SH2-bearing signalling molecules (Taniguchi et al., 1995). Phosphorylated STATs 
dimerize and translocate to the nucleus where they regulate gene transcription. The 
specificity of JAK/STAT gene activation is controlled by the type of STAT recruited to 
the phosphorylated receptor.
The role this pathway may have in ET signalling is unclear. Reports to date suggest that 
ET-1 attenuates the interleukine-induced STAT activation (Booz et a l ,  2002), but also 
that ET-1 through E T a receptor activates the STAT pathway in transfected Chinese 
hamster ovary (CHO) cells (Peeler et a l ,  1996). As this field is rather unexplored and 
there are indications that other vasoactive peptides induce STAT signalling, it is 
possible that the growing list of ET targets will include members of the JAK/STAT 
pathway in certain cells.
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1.5.6 Other signalling pathways
Recent investigations by Kawanabe et al. demonstrated that ET-1 induces the activation 
of phosphoinositide 3-kinase (PI3K), with the purpose of regulating Ca2+-channels 
(Kawanabe et al., 2002; Kawanabe et al., 2003; Kawanabe et al., 2004). Another group 
showed that ET-1 stimulated nitric oxide synthase (eNOS) via the PI3K-dependent 
pathway (Herrera and Garvin, 2004). These reports highlight that the PI3K pathway 
may also be one of the mechanisms of ET-signalling but the exact role of this is not yet 
known. The PI3-kinases phosphorylate the hydroxyl group of the phosphatydylinositol 
lipids.
Protein phosphatases together with kinases are integral components of cell signalling.
The activity of phosphatases can either function as a negative regulation of signalling,
by rendering proteins inactive, or they can activate certain proteins by
dephosphorylating their resting-cell phosphorylated form. Undoubtedly protein
phosphatases play a major role in ET signalling. Examples are the phosphatases
(unidentified) responsible for the activation of Src and full activation of c-Jun
(Chackalaparampil et al., 1994; Boyle et al., 1991). Additionally ET-1 activates protein
2+phosphatase 2B, also known as calcineurin, which has Ca -CaM as a regulatory subunit 
(Zhu et al., 2000).
1.5.7 Termination of signalling
GPCR mediated signals are terminated by receptor desensitisation. A negative 
feedback signal, mediated by a G(3y subunit, mobilizes receptor kinases (GRKs) that 
phosphorylate the C-terminal domain of the receptor. Phosphorylation of the receptor
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allows the binding of arrestins which prepare receptors for removal by endocytosis 
(Goodman et al., 1996). Receptor endocytosis can happen via two mechanisms: 
clathrin coated pits and/or caveolae. Both processes of receptor internalization were 
reported for ET receptors (Okamoto et al., 2000; Bremnes et al., 2000). Deactivated 
receptors can be either degraded (E T bR ) or recycled (E T aR ) (Bremnes et al., 2 0 0 0 ).
1.6 Unexplored issues of ET-signalling and how proteomics can help
1.6.1 Unexplored issues
The concept of one receptor for each signalling pathway has for some time been shown 
to be flawed. Instead it has been shown that pathways interconnect with the pathways 
from other receptors forming a network of interacting proteins allowing a diverse 
control over cellular signalling (Daub et al., 1996). In this network some proteins 
transfer the signals themselves by phosphorylation, dephosphorylation and hydrolysis. 
Other proteins have no catalytic function but instead function as adaptor proteins to 
bring together components that are supposed to interact with each other. This theory of 
cell signalling where molecules are not dynamically moving around the cell, but rather 
form molecular assemblies through which signals are propagated is relatively new (Hur 
and Kim, 2002). In this way new members of proteins such as “scaffold” and “anchor” 
proteins, are introduced into the “club” of cell signalling members. In addition to 
activating the classical second messenger cascade GPCRs can also activate the MAPK 
cascade and transactivate another tyrosine kinase receptor, thereby inducing a novel 
signalling pathway (van Biesen et al., 1996; Prenzel et al., 1999;). With the emerging 
knowledge about GPCR oligomerization, it will be interesting to discover the effects 
this has on the cellular signalling mediated by such receptors. Yet another characteristic
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of GPCRs is that they do not couple solely to G proteins, but can interact with other 
types of molecules implying even greater complexity in their signalling (Hall et al., 
1999).
Despite the 15 year awareness of the existence of ET, the knowledge of its biological 
activities is still poorly understood when compared to the knowledge of other growth 
factors. The reason for this perhaps lies in the diversity of ET peptides and their 
receptors and the heterogeneity of tissue responses and signalling pathways that 
endothelins activate. Although a number of components of major signalling cascades 
triggered by ET-1 (discussed earlier) have been established, there are still a lot of 
underlying issues that need to be explored, for example: what are the exact mechanisms 
of Raf activation in certain cell types? What other transcripition factors are activated by 
ET-1? Which phosphatase is crucial for the activation of Src and what are the 
downstream targets of Src leading to the mitogenic response? What is the role of FAK 
and Src in focal adhesion formation by ET-1 and how is this signal transduced to the 
nucleus? Is ET-1 an inhibitor or activator of JAK/STAT pathway, and in what cells? 
What are the exact roles of the activation of SAPKs and p38 MAPK and what are their 
upstream signalling molecules? What is the significance of the activation of all three 
major MAPK pathways in a certain cell (ERK, SAPK and p38)? Does ET-1 activate 
PI3K pathway in all cells and if so what are the components of the pathway and what is 
its role? How and why do certain pathways crosstalk and what is the key output signal 
that they determine? The number of questions seems endless and is further complicated 
by the ever-expanding list of proteins and possible crosstalks activated by ET in 
different cells.
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1.6.2 How can proteomics help?
Most methods commonly used in the study of signalling pathways are methods 
generally applied in protein biochemistry. These include immunochemistry, 
chromatography, molecular biology, electrophysiology techniques as well as many 
others. Proteomics makes use of these classical methods but takes the study of cellular 
signalling one step further by employing 2D PAGE and/or various types of mass 
spectrometry (Godovac-Zimmermann and Brown, 2001 and 2003). 2D PAGE is a 
technique for the separation of proteins based on their molecular weights and their 
charge. The resultant protein map represents a high-resolution display of a few 
thousand cell proteins. These proteins can then be qualitatively and quantitatively 
analysed by the differential display of 2D maps from distinct cell conditions (for 
example control vs stimulation or health vs disease) and can be identified by mass 
spectrometry (MS). Additionally, posttranslational modifications of proteins can be 
further identified by the application of electrospray ionisation mass spectrometry (ESI- 
MS) which allows the sequencing of peptides by MS/MS analysis (tandem mass 
spectrometry) (Fig. 1-4).
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Figure 1-4 General strategy for proteomic analysis of signal transduction pathways.
The application of proteomics in elucidating signalling pathways has advanced in recent 
years and many groups focus their research on developing new proteomics-compatible 
techniques to help enhance the features of proteins interesting for signalling (Blagoev et 
a l ,  2003; Ibarrola et al., 2004). There are a number of papers describing fruitful 
applications of proteomics in the study of signal transduction pathways. For example 
2D separation accompanied by phosphoprotein detection revealed proteins 
phosphorylated on Ser and Tyr upon PDGF stimulation (Soskic et al., 1999 b). 
Kanamoto et al. (2002) identified 38 proteins that changed their expression level in 
response to TGF|3 treatment in MvlLu cells. Amongst them the down-regulation of 
RAD51, a new downstream target of TGFp, was demonstrated to influence genome 
instability. Using proteomics Pandey et al. (2002) identified a novel protein that was 
found to negatively regulate the EGFR-induced mitogenic signal. Other groups focused 
on the proteomic analysis of specialized cellular compartments, such as lipid rafts,
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centrosomes or splicesosomes, and revealed a set of new associated proteins providing 
evidence for additional roles of these cellular protein-organizing centres (Andersen et 
al., 2003; Foster et al., 2003; Zhou et al., 2002).
Proteomics can not answer all the questions posed for the ET signalling pathway and 
like any other method has its limitations. These vary from simple ones like the 
extraction and solubility of very hydrophobic proteins to much more complex problems 
e.g. precise (absolute) quantification, sensitivity (in detection of proteins and MS 
characterization), MS identification of protein isoforms and the resolution of proteins 
(reviewed in Godovac-Zimmermann et al., 2005). The more complex problems become 
especially important when applying proteomics analysis to higher eukaryotes where a 
large number of proteins obtained from a relatively small number of genes form diverse 
cells. The mechanisms that higher eukaryotes use to regulate the complex function of a 
cell include alternative splicing, post-translational modifications and partitioning of one 
protein between different isoforms. The diversity and complexity of these mechanisms 
places an impetus on protemics to improve the existing and to develop new technologies 
capable of dealing with proteome of higher eukaryotes.
In addition to the above-mentioned limitations another weakness of current proteomics 
methods is the lack of quick and simple ways of analysing proteins as whole molecules 
as opposed to peptides obtained from protein digestion. If this problem were overcome, 
such analyses would enable unambiguous characterization of protein isoforms. This in 
turn would contribute to the understanding of functional processes with which specific 
isoforms are associated. In order to apply proteomics methods to signall tranduction of 
ET we have developed new methods and we pushed to the limit currently used 
methods.
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Two major areas that proteomics can address in ET biology are: the detection and 
identification of new targets downstream of the activated receptor and the qualitative 
and quantitative changes in ET signalling components (expression level, presence, 
position and extent of phosphorylation and/or other modifications). Furthermore 
proteomics could potentially answer even more specific questions, such as what is the 
phosphatase involved in Src activation.
1.7 Aims of Study
The aim of this thesis was to investigate the effect of ET-1 on gene expression and 
protein phosphorylation states in the cell using a proteomics based approach. In a wider 
context the results of these studies will provide a better understanding of the complex 
relationship between ET modulated proteins and consequently the events that regulate 
the response of a cell to ET-1.
More specifically the aims were:
1. To follow the qualitative and quantitative changes in gene expression in 
fibroblasts treated with ET-1 by global parallel proteomics analysis of de novo 
protein synthesis. The results of these experiments would provide an insight 
into which intracellular proteins are regulated by ET-1 on the level of gene 
transcription and consequently what are the possible cellular responses that are 
modulated.
2. To assess the functional activity of fibroblast ET receptors by monitoring the 
ET-1 induced calcium signal and the phosphorylation of MAP kinases.
3. To undertake a qualitative and quantitative global proteomics analysis of rapid 
changes in protein phosphorylation induced by brief stimulation with ET-1 with
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a view to identifying new targets downstream of the ET receptors and the nature 
of their behaviour after exposure to ET.
4. To investigate the phosphorylation states of RhoGDI in resting and ET- 
stimulated cells and to determine its phosphorylation sites using mass 
spectrometry.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Materials
Human lung fibroblasts CCD19Lu and FBS were taken from the European Cell 
Cultures. Normal Rat Kidney Fibroblasts (NRK-49F) and HeLa cells were kindly 
provided by Dr Jill Normann (Department of Medicine, Royal Free Campus, UCL). 
Rat renal microvascular endothelial cells (RMVEC) were a gift from Prof. Michael 
Goligorsky (New York Medical College, Valhalla, NY, USA). ET-1 was from 
Calbiochem (Nottingham, U.K.). Trypsin-EDTA, antibiotic/antimycotic, minimal 
essential medium, HBSS, Dulbeco’s modified Eagle medium nutrient mixture FI2 
Ham, molecular weight marker, nonessential amino acids (NEAA) and L-Glutamine 
were from Invitrogen (Paisley, U.K.). Immobiline DryStrips, L-[35S]methionine and 
Pharmalyte were from Amersham Pharmacia (Little Chalfont, U.K). Duracryl (30% 
acrylamide, 0.8% bis acrylamide) was from Genomic Solutions (Huntingdon, U.K.). 
Complete mini-protease inhibitor cocktail was from Roche Diagnostics Ltd. (Lewes, 
U.K.). Sequencing grade trypsin was from Promega (Southampton, U.K.). Prestained 
SDS-PAGE standards low range and acrylamide were from Bio-Rad Laboratories Ltd 
(Hemel Hempstead, U.K.). Ni-NTA agarose was from Qiagen Ltd. (Crawley, U.K.). 
All other chemicals were purchased from Sigma-Aldrich Company Ltd. (Poole, U.K.) 
unless otherwise stated and were of the best grade available.
2.2 Cell Culture
Two fibroblast cell lines were used during the course of this thesis: CCD19Lu and 
normal rat kidney fibroblasts clone 49 (NRK-49F). CCD19Lu was used for the gene
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expression studies. This is a human lung fibroblast cell line developed from a normal 
lung tissue. NRK-49F was used throughout the rest of the project due to failure of 
supply of CCD19Lu and their freezing incompetence. NRK-49F were derived from a 
mixed population of rat kidney and fibroblast cells. These cells are well characterized, 
they exhibit density-dependent growth inhibition and are used for growth factor 
bioassays.
RMVEC and HeLa cells were used for ET-1 binding experiments. HeLa cells were 
grown in Minimal Essential Medium (MEM) (Invitrogen Ltd., Paisley, U.K.) containing 
10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic (lOOx solution containing 
10,000U/ml penicillin-G, lOmg/ml streptomycin and 25p,g/ml amphotericin-B; Sigma). 
RMVEC were grown in DME Ham’s F12 medium containing 10% FBS and 1% 
antibiotic-antimycotic Cells were cultured at 37°C in a humidified atmosphere of 5% 
CO2 . RMVEC and HeLa cells were cultured in 10cm culture dishes (Triple Red; 
Thame, Oxfordshire, U.K.) and passaged at confluence using trypsin-EDTA 
(Invitrogen). Stocks of cells were frozen in 90% FBS, 10% dimethyl sulfoxide (DMSO; 
Sigma) and stored in liquid nitrogen (BOC; Surrey, U.K.).
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2.2.1 Culture o f human lung fibroblast CCD19Lu
CCD19Lu cells were acquired as frozen ampoules at passage 8 , from ECACC. The cell 
culture medium was prepared as follows:
Reagents Final
concentration
L-Glutamine 2mM
NEAA 1 %
FBS 1 0 %
Antibiotic/antimycotic mixture 0.80%
MEM with Earle's salts without L- 
Glutamine
500ml
Cells were grown in 10ml of medium in a water-saturated, 5% CO2 atmosphere at 37°C 
in p i0 0  polystyrene cell-culture dishes.
Cells were split 1:4 when they were 80-90% confluent. Before splitting they were 
washed twice with PBS. 5ml of trypsin/EDTA was added to the dish and gently 
agitated. The trypsin was then aspirated, and the dishes were left in the incubator at 
37°C for 2 mins. Afterwards they were checked under a microscope to ensure complete 
detachment from the dishes. They were then resuspended in a small volume of medium 
and centrifuged at 4°C for 5 mins at lOOOrpm. After centrifuging the washing medium 
was aspirated and the cell pellet was resuspended in an appropriate volume of fresh 
medium and plated.
Attempts were made to freeze CCD19Lu, using freezing media containing glycerol, 
DMSO, in FBS containing 10% DMSO and in preconditioned media taken from their 
own culture. However, all attempts were unsuccessful, and we were informed by the 
suppliers that they were unlikely to be successful under any feasible circumstances, so
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the cells were continually cultured until they reached the end of their lifespan. The cells 
were generally able to undergo 1 0  splittings before showing signs of ill-health, when 
they were destroyed, and a new vial was started.
2.2.2 Culture o f NRK-49F
NRK-49F cell line was grown in either p i00 dishes or 75cm2 flasks in the following 
medium:
Reagents Final
concentration
DMEM Nutirent Mixture FI2 Ham 500ml
Antibiotic/ antimycotic 1%
FBS 1 0 %
Cells were split when they were 70-80% confluent. Splitting involved washing the cells 
with 10ml PBS, trypsinizing them with 2ml of Trypsin-EDTA and leaving them to 
incubate at 37°C for 2 mins. Detachment of cells from the dishes could be seen by the 
naked eye. After detaching, the cells were resuspended in fresh medium and plated.
2.2.2.1 Freezing of NRK-49F cells
NRK-49F cells were grown until 70-80% confluent. They were trypsinized as described 
above. After trypsinization, the detached cells were resuspended in a small volume of 
medium and spun for 5 mins at lOOOrpm at 4°C. Supernatant was aspirated and the cell 
pellet was resuspended in freezing solution: 10% DMSO in FBS. The cells were first 
left for 1-2 days at -80°C, and then transferred to a liquid nitrogen container.
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2.3 Pulse labelling with [35S] methionine
Nearly confluent (80-90%) CCD19Lu cells were washed twice with a prewarmed 
labelling medium.
Reagents Final
concentration
MEM (Eagle) without L-Glutamine and L- 
Methionine
500ml
FBS 1 0 %
Antibiotic/antimycotic mixture 0.80%
L-Glutamine 2mM
NEAA 1 %
After washing, cells were incubated for 30 mins in 5ml of labelling medium in a 
humidified incubator at 37°C, 5% CO2. [35S] methionine was added to each dish to a 
final concentration of 30mCi/ml.
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2.4 Stimulation of CCD19Lu with ET-1
CCD19Lu cells were incubated with or without ET-1 (final concentration lOOnM) for 
various periods of time at 37°C. [35S] methionine was added to each dish 30 mins before 
the cells were harvested. After the induction time the cells were washed twice with 5ml 
of ice-cold PBS suplemented with the following:
Reagents Final
concentration
Na2P2C>7 (sodium pyrophosphate) 15mM
NaF (sodium fluroide) lOOmM
Na3V0 4  (sodium ortho vanadate) lOOmM
Leupeptin 2 mg/ml
Trypsin inhibitor soybean 2 mg/ml
Trypsin inhibitor limebean 2  mg/ml
Antipain 2 mg/ml
After washing cells were lysed in 270pl of isoelectric focusing (IEF) buffer:
Reagents Final
concentration
Urea 8 M
Thiourea 2M
Chaps 4%
DTT 65mM
Tris base lOmM
Ampholyte 0.80%
Triton X-100 1 %
Cells were scraped and sonicated (3 times with 15 second bursts at half-power at 1 
minute intervals). After sonication cells were spun at 4°C for 5 mins at 13,000rpm. The 
pellet was discarded and the supernatant frozen at -80°C.
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2.5.1 One-dimensional SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
This electrophoresis was based on the protocol originally proposed by Laemmli (1970). 
Acrylamide used for all gels was a mixture of 30% Acrylamide and 0.8% 
Bisacrylamide. Separating gels were prepared in the range from 10% - 12% depending 
on the size of proteins. The separating gel was prepared with different volumes of 30% 
Acrylamide and 0.8% Bisacrylamide, then 0.375M Tris-HCl pH 8 .8  and 0.1% SDS 
were added with APS and TEMED being used for polymerization. All stacking gels 
were of 5% acrylamide concentration and contained 0.125M Tris-HCl pH6 .8 , 0.1% 
SDS. The sizes of gels were either 15cm x 16cm (Hoefer SE600 system, Amersham 
Pharmacia) or 8.3cm x 7.3cm (Mini-Protean 3 system, Bio-Rad). Samples were 
prepared in SDS-PAGE sample buffer (see table below for preparation), vortexed and 
heated for 5 mins at 95°C.
5 x SDS-PAGE sample buffer:
Reagents Final
concentration
Tris-HCl pH 6 .8 0.225M
glycerol 50%
SDS 5%
bromophenol blue 0.05%
DTT 0.25M
Gels were run submerged in electrophoresis running buffer (0.198M glycine, 25mM 
Tris Base, 0.1% SDS) at a constant voltage of 100V (mini gels) or 200V (large gels). 
They were subsequently stained by either Coomasie R250 or by silver.
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2.5.2 Two-dimensional-poly acrylamide gel electrophoresis (2D PAGE)
2.5.2.1 1st dimension: Isoelectric focusing (1EF)
For the first dimension in 2D PAGE, 13 cm isoelectrofocusing strips (IPG) pH range 3- 
10 or 4-7 were used. 150-200pg of proteins in IEF buffer were loaded on a single strip. 
The rehydration step was included in the programme for isoelectric focusing. Strips 
were covered with mineral oil to prevent the sample from evaporating.
The following IEF programme was used:
Step Voltage Volt-
hours(Vh)
Gradient type
1 30 330 Step-n-hold
2 3000 1500 Step-n-hold
3 4000 4000 Step-n-hold
4 6000 60000 Step-n-hold
After focusing, strips were either frozen (-20°C) or prepared for the second dimension, 
SDS-PAGE.
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2.5.2.2 2nd dimension: SDS-PAGE
IPG strips were rinsed thoroughly with distilled water, and the excess water was drained 
onto a piece of filter paper. After this the strips were first treated for 20 mins with 2% 
DTT in equilibration buffer (30% glycerol v/v, 2% SDS w/v, 6 M Urea, 0.5mM Tris- 
HCl, pH 6 .8 ). The excess DTT was drained onto filter paper and IPG strips were 
treated with 4.5% Iodoacetamide in equilibration buffer for another 20 mins. The strips 
were then briefly washed with electrophoresis running buffer and were then cut at the 
edges (this is the area of very acidic or very basic gel where separation is very poor) and 
placed on top of a polyacrylamide gel. Gels (15cm x 16cm x 1mm) that were used were 
of 11 % acrylamide concentration.
Molecular weight markers were loaded onto a piece of filter paper and placed close to 
the acidic part of the IPG strip onto the polyacrylamide gel. The strip and the markers 
were overlayed with 0.5% boiling agarose prepared in stacking gel buffer (0.125M Tris- 
HCl pH6 .8 , 0 .1% SDS) with a trace of bromophenol blue. The purpose of agarose is to 
stop the strip from moving. The electrophoresis ran at a constant voltage of 200V for 
approximately 5-6 hours at 11°C. When the bromophenol blue dye reached the end of 
the gel the run was stopped and the gel was further stained with either silver or 
Coomasie brilliant blue R250.
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This procedure was adopted from Shevchenko et al. (1996). Gels were placed in fixing 
solution (12% CH3COOH and 50% methanol) and agitated for a minimum of 2 hours. 
They were then washed 3 times with 50 % ethanol with each wash lasting 20 mins. The 
gels were then pretreated for 1 min with 0 .0 2 % Na2S2C>3 and rinsed well with distilled 
water 3 times for 20 seconds each time. The staining step was performed in 0.1% 
AgNC>3 for 20 mins. Excess silver nitrate was washed off twice with water, and protein 
spots were detected with a solution containing 3% Na2CC>3, 0.0002% Na2S2C>3 and 
0.009% formaldehyde. When the spots became a dark brown colour, the gels were 
rinsed twice for 2 mins in distilled water. Staining was stopped by immersing the gels 
in the fixing solution for 10 mins. After this the gels were washed in 50% methanol, 
and finally in 5% methanol. Gels were then packed in plastic wraps with a small 
amount of 5% methanol, to stop them from drying and were stored at 4°C until the 
proteins were cut and analysed by mass spectrometry. For autoradiography purposes 
gels were rinsed in 5% CH3OH and 4% glycerol and dried between pieces of 
cellophane.
2.7 Autoradiography
Dried gels were exposed to autoradiography films for varying lengths of time at -80°C. 
At the end of the exposure the cassette was warmed to RT before being opened. The 
films were processed in an automated X-ray film processor (Fuji RGII).
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2.8 Image analysis
Gels and autoradiography films were scanned using a UMAX Power look III scanner. 
Image analysis, spot matching, the analyses of changes in protein synthesis or protein 
phosphorylation and the estimation of pI/Mw coordinates were undetaken using 
Melanie III software (Geneva Bioinformatics SA).
2.9 In-gel tryptic protein digestion
The procedure is a modification of the method originally proposed by Heilman et al. 
(1995). The protein spots were cut out from the SDS-polyacrylamide gels (silver 
stained in most cases; for a few proteins identified in Table 3-1 a Coomassie stained gel
-I
was used) and chopped into small pieces (1mm ). The gel pieces were treated with 
25mM NH4HCO3 for 15 mins. This step was repeated until the pH of the solution was 
alkaline. No destaining of silver-stained gels was performed. Spots from Coomassie 
stained gels were destained in 10% CH3OH and 10% CH 3COOH. Protein spots were 
then washed three times with acetonitrile and dried in the speed-vacuum concentrator 
for 30 mins. The dry gel clump was rehydrated in lOmM DTT and lOOmM NH4HCO3 
for 30 mins at 56°C, then spun down and the supernatant removed. Gel pieces were 
then treated with lOOmM Iodoacetamide in lOOmM Ammonium Bicarbonate for 30min 
at room temperature in the dark, then spun down and the liquid removed. The gel was 
washed again in acetonitrile and dried in the speed-vacuum concentrator. Trypsin 
solution was prepared by dissolving 20pg of trypsin (sequencing grade, Promega) in 
200pl of 25mM NH4HCO3 . 5pl of this solution was added to each sample, left to 
rehydrate on ice, and then if necessary more trypsin solution was added just to cover the 
gel, without letting it dry. These samples were then incubated overnight at 30°C.
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For the identification of low-intensity spots (Fig. 3-2) the same spot was cut out from 2- 
3 silver stained gels and processed together.
2.10 Mass spectrometric analysis
2.10.1 MALDI- TOF mass spectrometry
For MALDI-TOF mass spectrometry aliquots of 0.5pl of the digest solution were 
applied to a target plate and allowed to air-dry. Subsequently, 0.5|il of matrix solution 
(1% w/v a-cyano-4-hydroxycinamic acid in 50% acetonitrile and 0.1% v/v 
Trifluoroacetic acid) was applied to the dried sample and the sample was again allowed 
to dry. Spectra were obtained using a Bruker Biflex III spectrometer (Bremen, 
Germany) for the gene expression studies and later a Bruker Autoflex spectrometer in 
reflector mode. The spectrometer was calibrated using a mixture of 7 known peptides 
ranging in mass between 1046 and 3495 Daltons. Obtained spectra were processed 
manually using Bruker’s DataAnalysis software, version 1.6. Peptide spectra were 
internally calibrated using known autolytic peptides from trypsin. Protein fragments 
were identified using the MASCOT programme available at the Matrix Science web site 
(http://www.matrixscience.com) (for the identification of proteins in Table 5-1 local 
(intranet) Mascot version 2.1 was used), the MS-Fit programme available at the web site 
at the University of California at San Francisco (http://rafael.ucsf.edu/cgi-bin/msfit), the 
ProFound programme at the web site of Rockefeller University 
(http://prowl.rockefeller.edu/cgi-bin/ProFound) (for the identification of proteins in 
Table 3-1 the 1999/2000 version of Profound was used while proteins from Table 5-1 
were identified with the Version 4.10.5) and the Peptldent programme at the web site of 
EMBL in Heidelberg (http://www.embl-
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heidelberg.de/Services/PeptideSearch/FR_peptideSearchForm.html). Within search
paramerers 2  missed cuts, partial oxidation of methionine, carbamidomethylation and 
polyacrylamide adducts of cysteine were allowed. For CCD19Lu cells human database 
was searched. For NRK-49F cells mamallian and rodent protein databases were 
searched. Probability of identification was evaluated according to:
• the “P” value (probability based Mowse score, for searches in Mascot);
• the probability value, “Z” value for searches in Profound;
• The Mowse score, for searches in MS-Fit;
• the score for searches in Peptident;
• the sequence coverage in all programmes used; and
• the reproducibility of protein identification in all peptide mass fingerprinting
programmes used.
In addition to the above, the significance of a protein identification was evaluated by 
comparing the difference in scores between the first ranked protein and the proteins 
with lower ranks (second, third) in a search. The greater the difference, the higher the 
significance of a hit.
Even if the probability score in any single database search was not significant, 
identification of a protein was considered positive if the same hit was obtained in all 
other search programmes with highest rank, sequence coverage was high and observed 
Mw corresponded to the theoretical value.
2.10.2 ESI-Ion trap mass spectrometry
Tryptic digest samples were diluted 1:1 with 2% acetic acid in water. The samples were 
vortexed, then loaded into the micro-capillary for nanospray analysis. Nanospray mass 
spectrometry was performed using a Finningan-Matt LCQ (San Jose, CA, USA), in a
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positive ion mode. Collision energy changed between 20 and 40%. Peaks previously 
identified using MALDI-TOF MS were chosen for sequencing, both to confirm the 
identity of the protein, and the phosphorylation status of the tryptic peptides. 
Fragmentation spectra were compared to theoretical fragmentations of the likely 
sequences obtained from MS-Product (http://jspl.ludwig.edu.au), and the location of 
post-translational modifications was ascertained where possible. The likelihood of the 
modification of certain amino acids was determined using Scansite 
(http://scansite.mit.edu/motifscan) and Prosite (http:// ca.expasy.org/prosite/).
3-2)
2.11 ET-1 binding studies
2.11.1 Preparation o f membranes for binding studies
9-10 dishes of each cell line were used for membrane preparation. Cells (Renal 
microvascular endothelial cells (RMVEC), NRK-49F or HeLa) were grown until they 
were confluent. Dishes were then washed twice with 5ml ice-cold protease inhibited 
PBS (1 Complete mini protease inhibitor tablet /100ml of PBS). Cells were detached 
from the dish with l-2ml of Tryspin/EDTA and left in the 37°C incubator for a couple 
of mins. Cells were then collected with 2-3ml of protease inhibited PBS and spun at 
1500rpm for 5 mins at 4°C. The cell pellet was washed twice in 5ml of protease 
inhibited PBS. After the second wash the cell pellet was resuspended in 200|nl of PBS 
and 2ml of ice cold H2O and left on ice for 10 mins. Cells were harvested with a 25G 
needle and syringe and further lysed in a Dounce homogeniser. The suspension was 
spun in the Sorvall (SS34 rotor) for 60 mins at 4°C at 17,000rpm. The pellet was 
resuspended in 1ml of PBS and homogenised on ice using a Dounce homogeniser. An 
aliquot of 30pl was taken for Bicinchoninic acid (BCA) protein concentration
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evaluation and the rest of the membrane suspension was frozen at -80°C or used 
immediately.
2.11.2 Binding o f 125I-ET-l and competition with specific receptor inhibitors
All stock solutions were prepared in 0.1% BSA in PBS. For each sample a minimum of 
100p.g or more of membrane was used. The membranes and all other solutions were
1 9 Smixed together in 500pl eppendorf tubes. I-ET-1 was the last substance added. 
Samples were prepared as follows to make the final volume of 200pl:
Group Membranes
(us)
1 I-ET-1
(pM)
ET-1
(nM)
BQ788
(nM)
BQ485
(nM)
Total binding (ETAR+ETBR) 100 200
Non-specific (NS) 100 200 100
NS + ETaR 100 200 100
NS +ETbR 100 200 100
Total radioactivity added 200 100
NS + ETaR and NS + ETBR were measurements when ETaR or ETBR were blocked 
respectively. Each group contained three to four tubes. The tubes were incubated at RT 
for 2 hours. They were spun at 14,000rpm for 10 mins. Supernatant was discarded and 
the pellet was quickly washed once with lOOpl of PBS with 1% SDS. Care was taken 
not to disturb the pellet during washing. Afterwards the pellet was resuspended in 
lOOpl of PBS with 1% SDS and then mixed thoroughly with 5ml of scintillation fluid. 
The radioactivity was measured in a y-counter (Packard 2000 CA Tri-Carb Liquid 
scintillation analyzer).
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2.12 Measurement of Ca2+ level with FLIPR (Fluorometric Imaging Plate 
Reader)
Measurements were conducted with the help of Mr Saman Ranasinghe (Department of 
Physiology, UCL).
2.12.1 Preparation o f cells
2 days before the experiment, black-walled, clear-bottomed 96-well plates (Falcon) 
were treated with poly-L Lysine. The wells were loaded with 200pl of 0.01% Poly-L- 
Lysine, and left overnight at 4°C, still, covered with parafilm. The next day liquid was 
aspirated from the plates and NRK-49F cells were seeded at a density of about 50,000 
cells/well. The cells were plated in lOOpl of DMEM nutrient Mixture FI2 Ham with
0.5% FBS. Cells were grown overnight in a water-saturated, 5% CO2 atmosphere at 
37°C.
2.12.2 Calcium flux  assay
All reagents used were prepared in PBS unless otherwise stated. On the day of the 
experiment, media were removed, and the wells were washed twice with pre-warmed 
PBS. Cells were then incubated in lOOpl of fluo-4 (Cfin= 2pM; Molecular Probes) with 
probenecid (2.5mM) for 1 hour at RT in the dark. Fluo-4 stock solution was prepared in 
2.5% Pluronic acid solution in DMSO. Before loading it was diluted 1:1000 in PBS. 
After loading the cells, the fluo-4 was aspirated, the wells were rinsed with PBS and 
150pl of PBS was added to all wells. The wells that were to show specific receptor 
subtype activity were preincubated with specific inhibitors for ETa and ETb receptor,
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BQ485 (lOOnM) and BQ788 (lOOnM) respectively for 5 mins. These inhibitor 
solutions were then aspirated and replaced with 150pl of PBS and intracellular Ca2+ 
levels were subsequently assayed using the FLIPR (Molecular Devices) to 
simultaneously monitor fluo-4 fluorescence in all wells (A ,eXcita tio n  = 488nm, A ,e m jSSjon  =  
540nm). Cells were treated with a growing concentration of ET-1 (lOnM, lOOnM and 
ImM). ATP (at concentrations 5pM, lOpM and lOOpM) was used as a positive control 
and PBS and big-ET (ImM) as negative controls. Agonists were added to the cell plate 
at a velocity of 40jnl/s. Fluorescence intensity was measured for 15 mins. Agonists 
were added at the time point 30 seconds, and fluorescence intensity was captured every 
2 seconds for 5 mins and every 5 seconds for the last 10 mins.
2.13 ET-1 stimulation of NRK-49F cells
NRK-49F cells were grown until 50-60% confluent in DMEM Nutrient Mixture FI 2 
Ham supplemented with 10% FBS and 0.1% antibiotic/antimycotic mixture (starvation 
medium). The medium was then replaced with the same medium but with 0.5% FBS. 
The cells were left to starve for 48h. On the day of the experiment, media were 
replaced with 5ml of fresh starvation medium 2 hours before the stimulation 
experiment. Cells were treated with ET-1 (lOOnM) and incubated at 37°C for various 
periods of time. After incubation the dishes were placed on ice, washed twice with 5ml 
of ice-cold PBS and lysed in 0.5ml of either immunoprecipitation-lysis buffer, or lysis 
buffer for IMAC phosphoprotein purification (see 2.14 and 2.15 for buffer preparation).
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The method described here was developed in our laboratory during the course of this 
thesis (see Posters and Publications). 10-20xl06 cells (2 p i00 dishes) were used for one 
sample for IMAC. After stimulation the cells were lysed in the following buffer:
Reagents Final
concentration
Tris-HCl pH 7.4 50mM
Lithium dodecyl sulfate 6 %
Triton-XlOO 6 %
Na3V 0 4 ImM
NaF 5mM
p-glycerophosphate 5mM
EDTA 5mM
Complete mini protease inhibitor cocktail tablet 1
The cell suspension was sonicated using sonic ultrasound (3 bursts at halfpower at 1 
minute intervals) and spun for 20 mins at 13,000rpm at 4°C. LiCl was added to the 
supernatant to make the final concentration of 2M and the sample was vortexed briefly. 
One part of the bind mix (2M LiCl in lysis buffer containing 20% silica) was then 
mixed to 6  parts of protein solution and incubated for 5 mins on a rocking platform at 
RT. The suspension was centrifuged for 3 mins at 13,000 rpm and the supernatant was 
saved, and the silica was discarded. The protein solution was then rebuffered into 
binding buffer (50mM bis-(hydroxyethyl)-piperazine pH 3.4, 4% Zwittergent 3-12, 2% 
Triton X-100) using NAP-10 size exclusion columns (Amersham Pharmacia) according 
to the manufacturer’s instructions. The Fe3+ affinity column was prepared in the 
following way: 1ml of 50% slurry of Ni-NTA Agarose beads was pipetted into 2.5ml 
plastic columns. Ni ions were removed from the resin by washing the column with
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4ml of stripping buffer (50mM Tris-HCl pH 7.5, 2% Triton X-100, 0.1M EDTA, 0.5M 
NaCl). The column was then washed with 4ml of water to remove any trace of EDTA 
and was subsequently activated with 2ml of freshly dissolved FeClsx 6 H2O (27mg/ml in 
water). The column was then washed with 4ml of water and equilibrated with 4ml of 
binding buffer. 1.5ml of protein solution containing between 1-3 mg of protein were 
loaded on the Fe3+ affinity column. At all times the column was run by gravity force 
alone. After loading the sample the columns were washed with 3ml of binding buffer 
and then with 1ml of 25mM Na2SC>4 and 25mM imidazole in binding buffer. 
Phosphoproteins were eluted using 1ml of 50mM NaH2P0 4  x IH2O in binding buffer. 
The columns, after extensive washing with binding buffer and water, can be recycled 
starting with the stripping buffer step.
2.15 Protein precipitations
2.15.1 TCA precipitation
Protein samples were precipitated by adding ice-cold 60% TCA to make the final 
concentration of 11%. In the case of IMAC elution samples, phosphoproteins were 
precipitated with a solution of 60% TCA and 0.2% 1,10-phenantroline. Samples were 
vortexed briefly and left on ice for 20 mins. They were then spun for 10 mins at 13,000 
rpm at 4°C. Supernatant was aspirated and the protein pellets were washed once with 
ice-cold 5% TCA, and 4 times with ice-cold 80% acetone. Washing includes 5 mins 
incubation on ice and subsequently 5 mins spinning at 13,000rpm at 4°C. After the last 
wash the protein pellets were left on the bench to air-dry for 1 0  mins and were then 
resuspended in an appropriate buffer.
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2.15.2 Acetone precipitation
Proteins were precipitated from solutions using 4 volumes of ice-cold acetone. Samples
were left on ice for 5 mins and then spun for 5 mins at 4°C at 13,000rpm. The
supernatant was discarded and the pellet was washed once with ice-cold 80% acetone. 
The pellet was air-dried on the bench for a couple of mins and then resupended in an 
appropriate buffer.
2.16 Protein assays
2.16.1 Bicinchoninic acid (BCA) protein assay
This is a modification of a method originally proposed by Smith et al., (1985). The 
principle of the method is that BCA reduces divalent copper ion to monovalent ion in 
alkaline conditions. A molybdenum/tungsten purple product is produced with an 
absorbance maximum at A,=562nm. Reagents used for the assay are :
• Bicinchoninic acid solution; and
• Copper (II) sulfate pentahydrate 4% solution.
A standard curve was prepared with BSA. BSA concentrations were chosen in the 
range between 2pg and lOOpg, depending on the approximate estimation of the 
concentration of the unknown proteins.
BCA protein assays were performed in microtiter 96-well plates. The working BCA 
reagent solution was prepared by mixing 1 part of Copper (II) sulphate pentahydrate 4% 
solution to 50 parts Bicinchoninic acid solution. The working solution was added to the
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BSA and unknown protein sample in the ratio of 20:1. The plate was incubated for 30 
mins at 37°C. After incubation the plate was cooled to RT and absorbance measured at 
X=595nm. Buffer corresponding to each set of samples was used as a control. The 
absorbance of the control was subtracted from the absorbance of the samples to obtain 
the net absorbance of the proteins. A standard curve was plotted as the net absorbance 
at ^=595nm vs. the known |Ltg of BSA. This curve was used to determine the amount of 
protein in unknown samples. This method is not compatible with reducing agents such 
as DTT.
2.16.2 Modified Bradford protein assay compatible with IEF buffer
The method was developed by Proteosys AG, Mainz, Germany and is based on methods 
originally proposed by Ramagli and Rodriguez (1985) and Zor and Selinger (1996).
Reagents:
• Coomassie working solution: Coomassie reagent (BioRad) was diluted 1:4 with 
H20;
• 0.02N HC1;
• Diluted IEF buffer: IEF buffer (see section 2.4) was diluted 1:5 with 0.02 N 
HC1; and
• Standard protein stock solution: lOmg/ml BSA (fraction V, Sigma) in IEF 
buffer. Stock solution was frozen in lOOpl aliquots.
Dilution series of BSA for the standard curve were prepared by diluting the BSA stock 
solution with dilute IEF buffer. Unknown protein samples were diluted 1:5 with 0.02N 
HC1. Each protein sample was then mixed in the ratio of 1:40 with Coomassie working
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solution, incubated for 5 mins at RT and the absorbance was read at X = 595nm and at X 
= 450nm. To determine the protein concentration of the unknown samples, the ratio of 
-^595/^450 was plotted against the amount of standard protein. Each experiment was 
carried out in triplicate.
2.17 Western Blot
Reagent solutions prepared for Western Blot are:
• Transfer buffer: 20% methanol, 0.1% SDS, 25mM Tris base and 192mM 
glycine;
• TBS (Tris-buffered saline): 10 mM Tris-HCl pH 7.4, 170 mM NaCl;
• TBS/Tween: 0.1% Tween 20 in TBS;
• Ponceau stain: 0.1% ponceau dye in 7% TCA; and
• Blocking buffer: 5% nonfat dry milk, 1% BSA in TBS/Tween buffer.
For Western Blots proteins were first separated on 10% SDS-PAGE gels, and then 
transferred onto a nitrocellulose membrane in a semi-dry blotting system. The transfer 
was performed at 15V for 30 mins and then at 25V for 90 mins. The transfer of the 
proteins was checked with ponceau staining. Membranes were blocked in blocking 
buffer for 2 hours at RT or overnight at 4°C. Following this the membranes were 
washed 4 times for 5 mins with 50ml TBS/Tween buffer and incubated with the primary 
antibody overnight at 4°C. The primary antibody was diluted in TBS/Tween buffer 
according to the manufacturer’s advice. Membranes were washed 4 times with 50ml 
TBS/Tween for 5 mins and incubated with the secondary antibody for 1-2 hours at RT. 
Secondary antibodies were mostly horseradish peroxidase conjugated, and in some
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cases they were alkaline phosphatase conjugated. The dilutions of secondary antibodies 
were 1:10,000 in TBS/Tween (for ALP conjugated or 1:4000 of TBS/Tween buffer for 
ALP conjugated antibodies). After incubation the membranes were washed 3 times for 
5 mins with 50ml of TBS/Tween and were then washed once with 50ml of TBS.
2.17.1 Chemiluminescence detection
After washing the nitrocellulose membranes, the washing buffer was poured off and the 
membranes were covered with a 1:1 mixture of Amersham "ECL" detection reagents, 
just enough liquid to cover the blot. Membranes were incubated for 1 min and the 
excess liquid was drained away on a filter paper leaving the blot moist. The blot was 
then wrapped in saran wrap and exposed serially to film in a cassette for 1 mins, 2 mins 
and 5 mins. For 2D electrophoresis blots Amersham “ECL Plus” reagents were used in 
a ratio of 40:1. Membranes were incubated with the reagent mix for 5 mins and were 
then exposed to film and developed.
2.17.2 Alkaline phosphatase detection
The following stock solutions were prepared:
1. NBT: Dissolve 5g of NBT in 10ml of 70% dimethylformamide (DMF);
2. BCIP: Dissolve 0.5g of BCIP (disodium salt) in 10ml of DMF; and
3. ALP buffer: lOOmM NaCl, 5mM MgCl2, lOOmM Tris (pH 9.5).
All stocks are stable at 4°C for at least 1 year.
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Just prior to developing, fresh substrate solution was prepared. 66pl of NBT stock 
solution was added to 10ml of ALP buffer, mixed well and the 33pl of BCIP stock was 
added. The working solution should be used within 1 hour. This solution was added to 
the blots with enough being used to cover the membranes and the stain was developed 
at RT with agitation until it was suitably dark. Rinsing the membranes with PBS 
containing 20mM EDTA chelating the Mg2+ ions stopped the reaction.
2.17.3 Stripping and reprobing membranes
This method can be used to retest blots that were detected with the chemiluminescent 
method.
The following stripping buffer was prepared: 62.5mM Tris-HCl pH6.8, lOmM p- 
mercaptoethanol and 2% SDS TBS/Tween buffer.
Stripping buffer was pre-warmed for 5 mins at 60°C. Membranes were soaked in 
stripping buffer and slowly agitated for 30 mins at 60°C. After incubation the 
membranes were washed with plenty of TBS/Tween buffer twice for 10 mins. The 
membrane could then be reprobed following the Western Blot procedure starting from 
the step of blocking of the membranes.
2.18 Immunoprecipitation of RhoGDI
After stimulation with ET-1 (see 2.13), NRK-49F cells were washed with PBS and 
scraped in lysis buffer containing Tris-buffered saline with 1% Triton X-100, ImM 
Na3V0 4 , 5mM NaF, 5mM p-glycerophosphate, 5mM EDTA, 2mM Na2P2C>7 and 1
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Complete Mini Inhibitor cocktail tablet. Cells were disrupted by repeated aspiration 
through a 21 gauge needle and sonication (3 bursts for 10 seconds each 1 min apart). 
Cell homogenates were transferred to a microcentrifuge and centrifuged at 13,000 rpm, 
30 mins at 4°C. The protein concentration was determined from the supernatants with 
the BCA. Equal amounts of proteins in the supernatants were precleared with 0.1 pg 
rabbit IgG, 20pl of protein A-sepharose and 50pl Sepharose CL4B for 30 mins rotating 
at 4°C. The pellet was collected by centrifugation at 2,500 rpm for 30 seconds at 4° C 
and was discarded. The supernatant was transferred to a fresh microcentrifuge tube and 
incubated for lh at 4°C with 2pg of anti-Rho GDI antibodies per 500pg of cell proteins. 
Protein A-conjugated agarose beads (Perbio) were added and incubated overnight. 
Immunoprecipitates were collected by centrifuging at 2,500 rpm for 5 mins at 4°C. 
Supernatant was discarded and pellets were washed 3 times with 500pl ice cold lysis 
buffer. Finally, the pellets were washed with 500pl of ice-cold lOmM Tris-HCl pH 7.4. 
Bound proteins were eluted with 200pl of IEF buffer without DTT for 1.5h at RT. DTT 
was added to the sample at a final concentration of 65mM prior to isoelectric focusing 
and 2D gel electrophoresis.
2.19 Stable isotope labelling by amino acids in cell culture (SILAC)
2.19.1 Cell culture media preparation and cell culture conditions
DMEM Nutrient mixture FI2 Ham without arginine was used. The arginine-free 
medium was divided into two lots and L -arginine (Sigma) and L-arginine-U-13C6 
(Cambridge isotope labs) were added separately. The medium with its full complement 
of amino acids was sterile filtered through a 0.22pm filter (Millipore, Bedford MA) and 
stored at 4°C for later use.
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NRK-49F cell line was grown in DMEM Nutrient mixture FI 2 Ham, prepared as 
described earlier (see 2.2.2), supplemented with 10% filtered fetal bovine serum plus 
antibiotics, in a humidified atmosphere with 5% CO2 in air. Cell lines were grown for 
at least six cell divisions in labelling media containing either normal arginine or 13C6- 
Arg before the stimulation experiment (see 2.13).
2.19.2 Mixing experiments
For this kind of experiment in addition to the control (no stimulation) only one 
stimulation time point was used (4 mins with ET-1 (lOOnM)). After stimulation and 
lysis of the NRK-49F cells, protein concentrations were determined using the BCA 
protein assay and then lysates (control and stimulation) were combined in the ratio of 
1:1 (normal Arg: 13C6-Arg). The mixed cell lysates were then used for RhoGDI 
immunoprecipitation.
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CHAPTER 3. PROTEOMICS MAPPING OF ET-1 INDUCED 
GENE EXPRESSION CHANGES IN HUMAN LUNG 
FIBROBLASTS
3.1 Introduction
ET regulates cell growth and proliferation by activating signalling cascades that follow 
the pathway to the nucleus where they culminate in the activation of gene expression 
(Cazaubon et al., 1993; Sakurai et al., 1994; Yang et al., 1999; Hafizi et al., 1999). The 
transcription of early genes, c-jun, c-fos and c-myc, was demonstrated within 3 hours of 
ET-1 stimulation in fibroblasts and mesangial cells (Pribnow et a l, 1992; Simonson et 
al., 1992). Neyses et al. (1991) showed that ET-1 also induces new proteins synthesis 
in rat cardiomyocytes and that this process is controlled by the transcription of the early 
growth response-1 (Egr-1) gene. In addition, ET’s role in regulating cell cycle 
progression was connected with de novo synthesis of proteins in mouse fibroblasts, rat 
astrocytes and mesangial cells (Suzuki et al., 1999; Pedram et al., 1998; Teixeira et a l, 
2000).
At present, changes in gene expression are usually monitored by nucleotide-based 
methodologies such as expression profiling (Hughes and Shoemaker, 2001). However, 
the nucleotide-based methods have a number of technical and conceptual disadvantages 
compared to direct analysis of cellular proteins: (A) the old paradigm of one gene equals 
one protein is not correct for eukaryotic cells where splice variants, posttranslational 
modifications, etc. lead to perhaps six to eight proteins per gene on average (Strohman, 
1994); (B) while 2D electrophoresis methods are commonly used to resolve and display 
most cellular proteins (O’Farrell, 1975), analogous multidimensional display methods
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are not available for polynucleotides (mRNA); (C) the amplification of different 
mRNAs may not be quantitatively faithful, and the correlation between mRNA levels 
and cellular protein levels is not high (Anderson and Seilheimer, 1997; Gygi et al., 
1999; Griffin et al., 2002); (D) the nucleotide-based methods are not suitable for 
following the plethora of posttranslational modifications of proteins which are vital to 
cellular response and regulation.
In the recent years proteomics approaches to studying gene expression have been 
successfully applied. For example Kanamoto et al. (2002) followed changes in protein 
abundances by using 2D differential display of proteins in stimulated versus 
unstimulated systems. Another approach uses liquid chromatography coupled to 
Fourier Transform Ion Cyclotron Resonance (FTICR) mass spectrometry to study gene 
expression in microorganisms (Pasa-Tolic et al., 2002; Kolker et al., 2005). In addition 
to this, metabolic labelling was used to proteomically detect expression levels of 
proteins in nematodes (Krijgsveld et al., 2003).
The sections of this chapter which follow describe a functional proteomics approach to 
studying early gene expression after ET-1 stimulation of human lung fibroblasts. The 
experimental strategy applied uses pulsed [35S] methionine labelling to detect newly 
synthesized proteins. For proteins which showed changes in new protein synthesis 
between stimulated and unstimulated cells, the identity of the protein was determined by 
high-sensitivity MALDI-TOF mass spectrometry.
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3.2 Results
Confluent dishes of human lung fibroblasts CCD19Lu were stimulated with ET-1 
(lOOnM) for 30, 45, 60, 120 and 240 mins respectively. All dishes were stimulated at 
the same time point (0 min). 35S-Met (Cfin=700fiCi/dish) was added to the cells 30 mins 
before cells were collected for harvesting (Fig. 3-1). Each dish of cells had its own 
control being dishes of cells that were labelled with 35S-Met but not stimulated with ET- 
1.
30 mins
ET-1
S-Met
time
Figure 3-1 Schematic representation of the ET-1 time course experiment with 35S-Met 
labelling. C ells  w ere  s tim ula ted  w ith  ET-1 at tim e t=0. 30  m ins befo re  cells w ere  h a rv ested  3 5 S- 
M et w as added  to  the d ishes. C ells w ere harvested  afte r incubation  w ith  ET-1 fo r a certa in  
period  o f  tim e ( tm).
Proteins from the cell extract were first separated according to their isoelectric point (pi) 
values on immobilized pH gradient strips (pH 4-7). After first dimension separation the 
proteins were separated again on SDS-PAGE according to their molecular weights and 
their electrophoretic mobility. The 2D protein map created from these two separation 
processes was stained with silver (Fig. 3-2 A).
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F ig u re  3-2 2D  m ap o f  proteins fro m  hu m a n  lu n g  fib rob lasts . (A) Proteins separated by 
isoelectric focusing and SDS-PAGE were stained with silver. (B) New protein synthesis was 
detected with 35S labelling of proteins. The image shows an autoradiograph of the gel im age in 
A. The proteins that were identified with M A LD I-TOF peptide fingerprinting are labelled on 
the gels. Spot identification num bers correspond to Table 3-1.
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Many thousands of proteins are expressed in a typical eukaryotic cell, and this is 
reflected in the complexity of the 2D PAGE patterns observed for total protein extracts 
from CCD19Lu (Fig. 3-2 A). Around 2000 total proteins were reproducibly present on 
the 2D PAGE gels of human lung fibroblasts. In contrast, the response of cells to a 
stimulus may only involve new protein synthesis for a limited subset of the total cellular 
proteins. A much smaller number of proteins showed detectable amounts of new 
protein synthesis within 4 hours of ET-1 stimulation (Fig. 3-2 B).
To detect which of the proteins in the silver stained image had changed in their 
expression level, the 2D gels obtained were dried between cellophane paper and placed 
in direct contact with autoradiography film and enclosed in a light-tight cassette for 3 
days at -80°C. After the exposure time, the films were photographically processed. 
The images obtained (Figs.3-2 B, 3-3) show a 2D map of proteins with 35S-Met 
incorporation as a result of de novo protein synthesis.
The autoradiographs obtained were scanned and analysed with Melanie III software 
(Genebio, Geneva Bioinformatics SA). This software enabled detection of protein 
spots, matching them against those on the control gels, analysing the changes in protein 
synthesis, quantifying these changes and estimating pi and Mw coordinates and 
statistical analysis. Separate analyses for each set of gels were undertaken (control gel 
and its corresponding stimulated gel). The proteins that showed variations in intensity 
between stimulated gels and control gels provided an indication of which spots were 
good candidates to be cut out and identified. A total of about 40 proteins showed 
detectable differences in protein synthesis between stimulated and unstimulated cells. 
For 22 of these proteins, which showed the largest changes in synthesis, their identity 
has been determined by MALDI-TOF mass spectrometry (Table 3-1). These spots were
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then cut out of the gels and digested with trypsin. The resulting peptide-digests were 
analysed in a MALDI-TOF mass spectrometer. The mass spectra obtained were 
processed manually with the help of Bruker’s data analysis software. This involved 
recalibrating the spectra and labelling the peaks. The peak values were then run through 
the search engines of several protein databases.
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F igure 3-3 2D maps o f  newly synthesised proteins after ET-1 stimulation o f  hum an lung fibroblasts. Incorporation o f 35S-M et in proteins was 
monitored after cells were incubated with ET-1 (lower panel) or without ET-1 (upper panel) for 30 mins (gels 1 and 6 ), 45 mins (gels 2 and 7), 60 mins 
(gels 3 and 8 ), 120 mins (gels 4 and 9) and 240 mins (gels 5 and 10). Autoradiographs o f each time point are presented.
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For most of these proteins the mass spectrometry identifications were straightforward. 
Specific splice variants were observed for vinculin and nucleolar transcription factor 
(Table 3-1). In addition, conflicts in the sequence databases were resolved, e.g., the 
Thr/Ala conflict at position 4 of Ras-related protein Rab-14 (Appendix 1). A low 
molecular weight form of Rab-14 (Table 3-1) was observed. A particularly interesting 
case was the observation of two forms of Rab-14 (s23 and s28, Table 3-1) which 
showed very different new protein synthesis (see below). From the mass spectrometry 
results, the higher molecular weight form of Rab-14 appears to correspond to the 
complete gene sequence, whereas the lower molecular weight form appears to 
correspond to a splice variant with deletions at at least one end of the sequence 
(Appendix 1).
The changes in new protein synthesis were time dependent, and groups of proteins 
showing different kinetic behaviour could be observed (Fig. 3-4). Thus, for example, 
filamin, Sox5, and plasminogen activator inhibitor 2 all showed rapid changes in protein 
synthesis between 30 and 60 mins followed by a constant level of up-regulation 
(filamin, Sox5) or down-regulation (plasminogen activator inhibitor 2) at later times 
(Fig. 3-4 panel A). Other groups of proteins showed very different kinetic behaviour 
(Fig. 3-4 and Table 3-1). The Rab-14 (long) and Rab-14 (short) isoforms also showed 
very different kinetic behaviour (Fig. 3-4 panels D and E).
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Spot Gene1 Protein G i 2 Mw
obs. 3
Mw pi
obs.
Pi no of 
peptides4
%
coverage5
A mass6 Score7
1. Cytoskeletal proteins
si VCL Vinculin 4507877 117 115 5.8 6 . 1 2 0 40 0 . 1 2 119
sl5  TPM2 Tropomyosin 2 42476296 33 35 4.6 4.5 6 19 0.15 8 8
sl7  TPM3 Tropomyosin 3 136085 33 33 4.6 4.6 5 18 0.06 61
S29 MYL6 Myosin light polypeptide 6 17986264 17 14 4.46 4.5 6 45 0.09 50
2. Folding Accessory Proteins
S5 HSPA5 Heat shock 70 kDa 
protein 5 (GRP78)
6470150 71 78 5.9 5.0 1 2 24 0.24 139
3. Enzym es
s3 GANAB Glucosidase 2274968 107 107 5.7 5.8 13 2 0 0.26 60
s22 CYP11A 
1
Cytochrome P-450-scc 189438 28 29 7.2 6 . 1 6 26 0 . 1 52
s24 OAZ Ornithine decarboxylase 
antizyme
852428 24 27 7.8 6 . 2 5 2 0 0.04 48
Table 3-1 Proteins identified by MALDI-TOF mass spectrometry. (Continued overleaf)
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Spot Gene1 Protein Gi2 Mw
obs.3
Mw pi
obs.
pi no of 
peptides4
%
coverage5
A mass6 Score7
4. R egulatory proteins
s2 SF3B2 Splicing factor 3B subunit 2 55749531 98 108 5.5 5.34 9 11 0.19 61
s4 UBTF Nucleolar transcription factor 1 
(UBF-1)
136652 89 91 5.6 6.3 13 19 0.11 87
s l4 SOX5 SRY (sex determining region Y)- 
box 5
1881852 39 40 6.5 6.0 10 25 0.16 79
s23 RAB14 Ras-related protein Rab-14. 20379074 24 25 7.8 6.1 6 33 0.29 43
s28 RAB14 Ras-related protein Rab-14 6563200 24 21 5.8 6.18 6 40 0.05 62
s31 RAB3A RAB3A, member RAS oncogene 
family
4506367 25 25 4.9 4.9 7 33 0.14 60
s33 RPSA 40S ribosomal protein SA; laminin- 
binding protein
125969 33 48 4.8 4.8 6 32 0.12 86
s35 CDKN1B Cyclin-dependent kinase inhibitor 
IB
1168871 22 22 6.5 6.3 6 32 0.21 61
Table 3-1 (cont’d) Proteins identified by MALDI-TOF mass spectrometry. (Continued overleaf)
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Spot Gene1 Protein Gi2 Mw
obs.3
Mw pi
obs.
pi no of 
peptides4
%
coverage5
A mass6 Score7
5. O ther
s7 FLNC Filamin C, gamma 938227 24 25 4.8 4.7 5 35 0.15 53*
s l l SERPINB2 Plasminogen activator inhibitor-2 
precursor
1352712 47 47 5.5 5.5 5 12 0.05 86
s20 ANXA4 Annexin 4 1703319 36 33 5.8 6.4 5 21 0.14 43
s25 TPT1 Tumour protein, translationally- 
controlled 1
136479 20 24 4.8 4.8 5 21 0.04 71
s26 BCL2A1 Bcl2-related protein A l 4757840 20 21 5.3 5.6 5 24 0.21 60
s30 NPM1 Nucleophosmin 825671 31 37 4.7 4.7 4 26 0.13 40
Table 3-1 (cont’d) Proteins identified by MALDI-TOF mass spectrometry. (1) Name of the gene coding for the identified protein; (2) NCBI sequence 
identifier; (3) Mw estimated from SDS-PAGE; (4) Number of MS identified peptides in the database search; (5) Percentage of protein sequence covered by the 
identified peptides; (6) Average deviation bewteen theoretical and experimental masses for each matched peptide; (7) Probability based Mowse score taken from 
Mascot.
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F ig u re  3-4 E T-1  induced  changes in new  pro te in  syn thesis are tem porally dependent.
(Continued overleaf)
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Figure 3-4 (cont’d) ET-1 induced  changes in new  pro te in  syn thesis are tem porally  
dependent. (Continued overleaf)
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Figure 3-4 (cont’d) ET-1 induced  changes in new  pro te in  syn thesis are tem porally  
dependent. The level o f new protein synthesis is presented as the ratio o f spot intensities in 
cells stim ulated with ET-1 to spot intensities in unstim ulated cells. This ratio is plotted against 
ET-1 incubation time. Separate panels have been used to group proteins which show sim ilar 
time dependence (panels A-E). Statistical analysis was carried out by D r V ukic Soskic 
(Proteosys AG, M ainz, Germany).
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Functional group Protein Function
Cytoskeletal Tropomyosin Binds to actin filaments in muscle and non-muscle cells. In non-muscle cells it is implicated in stabilizing 
the cytoskeleton.
Vinculin Cytoskeletal protein associated with cell-cell and cell-matrix junctions, where it is thought to function as one 
of several interacting proteins involved in anchoring F-actin to the membrane. Multiple alternatively spliced 
transcript variants have been found for this gene, but the biological validity of some variants has not been 
determined.
Myosin light chain Myosin is a hexameric ATPase cellular motor protein. Myosin alkali light chain is expressed in smooth 
muscle and non-muscle tissues and is a regulatory light chain of myosin.
Chaperones Heat shock 70 kDa 
protein 5
Member of the heat-shock protein-70 (HSP70) family and is involved in the folding and assembly of 
proteins in the endoplasmic reticulum (ER). May play a key role in monitoring protein transport through the 
cell. Its (over)expression is associated with reduced apoptosis and cell transformation.
Enzymes Glucosidase A metabolic enzyme involved in processing oligosacharides, located in ER and Golgi.
Cytochrome P450 Ubiquitously expressed. Large family of enzymes. Part of the pathway of cholesterol biosynthesis.
Ornithine decarboxylase Plays a role in the regulation of polyamine synthesis by binding to and inhibiting ornithine decarboxylase.
antizyme Antizyme expression is auto-regulated by polyamine-enhanced translational frameshifting.
Table 3-2 Summary of identified proteins and their putative functions. (Continued overleaf)
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Functional group Protein Function
Regulatory Splicing factor 3B Together with splicing factor 3a and a 12S RNA unit, forms the U2 small nuclear ribonucleoproteins complex
subunit 2 (U2 snRNP). Involved in mRNA processing.
Nucleolar transcription 
factor 1
A transcription factor required for the expression of ribosomal RNAs.
SRY (sex determining A transcription factor involved in the regulation of embryonic development and in the determination of the
region Y)-box 5 cell fate.
Rab-14 Belongs to small GTPase family. Important in intracellular vesicle traficking.
Rab 3A Belongs to small GTPase family. Important in exocytosis, neurotransmitter secretion.
40S ribosomal protein SA A structural constituent o f ribosomes, also known as laminin binding receptor. Has a role in cell adhesion 
and is downstream of S6 kinase.
Cyclin-dependent kinase 
inhibitor IB
Binds to and prevents the activation of cyclin complexes, and thus controls the cell cycle progression at G l.
Table 3-2 (cont’d) Summary of identified proteins and their putative functions. (Continued overleaf)
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Functional group Protein Function
Other (unknown) Annexins A family of Ca2+-dependent phospholipid binding proteins with various roles: in cell motility, inflammation, 
signal transduction, excocytotic and endocytotic pathways.
Filamin Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. 
Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range 
of cytoplasmic signalling proteins.
Plasminogen activator 
inhibitor- 2
Inhibits urokinase-type plasminogen activator. Inhibits TNF-alpha induced apoptosis.
Tumour protein, 
translationally-controlled 
1
Found in normal and tumour cells. Unknown function.
Bcl-2-related protein A l A member of the BCL-2 protein family which act as anti- and pro-apoptotic regulators that are involved in a 
wide variety of cellular activities. This protein is up-regulated by different extracellular signals such as NF- 
kappa B, TNF and IL-1.
Nucleophosmin Ubiquitously expressed phosphoprotein involved in ribosome assembly/transport, cytoplasmic/nuclear 
trafficking, regulation of DNA polymerase alpha activity, centrosome duplication, and regulation o f p53.
Table 3-2 (cont’d) Summary of identified proteins and their putative functions. Proteins whose abundance was altered by ET-1 stimulation were grouped 
according to their putative roles in the cell and the reported areas of functions within a cell are summarized. Information was collected from Human Genome 
resources at http://www.ncbi.nlm.nih.gov/genome/guide/human/ and from Uniprot protein resource at http://www.expasy.uniprot.org/. See discussion for references.
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3.3 Discussion
The purpose of this study was to investigate the immediate short-term response of 
human lung fibroblasts to stimulation with ET-1 by monitoring the level of synthesis of 
new proteins using proteomics tools. Newly synthesised proteins were pulse labelled 
with 35S-methionine. Out of approximately 2000 protein spots seen on the gel, 40 spots 
showed a change in intensity between unstimulated and stimulated cells. Of these 22 
were unambiguously identified (Figs. 3-2, 3-3 and Table 3-1).
The set of proteins which show significant changes in protein synthesis over short time 
periods after ET stimulation (Table 3-1) includes proteins which have been implicated 
in a very wide range of different cellular and extracellular processes. This diversity 
presumably reflects the fact that the cell’s response to a mitogenic signal such as ET 
stimulation results in major changes in cellular function at many levels. These changes 
include intracellular changes connected ultimately with cell division, extracellular 
interactions with neighboring cells, and homeostasis at the organismal level. On the 
other hand, the number of proteins observed in the early response to ET stimulation is a 
very small subset of the total human genome, suggesting that the proteins that have been 
observed may have key roles in facilitating and directing this response. The 
observations set out in this chapter may suggest new roles or reinterpretations of the 
roles of individual proteins in human lung fibroblasts.
Changes in the fluxes of new protein synthesis were highly time dependent and the 
induction of these changes occurred on a similar time scale to signalling responses 
observed by phosphorylation/dephosphorylation (Godovac-Zimmermann et al., 1999).
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This supports the propostion that the observed changes in protein synthesis are a direct 
consequence of ET-1 signalling.
One of the most interesting groups of kinetically related proteins is the group shown in 
Figure 3-5 panel E: Rab3A, Rab-14 (long), annexin IV, Bcl2-related protein A l, 
translationally controlled tumour protein, and heat shock 70 kDa protein 5 (GRP78). 
Rab proteins are known to be important in intracellular vesicle trafficking (Takai et a l, 
2001). Rab-14 has been observed in brain, spinal cord, heart, kidney, and lung cells, but 
there do not seem to be any studies of its physiological function nor any reports of 
variant isoforms. In contrast, Rab3A is one of the best studied of the many Rab proteins 
and is known to play a key regulatory role in Ca2+-dependent exocytosis, particularly in 
neurotransmitter release from nerve terminals (Takai et a l, 2 0 0 1 ).
The translationally controlled tumour proteins (TCTPs) are a highly conserved and 
abundantly expressed family of eukaryotic proteins. They are implicated in cell growth 
and the human acute allergic response but their intracellular biochemical function has 
remained elusive. Recently, on the basis of the solution structure of the TCTP from 
Schizosaccharomyces pombe (Thaw et a l, 2001), it has been suggested that the TCTPs 
might form a structural superfamily with the Mss4/Dss4 family of proteins. These latter 
proteins bind to the GDP/GTP free form of Rab proteins and have been termed “guanine 
nucleotide-free chaperones”. The result in this chapter is the first reported experimental 
observation of a possible functional linkage between Rab proteins and TCTP. 
Furthermore, given the role of Rab3A in Ca2+-dependent exocytosis and the fact that the 
TCTPs are also calcium binding proteins (Kim et a l, 2000), it is intriguing that annexin 
IV is also included in this group of kinetically related proteins, albeit with changes in
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new protein synthesis which are the opposite of those observed for Rab3A, Rab-14, and 
TCTP (Fig. 3-4 panel E).
The annexins are a family of calcium and phospholipid binding proteins whose 
physiological functions are poorly understood and for which many diverse functions 
have been proposed, including in vesicle trafficking and as intracellular ion channel 
regulators (Hawkins et a l, 2000). Furthermore, new synthesis of heat shock 70 kDa 
protein 5 parallels that of annexin IV, suggesting that it might be especially important 
for the folding of annexin IV. Finally, Bcl2-related protein A l is a well-known 
antiapoptotic protein (Jaatela, 1999).
It seems likely that this group of proteins is involved in some form of vesicular 
trafficking which, despite the large changes in Rab3A, seems unlikely to be an 
exocytotic process and might be related to the endocytosis and recycling of the ET 
receptor (Bremnes et a l, 2000). However, this group of proteins might also be involved 
in cytoskeletal rearrangements given recent reports that Rab proteins may be involved in 
microtubules (Takai et a l, 2001; Somsel Rodman and Wandinger-Ness, 2000) and that 
TCTP has been reported to bind to microtubules (Gachet et a l, 1999). In addition the 
link between heat shock 70 kDa protein 5, Bcl2-related protein A l and apoptosis 
indicates that the proteins from this group might be important in cell survival 
(Breckenridge et a l., 2003).
A curious feature of the experiments presented in this chapter was that an isoform of 
Rab-14 with a lower Mw (s28, Table 3-1) and very different kinetic behaviour (Fig. 3-4 
panel D) was also observed. The very different kinetic behaviour of the two isoforms of 
Rab 14 presumably reflects the regulation of the response to ET at the level of mRNA
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splicing. The variant form of Rab 14 was grouped kinetically with nucleophosmin (Fig. 
3-4 panel D), which is an abundant, multifunctional nucleolar protein (Table 3-2). 
Nucleophosmin has been reported to have a possible role in the assembly and/or 
transport of ribosomes, molecular chaperone activity and ribonuclease activity 
(Hingorani et al., 2000). Other reports show that nucleophosmin is important in 
centrosome duplication via phosphorylation by cell cycle kinases (Okuda et al., 2000; 
Tokuyama et al., 2001). Cyclin-dependent kinase (CDK) inhibitor IB followed a 
similar expression pattern and is included in this kinetically related group of proteins. 
Up-regulation of this protein negatively regulates cell proliferation (Polyak et al., 1994). 
These results suggest that this group of proteins are not involved in ET’s proliferative 
effects and may have other functions.
The present results also monitor a couple of proteins which are generally connected 
with various aspects of RNA synthesis. These include proteins involved in the 
transcription of rRNA (nucleolar transcription factor 1) or in RNA splicing (splicing 
factor 3b, subunit 2) (Table 3-2). Nucleolar transcription factor 1 (UBF-1) is one of the 
essential components of the initiation complex for RNA polymerase I (Hannan et al., 
1998). For nucleolar transcription factor 1, the following contributes to the regulation 
of rRNA transcription:
• the quantity of this protein (Hannan et al., 1998);
• posttranslational phosphorylation by G1-specific cdk-cyclins (Voit et al., 1999);
• acetylation (Hannan et al., 2000); and
• interactions with the product of the retinoblastoma susceptibility gene Rb 
(Pelletier et al., 2000).
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In these experiments it was observed that the expression of UBF-1 is down-regulated by 
about 40% within 30 mins of ET-1 stimulation and remains suppressed (Fig. 3-4 panel 
F). This would seem to be consistent with reports that this protein is inactive in early 
G1 phase (Klein and Grummt, 1999). Very different behaviour is shown by splicing 
factor 3b, subunit 2. This protein is up-regulated by about 80% 30 mins after 
stimulation with ET-1 followed by a slow decrease to the synthesis levels observed in 
unstimulated cells (Fig. 3-4 panel C). It is particularly interesting that changes in 
synthesis were observed for single proteins that are components of large multiprotein 
complexes, e.g., only subunit 2 of the 4 different proteins comprising splicing factor 3b. 
This seemingly anomalous result might be explained if these proteins have special roles 
in the initiation or localization of such complexes.
40S ribosomal protein SA showed an initial up-regulation of about 80% at 30 mins 
followed by a slow decay to normal synthesis levels (Fig. 3-4 panel B). It is likely that 
this is connected to its alternative role as a laminin binding protein at the cell surface 
(Buto et al., 1998) rather than as a component of the ribosome. The up-regulation of 
this protein is observed in a variety of different types of cancer (Menard et al., 1998). 
The same protein is identified later in this thesis (see Chapter 5, Table 5-1) where it was 
phosphorylated upon ET-1 stimulation of rat fibroblasts. 40S ribosomal protein is 
phosphorylated by S6  kinase, which has been reported to be activated by ET in cardiac 
myocites (Wang et al., 2 0 0 1 ).
The proteins shown in Table 3-1 also include a number of proteins involved in 
cytoskeletal interactions. Cytoskeletal interactions are known to be important in a wide 
variety of cellular processes including signalling systems, cell-cell interactions, and
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mitosis. The up-regulation in some cytoskeletal proteins could suggest that ET induces 
cytoskeletal reorganisation (Gohla et al., 1999).
One of the more unexpected results of the experiments set out in this chapter was the 
observation of the up-regulation of the transcription factor Sox5 (also known as SRY 
(sex determining region Y)-box 5) (Fig. 3-4 panel A). This protein has previously only 
been reported in the context of spermatogenesis with localization in the adult testis 
(Bowles et al., 2000; Wegner, 1999). Although the Sox transcription factors have been 
widely studied, this has usually been in the context of cellular differentiation and 
embryonic development. Among the hundreds of papers on Sox transcription factors, 
only a few deal specifically with Sox5, and there do not seem to be any reports dealing 
with the involvement of Sox5 in response to a signalling process or with the role of 
Sox5 in fibroblasts. Neither is there any evidence suggesting why Sox5 might be 
functionally linked with filamin or plasminogen activator inhibitor 2 (Fig. 3-4 panel A). 
It can be speculated either that Sox5 may have other types of roles or that it is 
particularly important in maintaining the identity of the differentiated human lung 
fibroblasts.
Together with the kinetic groupings, which may reflect functional links, these 
experiments provide a framework for further investigation. A few proteins were 
identified for which either:
• the variant observed seems not to be present in sequence databases (short form 
of Rab-14); or
• the previously discussed functional roles do not give any clear relationship to ET 
stimulation (Sox5); or
• they do not have any known functional role at present (TCTP, Table 3-2).
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All of these are candidates for further investigation.
The proteins which showed changes in new protein synthesis in the experiments 
presented in this chapter were different to those observed in previous studies of ET 
stimulation of: mouse fibroblast cells (Suzuki et al., 1999); astrocytes (Pedram et al., 
1998; Teixeira et al., 2000); and rat mesangial cells (Terada et al., 1998). These earlier 
studies investigated ET’s effects on cell cycle progression and showed strong increases 
of cyclins D1 and D3, cdk4 kinase, pl6INK4, p21cipl, and the phosphorylated form of 
pRb. Changes in the expression of several protooncogenes (c-fos, c-jun, c-myc from 
vascular smooth muscle cells and Egr-1 from cardiomyocites) following ET stimulation 
have also been reported (Reiss et al., 1993; Simonson et al., 1992; Yang et al., 1999; 
Neyses et al., 1991). The difference in proteins observed may be a consequence of the 
different cells but probably also reflects the different time scales of the experimental 
protocols. The previous experiments measured changes in total protein concentrations 
of maximally 2-5-fold following 4-24 h of constant exposure to ET (Reiss et al., 1993; 
Yang et al., 1999; Suzuki et al., 1999; Pedram et al., 1998; Teixeira et al., 2000; Terada 
et al., 1998). This type of experiment measures the adaptation of the cells to long-term 
exposure to ET and therefore may reflect generalized changes consistent with cell 
growth rather than new protein synthesis that is an early consequence of ET stimulation. 
The detection of cellular responses after short time exposures to ET is likely to be more 
informative about the immediate interconnectivities of cellular pathways.
Apart from the 25-fold change in the rates of new protein synthesis for Rab-14 (long) 
observed over the time course of the experiments, all of the other proteins showed 
changes of less than 5-fold and many were less than 2-fold (Fig. 3-4). This seems to be 
consistent with the growing number of expression profiling experiments that typically
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observe limited changes in a large number of mRNAs rather than on/off behaviour for a 
few genes (Miklos and Maleszka, 2001).
3.4 Conclusions
• ET-1 stimulated de novo protein synthesis in human lung fibroblasts within 4 
hours of stimulation.
• The level of protein expression depended on the length of the cell’s exposure to 
ET-1.
• 22 proteins with the biggest patterns of change (ET-1 stimulated/unstimulated) 
were identified amongst which there were at least four functionally distinct 
groups of proteins: cytoskeletal, chaperones, regulatory proteins, enzymes and 
proteins with multiple or not clearly defined functions. This implies that ET 
stimulation results in major changes in cellular function at many levels.
•  Proteins that followed similar temporal patterns of up/down- regulation after 
ET-1 stimulation were grouped together (Fig. 3-4). Such clustering could 
possibly indicate functional correlations between proteins of the same kinetic 
group.
• The results obtained support and further develop the idea of partitioning of 
functional processes downstream of ET receptors (Stannard et al., 2003 a; 
Godovac-Zimmerman and Brown, 2003). The architecture of the signal is likely 
to follow the pattern of parallel activation of different pathways rather than one 
signalling pathway which at a certain point diverges into several different 
branches.
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CHAPTER 4. CHARACTERIZATION OF ET RECEPTORS IN 
NRK-49F CELLS
4.1 Introduction
The two GPCR through which ET acts are ETaR and ET bR. Both ET aR and ETbR are 
widely distributed throughout various cells (Rubanyi and Polokoff, 1994). ETAR is 
predominantly expressed in vascular smooth muscle cells and causes prolonged 
vasoconstriction (Pollock et al., 1995). ETbR is predominantly expressed in endothelial 
cells and causes vasodilation (de Nucci et al.f 1988). In addition it was recently 
suggested that complex interactions between the two ET receptor subtypes in renal 
microcirculation can modulate renal function. ETbR stimulation produced renal 
vasoconstriction but when co-stimulated with ETaR the net effect was vasodilation (Just 
et al., 2004).
The vasoconstrictive effects of ET are mediated through the increase of intracellular 
calcium (Ca2+) levels, initially via IP3 triggered release of Ca2+ from the endoplasmic 
reticulum and later via the influx of extracellular ions through Ca2+-channels (Pollock et 
al., 1995; Iwamuro et al., 1999). In addition to cell contraction, Ca2+ signalling is 
responsible for other biological effects of ET-1 (discussed in Chapter 1) and can be 
described as a marker of the ET induced cell signal.
ET’s mitogenic effect is mediated via the activation of MAPK signalling cascades 
(Simmonson et al., 1992; Cazaubon et al., 1993). All three members of MAPKs (ERK, 
JNK and p38) were reported to take part in ET signalling in different cells and tissues 
(Cazaubon et al., 1993; Clerk et al., 1998; Bogoyevitch et a l, 1995).
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The aim of the experiments presented in this chapter was to establish the suitability of 
NRK-49F cells for studying the signal transduction pathways of ET. NRK cells are an 
immortalized rat kidney cell line often applied in studies of growth factors and cell 
transformation (Lahaye et a l, 1999). In the experiments presented in this chapter 
radioligand binding assays were used to perform an initial screening of several cell lines 
(RMVEC, HeLa and NRK-49F) for the presence of ET receptors. The expression of 
ETa and ETb receptor types was evaluated using selective competitive antagonists. The 
functional activity of the receptors was measured by the ability of a ligand-occupied
9-4-receptor to induce a Ca response and to activate the phosphorylation of various MAP 
kinases in NRK-49F cells. These studies revealed that both ET receptors are present 
and functionally active in rat fibroblasts. ET induced an elevation of calcium and the 
activation of c-Raf-1 as well as the activation of both ERK1/2 and p38MAPK in NRK- 
49F cells. These findings provided a good model system to further study the 
mechanisms of ET-mediated cellular actions.
4.2 Results
4.2.1 Binding studies fo r  testing the expression o f E T receptors
Radio-labelled ligand binding experiments were performed as initial screening studies 
for the presence of ET receptors on three cell lines: RMVEC, NRK-49F and HeLa cells. 
Membranes isolated from these cells were used for competitive binding experiments to 
estimate the binding sites for endothelin. If a radio-labelled ligand is allowed to bind to 
a cell or membrane sample, the binding can be indirectly measured by measuring the 
radioactivity of that sample. In the first stage of the binding studies the membranes 
were incubated with 125I-ET-1 (200pM) alone and the total binding of the radioactive
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ligand to the cell membranes (to both receptors) was determined (ETaR+ETbR, Figs. 4 - 
1, 4-2 and 4-3). To estimate the binding to non-specific sites (NS), the membranes were 
incubated with the radioactive ligand but in the presence of an excess of unlabelled ET- 
1 (lpM ). Specific binding was determined from the difference between the total and 
the non-specific binding. The difference between the total and the non-specific binding 
in RMVEC was statistically insignificant and showed that these cells do not express ET 
receptors (Fig. 4-1). Specific binding in both NRK and HeLa cells was statistically 
significant (Figs. 4-2 and 4-3), indicating the presence of ET receptors in these cells.
To differentiate between ET receptor subtypes (ETA and ET b) specific competitive 
antagonists for ETA and ETb receptors were used. BQ485 was used as an ETAR 
antagonist with IC50 = 3.4 nM for ETAR (Itoh et a l, 1993). To selectively block ETBR, 
the BQ788 antagonist was used, with IC50 = 1.2nM for ETbR (Ishikawa et a l, 1994). 
Membranes were incubated with 125I-ET-1 (200pM) in the presence of lOOnM BQ485 
(NS+ETaR) or lOOnM BQ788 (NS+ETbR). Binding to a specific type of ET receptor 
was determined as follows:
ETaR binding sites = (ETaR+ETbR) -  (NS+ETbR)
ETbR binding sites = (ETAR+ETBR) -  (NS+ETAR)
An unpaired t-test was used to compare the data of total radioactivity binding and 
binding in the presence of selective receptor antagonist. Both NRK-49F and HeLa cells 
express both ETA and ETb receptors (Figs. 4-2 and 4-3). From the results obtained it 
appears that the ETbR type is the predominant species in NRK-49F and HeLa cells.
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Figure 4-1 B in d in g  o f  nsI - E T - l  to R M V E C . M em branes from  R M V E C  w ere incubated  
w ith 125I-ET-1 (200pM ). B ound rad ioactiv ity  w as m easured  in the p resence of: lp M  un labelled  
ET-1 (N S), lOOnm B Q 485 (N S +E T BR), lOOnM B Q 788 (N S + E T A R ) or w ith no com petito r 
(E T aR + E T bR). T he d ifference betw een E T AR + E T BR and  N S rep resen ts the to tal specific 
b ind ing  to  bo th  receptors. T he data show n are the m ean  values o f  n= 3±S E M  excep t for 
E T aR + E T bR group  w here n=4.
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Figure 4-2 B in d in g  o f nsI - E T - l  to N R K -4 9 F  cells. M em branes from  N R K -49F  cells w ere 
incubated w ith l2 5I-E T -l (200pM ). B ound rad ioactiv ity  w as m easured  in the p resence of: lfiM  
unlabelled  ET-1 (N S), lOOnm BQ 485 (N S + E T BR), lOOnM B Q 788 (N S + E T AR) o r w ith  no 
com petito r (E T AR + E T BR). T he d ifference betw een  E T AR + E T BR  and NS represen ts the total 
specific b ind ing  to  bo th  receptors. T otal rad ioactiv ity  added gave a coun t o f  16,900 cpm . T he 
data show n are the  m ean values o f  n=3±SEM  except for E T AR + E T BR and NS groups w here 
n=4. *, p<0.05; ***, p<0.0001.
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Figure 4-3 B in d in g  o f  I25I-E T -1  to H eL a  cells. M em branes from  H eL a ce lls  w ere 
incubated  w ith 125I-ET-1 (200pM ). B ound rad ioactiv ity  w as m easured  in the  p resence of: lp M  
un labelled  ET-1 (N S), lOOnm BQ 485 (N S +E T BR), lOOnM B Q 788 (N S + E T AR ) or w ith no 
com petito r (E T AR + E T BR). T he d ifference betw een  E T AR + E T BR and  NS rep resen ts the to tal 
specific b ind ing  to both  receptors. T he data show n are the m ean  values o f  n=3±S E M . *, 
p<0.05; * * * ,p< 0 .0001 .
1 0 2
Chapter 4
4.2.2 Characterization of functional activity of ET receptors -  signal transduction
4.2.2.1 Ca2+flux studies
One of the most common methods that ET uses to transmit the signal into the cell is by 
raising the level of intracellular calcium. To determine whether NRK cells were a good 
model system for studying ET-receptor signal transduction Fluorometric Imaging Plate 
Reader (FLIPR) calcium assays were conducted. The experiments were based on 
measuring the changes in Ca2+ levels after stimulating the cells with endothelin. In the 
experiments PBS and Big-ET (lpM ) were used as negative controls (no rise in 
intracellular Ca2+). Big-ET is the functionally inactive precursor of ET (Xu et al., 1994). 
A positive control, ATP was also used.
Confluent quiescent cells were loaded with Fluo-4, a cell permeable calcium indicator 
dye (Excitation = 488 nm, Emission = 520 nm) before being stimulated. The cells were 
stimulated at a time point of 30 seconds, and fluorescence was measured every 2 
seconds for the first 5 mins and then every 5 seconds for the next 10 mins. All 
measurements were repeated six times. The results of this study revealed increases in 
intracellular calcium in response to ET-1 (Fig. 4-4). In figure 4-4 panel A shows the 
effect of increasing concentrations of ET-1 on the intracellular Ca2+ signal. ET-1 was 
administered to the cells in three different concentrations: lOnM, lOOnM and lpM. A 
lOnM concentration of ET-1 was not enough to induce a strong Ca2+ signal, although 
there was a slight rise (panel A, Fig. 4-4,). lOOnM and lpM  ET-1 produced a Ca2+
9 4 -response that saturated very quickly. The Ca signal started 6 seconds after the cells 
were stimulated and peaked after 25 seconds. After this time the Ca2+ level gradually 
went back to normal and reached the baseline 4 mins after the stimulation started.
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Figure 4-4 (cont’d) Ca2+ response in N R K  cells to the  application o f  ET-1. (A) A
fluorescent imaging plate reader (FLIPR) assay m easuring intracellular levels o f C a2+ was used 
to detect responsiveness of fluo-4 loaded N RK  cells to ET-1. PBS and Big-ET were used as 
controls. (B) Ca2+level was m easured in the presence o f ETB receptor antagonist, BQ 788 or, (C) 
in the presence o f ETA receptor antagonist, BQ485, after the induction o f cells w ith increasing 
concentrations o f ET-1. (D) ATP was used as a positive control for the assay. D ata are the 
average of n = 6  ±  SEM. M easurem ents were carried out with the help o f  M r S. Ranasinghe 
(Dept, o f Physiology, UCL).
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In panel B of the same figure the same effect as in panel A was monitored but this time 
in the presence of a constant concentration of BQ788 (lOOnM). As BQ788 selectively 
binds to the ETB receptor and chemically modifies it with no agonist activity (Ishikawa 
et a l, 1994), the remainder of the Ca2+ signal would result from the activity of the ETa 
receptor. As seen from the graph (Fig. 4-4 panel B) lOnM ET-1 did not induce a Ca2+ 
response, but lOOnM and lpM did induce a response. Data from this experiment were 
compared to the corresponding data from panel A using a paired t-test. A statistically 
significant difference was found (p<0.0001) suggesting that although the signal exists 
when ETbR is blocked, it is somewhat lower in intensity than without the antagonist. 
When ETa receptor was blocked with lOOnM BQ485, the administration of ET-1 
(lOnM and lOOnM) did not cause a rise in intracellular Ca2+ (Fig. 4-4 panel C). The 
highest concentration of ET-1 (lpM ) was able to induce a Ca2+ signal in the presence of 
ETaR antagonist, but the start of the signal was much slower: it started 1 min after the 
addition of ET-1. In addition, the intensity of the Ca signal was significantly lower 
(p<0.0001) when compared to the signal intensity induced by lpM ET-1 in the absence 
of antagonists (Fig. 4-4 panel A).
42.2.2 Activation o f MAP kinase cascades in NRK-49F cells induced by ET-1
It has been suggested that the MAPK pathway is involved in the mitogenic activity of 
endothelins (Cazaubon et al., 1993; Simonson et al., 1992)). To assess whether MAPK 
signalling pathways are activated by ET in NRK-49F cells, antibodies which recognise 
the phosphorylated form of several members of the MAPK signalling pathway family 
were used. Changes in phosphorylation over time for p42/44 MAPK, ERK1/ERK2 
(p38MAPK) and c-Raf 1 were followed not only in the whole cell extracts but also in 
the Immobilized Metal Ion Affinity Chromatography (IMAC) - enriched
106
Chapter 4
phosphoprotein fractions (Figs. 4-5, 4-6 and 4-7). ET-1 (lOOnM) stimulated extensive 
phosphorylation of both ERK1/ERK2 (Fig. 4-5) and p38MAPK (Fig. 4-6). The 
activation of these kinases was rapid and peaked within 2 mins for ERK1/ERK2 and 
within 5 mins for p38MAPK. Phosphorylation of both MAP kinases remained above 
basal levels at 20 mins.
ET-1 stimulated phosphorylation of JNK was also analyzed with the phospho-SAPK 
(stress activated protein kinase)/JNK antibody. This antibody detects endogenous levels 
of p46 and p54 SAPK/JNK dually phosphorylated at threonine 183 and tyrosine 185. 
No changes in phosphorylation were observed for SAPK/JNK in either total cell extract 
or phosphoprotein enriched extract.
The effect of ET-induced phosphorylation on Raf was also observed (Fig. 4-7). Again 
the activation of this protein happened within 5 mins of inducing the activation of the 
receptors. Phosphorylation of Raf was observed only in the enriched phosphoprotein 
fraction. In the total cell extract the phosphorylation of this protein could not be 
detected.
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Figure 4-5 Effect of ET-1 on the phosphorylation of ERK1/ERK2.
Q uiescen t N R K  cells w ere treated  w ith or w ithout ET-1 (lOOnM ) for the ind icated  period  o f 
tim e. P roteins w ere separated  on SD S-PA G E either im m edia te ly  afte r cell d isrup tion , or after 
the purifica tion  o f phosphopro teins using IM AC. G el separated  p ro teins w ere transferred  on to  a 
n itrocellu lose m em brane and incubated w ith e ither a n ti-E R K l/E R K 2  or antiphospho- 
E R K 1/E R K 2 antibodies. A fter the incubation  w ith the  p rim ary  an tibody  m em branes w ere 
incubated  w ith secondary  anti rabbit antibody and p ro tein  bands w ere detec ted  w ith a 
chem ilum inescence detection kit. T he im ages are the rep resen ta tive  im ages o f  th ree individual 
experim ents.
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Figure 4-6 Effect of ET-1 on the phosphorylation of p38MAPK.
Q uiescen t N R K  cells w ere treated  w ith or w ithout ET-1 (lO OnM ) fo r the ind icated  period  o f  
tim e. P roteins w ere separated  on SD S-PA G E either im m edia te ly  afte r cell d isrup tion , o r after 
the purification  o f  phosphopro teins using IM A C. G el separated  p ro te ins w ere transferred  onto  a 
n itrocellu lose m em brane and incubated w ith either an ti-p38  M A P  K inase or an ti-phospho-p38  
M A P K inase antibodies. A fter the incubation  w ith the p rim ary  an tibody  the m em branes w ere 
incubated  w ith secondary  anti-rabbit antibody and  p ro tein  bands w ere detec ted  w ith  a  
chem ilum inescence detection kit. T he im ages are the rep resen ta tive  im ages o f  th ree ind iv idual 
experim ents.
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Figure 4-7 Effect of ET-1 on the phosphorylation of Raf
Q uiescen t N R K  cells w ere treated  w ith or w ithout ET-1 (lOOnM ) fo r the ind icated  period  o f  
tim e. P ro te ins w ere separated  on SD S-PA G E after the pu rifica tion  o f  phosphopro te ins using 
IM A C  and  transferred  onto n itrocellu lose m em branes. M em branes w ere incubated  w ith  anti 
phospho -R af antibody and subsequently  w ith secondary  an ti-rabb it antibody. S ignals w ere 
detected  using alkaline phosphatase detection.
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4.3 Discussion
4.3.1 Binding studies for testing the expression o fE T receptors
In mammalian tissues two types of ET receptors have been found and cloned so far: 
ETaR and ETbR (Haendler et al., 1992) and these are widely distributed throughout 
different cells and tissues. There has been speculation about the existence of other sub- 
types of ETaR and ETbR (Endoh et al., 1998; Gellai et al., 1996) but to date the 
experimental data supporting these findings have only been of a pharmacological 
nature.
ETa and ETb receptors can be present in any given tissue together or alone. Initial 
binding experiments were carried out in order to find a model cell system for the study 
of the ET receptor signalling pathways. RMVEC, NRK-49F and HeLa cell lines were 
tested for the presence of the receptors for ET using radioactively labelled 125I-ET-1. 
Total radioligand binding was measured first. After this, the radiolabelled ligand was 
displaced by the cold ligand and whatever radioactivity was left over after the 
displacement was attributed to non-specific binding. The difference between total and 
non-specific binding provides the specific binding to ET receptors. RMVEC cells did 
not show a significant difference between the total bound radioactivity and the non­
specific binding (Fig. 4-1). These results suggest that these cells do not express ET 
receptors. In both NRK-49F and HeLa cells the difference between the total and the 
non-specific binding was significant (***, p<0.0001) indicating the presence of ET 
receptors (Figs. 4-2 and 4-3). To test whether both receptor types were present in NRK- 
49F and HeLa cells, antagonists that specifically block the receptor subtypes were used. 
The results from these experiments showed that both ETAR and ETbR are present in
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both cell lines (Figs. 4-2 and 4-3). A statistical evaluation of these results indicated that 
the ETbR is the predominant receptor type in both NRK-49F cells and HeLa cells 
(p<0.0001). Earlier binding studies of different endothelins indicated the majority of 
ET receptors in NRK-49F to be of the ETAR type (Yumet et a l, 1995). However, 
binding studies made by others showed that 125I-ET-1 binding was displaced by 
unlabelled ET-2 in a similar dose response indicating the presence of both ETAR and 
ETbR in NRK-49F cells (Kusuhara et a l, 1992). In addition, results from our 
laboratory confirmed the presence of both ETAR and ETBR in NRK-49F using specific 
ET receptor antibodies (see Posters and Publications). The identity of the proteins 
recognised as ETAR and ETbR, and the specificity of the corresponding antibodies were 
further proved by MALDI-TOF MS.
Reports regarding the expression of ET receptors on HeLa cells are different. Karne et 
a l, (1993) reported that binding studies on HeLa cells showed no presence of ET 
receptors. Binding experiments by another group showed that both ET receptors are 
present in HeLa cells with ETAR being the predominant type (Drimal et a l, 2000). 
Takahashi et al, (2002) demonstrated weak mRNA expression of both ET receptors in 
HeLa cells.
The recent production of several specific ETAR and ETbR antibodies has facilitated the 
study of ET receptors by allowing the use of Western Blot and immunoprecipitation 
techniques. These techniques will allow a more direct quantification of receptors in 
different cell types and in cells exposed to different stimuli than techniques based solely 
on binding assays.
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4.3.2.1 Ca2+flux studies
It is known that ET-1 starts its signal in the cell after binding to the G protein-coupled 
receptor, which in turn activates G proteins of the Gq/n , G12/13 and Gj families (Aramori 
et al., 1992; Takigawa et al., 1995). ET receptors have been associated with different G 
proteins depending on the cell type where they are expressed. The most common feature 
of the ET signalling cascade is its ability to increase the levels of intracellular calcium. 
ET-1 does so through the activation of PLC (see Chapter 1), which hydrolyses PIP2 to 
IP3 and DAG (Pollock et a l, 1995). IP3 binds to specific receptor ion channels on the 
membrane of the endoplasmic reticulum and initiates the release of the Ca2+ stored in 
this organelle. Both types of ET receptors were shown to be able to elevate Ca2+ levels 
in the cell upon binding of the ligand (Touyz et al., 1995; Hyvelin et al., 1998).
In order to test the responsiveness of NRK-49F cells to ET-1, measurements of the level 
of intracellular calcium were carried out after stimulating the cells with ET. These 
experiments were performed using FLIPR. The cells were first pre-loaded with a Fluo- 
4 calcium indicator dye and were then treated with different agonists or antagonists.
94 -The dye indicates the change in Ca concentration via its fluorescent spectral change 
upon binding to Ca2+ (Minta et al., 1989). PBS and Big-ET were used as controls.
The Ca2+ signal was monitored after treating the cells with three different concentrations 
of ET-1: lOnM, lOOnM and lpM. The lowest concentration of ET-1, lOnM was not 
able to give a strong Ca2+ signal, but higher concentrations succeeded in elevating the 
level of intracellular calcium to a maximum after 6 seconds (Fig. 4-4, panel A). The
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intensity of the signal peaked 25 seconds after stimulation and then gradually reached 
basal level after approximately 5 mins. These results agree with previous data reporting 
that ET-1 induces PLC and therefore the increase in Ca2+ in NRK cells (Lahaye et al., 
1999; Kusuhara et al., 1992).
ETa and ETb receptor antagonists were then used to see which of these two receptor
9 -4-subtypes generates the Ca signal in NRK-49F cells. As seen in panel B of Fig. 4-4, 
the ETa receptor was able to stimulate the calcium response in a similar fashion to that 
displayed when no receptor antagonists were present. However, the signal induced by 
ETaR alone (panel B) is lower in intensity (p<0.0001) than the full Ca2+ signal (panel 
A).
ETb receptor alone was not able to induce the Ca2+ signal (Fig. 4-4, panel C). There are 
several possible explanations for these results. One explanation could be that the 
downstream signalling of the ETb receptor is not coupled to the signalling of Ca2+ in 
this type of cell. l|i.M concentration of ET-1 was able to induce a small and slow 
calcium response when the ETA receptor was blocked. However, this could result from 
the fact that in such large quantities ET is able to push the antagonist out of the receptor 
and thereby induce a signal through the ETa receptor. A second explanation is that the 
ETa and ETb receptors function together to give a full rise in intracellular calcium. 
Recently demonstrated constitutive or ligand induced oligomerization of several GPCRs 
(Pagano et al., 2001; Terillon et al., 2004; Balasubramanian et al., 2004; Guo et al., 
2003) has also led to the discovery that ET receptors can form both hetero- (ETaR- 
ETbR) and homodimers (ETaR-ETaR and ETbR-ETbR ) that are constitutively 
expressed (Gregan et al., 2004 a, b). Perhaps the heterodimerization of ET receptors is 
necessary for enhanced signalling in certain cases like the one described in this chapter.
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In summary the results of the calcium measurement experiments showed that both 
receptors together activate a strong signal that mobilizes the intracellular pools of 
calcium in NRK-49F cells and that the ETa receptor alone is capable of inducing a 
calcium response in these cells.
4.3.2.2 Effects of ET-1 on MAP kinase cascades in NRK-49F cells
The role of ET in activating the three MAPK cascades has been studied extensively in a 
variety of cells (Simonson et al., 1992; Cazaubon et al., 1993; Clerk et al., 1998). It has 
also been shown that ET-1 has cell proliferative effects in NRK-49F cells (Yeh et al., 
1991). The results presented in this chapter showed that ET-1 activates two MAP 
kinases: ERK1/ERK2 and p38MAPK (Figs. 4-5 and 4-6) in NRK-49F cells. ET-1 
induced phosphorylation of ERK1/ERK2 happened within the first 2 mins of cell 
stimulation (Fig. 4-5). This effect decreased later (15 mins) but was still present even 
after 30 mins. Phosphorylation of Raf was also observed (Fig. 4-7) after 5 mins of cell 
stimulation with ET-1. This result is expected, as Raf is upstream of ERK1/ERK2 in 
this signalling cascade. ET-1 could activate the c-Raf/ERK cascade in NRK-49F cells 
via several distinct mechanisms:
• by Gq activation of PKC (via PLC) (Kolch et al., 1993);
• by activation of Ras (via G(3y subunit) (Herman and Simonson 1995); or
• by arrestin induced mobilization of Src to the GPCR, which in turn could trigger 
the signal leading to ERK (Luttrel et al., 1999; Hall et al., 1999).
It is also possible that the activation of the ERK1/ERK2 pathway occurs as a result of 
the transactivation of the EGF receptor as has been demonstrated in previous reports 
(Daub et al., 1996; Hua et al., 2003). In this way ET receptors borrow the signalling
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molecules from the tyrosine kinase receptor cascade to fulfil their mitogenic function. 
This kind of connection seems very probable when considering results from other 
groups showing that ET-1 stimulation increased the number of EGF receptors in the 
membranes of NRK cells (Kusuhara et a l, 1992; Yeh et al., 1991). In addition, ET-1 
induced anchorage-independent growth of NRK cells which was regulated by EGF 
(Yumet et al., 1995; Lahaye et a l, 1999).
Similarly to ERK1/ERK2, ET-1 influenced the phosphorylation states of p38MAPK 
(Fig. 4-6). p38MAPK was activated within the first 2 mins of cell stimulation. A 
second wave of phosphorylation was not observed for this enzyme over the studied 
period of time. Although it has been shown that ET-1 can induce the p38MAPK 
pathway (Clerk et a l, 1998), the exact mechanism of this activation is still not fully 
understood.
The phosphorylation of JNK was also analyzed within the same time period of ET-1 
stimulation in both whole cell extracts and enriched phosphoproteins. No changes were 
detected with the antibody used (phospho SAPK/JNK antibody from Cell Signaling 
Technology).
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4.4 Conclusions
• NRK-49F cells express both ETA and ETb receptors (ETb>ETa);
• ET-1 induced the rise of intracellular calcium predominantly through the 
activation of the ETA receptor in NRK-49F cells;
• ET-1 stimulated the activation of the Raf/ERK cascade; and
• ET-1 stimulated the activation of p38MAPK.
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CHAPTER 5. ET-1 INDUCED PHOSPHORYLATION CHANGES 
IN THE PROTEOME OF NRK-49F CELLS
5.1 Introduction
The binding of ET to ETAR and ETbR leads to the activation of G proteins (of the Gq/n 
and G12/13 families) which is followed by the activation of a variety of downstream 
effectors (Clerk et a l, 1998). Amongst the induced kinase cascades are members of the 
MAPKs, PKC and Tyr kinase signalling pathways (Cazaubon et al., 1993; Clerk et al., 
1998; Yamauchi et al., 2002). The activation of these pathways transmits E T -l’s signal 
to the nucleus where the transcription of protooncogenes is initiated. This results in cell 
growth and mitogenesis (Nelson et al., 2003).
In NRK cells ET-1 has transforming and proliferative activity (Kusuhara et al., 1992; 
Yeh et al., 1991). In these cells the binding of ET-1 to ETAR results in the mobilization 
of intracellular calcium and induces a rapid onset of second messenger production (Yeh 
et a l, 1991; Lahaye et al., 1999). In addition to this, ETAR activation was followed by 
the transcription of early response genes c-jun, jun B, and c-fos (Yumet et a l, 1995). 
ET-1 stimulated anchorage-independent cell growth and complemented the growth 
factor induced DNA-replication and Gl/S-phase transition in NRK cells (Kusuhara et 
al., 1992; Yeh et a l, 1991; Yumet et a l, 1995). In addition to this, ET-1 induced the 
up-regulation of EGF receptors in these cells (Yeh et a l, 1991; Yumet et a l, 1995).
With growing recognition of the importance of the role of ET-1 in tumour progression, 
a detailed understanding of the signal transduction pathways which influence the
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malignant transformation of cells is of considerable interest and NRK cells provide an 
excellent study-model.
Protein phosphorylation is important for the regulation of the activity of proteins in a 
wide variety of cellular functions including signal transduction, metabolism and 
apoptosis (Pawson and Nash, 2003; Hunter, 1995). One third of the proteins expressed 
in mammalian cells are phosphorylated at serine, threonine and, less commonly, 
tyrosine residues (Krebs, 1994). Phosphoproteins separated on gels can be followed by:
• Radiography after 32P radiolabelling (Kang et al., 1997; Immler et al., 1998);
• Immunostaining with phospho-specific antibodies (Stannard et al., 2003 b; Steen 
et a l ,  2002; Soskic et al., 1999 a); and
• Fluorescent phosphoprotein dyes (Ge et al., 2004; Schulenberg et al., 2004; 
Patton, 2002).
In addition to the above methods, immobilised metal-ion affinity chromatography 
(IMAC) is one of the most efficient approaches for the extraction and enrichment of 
phosphopeptides. The oxygen atoms in the phosphorylated side chains of serine, 
threonine and tyrosine, as well as carboxylic acids, show a high affinity for hard metal 
ions such as Fe(III) and this has been exploited to isolate phosphopeptides under acidic 
conditions (Chaga, 2001). Substantial progress has been made with this approach and 
its application as a reliable method for the analysis of phosphorylated peptides by mass 
spectrometry (Neville et al., 1997; Jin et al., 2004; Liu et al., 2004; Nuhse et al., 2003).
In an attempt to gain an insight into the regulatory mechanisms of ET signal 
transduction pathways the global effect of ET-1 on the phosphoproteome of NRK-49F 
cells was analysed. The qualitative, quantitative, and kinetic changes in the
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phosphorylation states of the proteins were assessed in the enriched phosphoproteome 
of rat kidney fibroblasts following brief stimulation with ET-1. Enrichment was 
achieved by a Fe3+ coupled IMAC methodology developed in our laboratory. The 
results presented in this chapter show that ET-1 modifies the phosphorylation status of 
different protein groups. This indicates that the mechanisms ET-1 uses to propagate its 
signal in NRK cells involve regulatory proteins and enzymes and that the mechanisms 
include gene expression, the modulation of the cytoskeleton and molecular chaperones 
and energy metabolism.
5.2 Results
5.2.1 Two-dimensional phosphoproteome maps of NRK-49F cells
To detect rapid changes in phosphorylation states of proteins, synchronized NRK-49F 
cells were stimulated for 2 and 4 mins with ET-1. The phosphoprotein fraction was 
selectively purified from the whole cell lysate by IMAC complexed with Fe3+. The 
obtained phosphoproteins were then separated according to their differential pi values 
on a 13 cm IPG strip (150pg/strip, pH range 4-7). After the separation in the first 
dimension, the strips containing proteins were loaded onto the second dimension, SDS- 
PAGE, which allowed additional separation according to molecular weight. The 
phosphoprotein 2D maps of NRK-49F cells were detected by staining the gels with 
silver (Fig. 5-1). Approximately 600 protein spots on a single gel were reproducibly 
detected after silver staining.
The phosphoproteome maps showed reduced complexity of pattern compared to the 
protein pattern observed on 2D maps of total cell-proteomes. The map is also unique in
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the sense that it contains only the phosphoproteins, making their detection much 
simpler. To assess the changes in differential phosphorylation states of proteins 
between the unstimulated and stimulated cells, gel images were analysed with Melanie 
III software. As the experiment was performed in triplicate, the software created a so 
called “synthetic gel” that represented the average gel out of triplicate sets of gels for 
each experimental condition (unstimulated and stimulated cells). A comparison of 
intensities was then performed between these average “synthetic” gels obtained from 
unstimulated and ET-1-stimulated NRK cells. For each spot, normalized volumes (the 
volume of the spot divided by the total volume over the whole gel, where the volume of 
the spot represents the integration of the optical density of the spot over the spot’s area) 
were calculated for each of the experimental conditions. From the results of the 
quantification analysis of the spots in the gels in Fig. 5-1, a number of quantitative 
changes in the intensity of the phosphoproteins were observed (see Fig. 5-2 and Fig. 5-3 
for examples of enlarged gel-sections and Fig. 5-4 for kinetic diagrams of 
phosphorylation changes).
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Figure 5-1 Quantitative changes in the total phosphoproteome ofNRK-49F cells after stimulation with ET-1.
Q uiescent N R K -49F  cells w ere treated  w ith ET-1 (lOOnM ) fo r 0, 2 and 4 m ins. A fter cell lysis the phosphopro tein  fraction w as enriched using an IM A C colum n 
and w as separated by  2D  PAG E. P rotein  spots w ere detected  w ith silver staining. Spot in tensities w ere analysed in M elan ie softw are for quantitative changes. The 
proteins that w ere identified  w ith  M A L D I-T O F  peptide fingerprin ting  are labelled on the gels. Spot iden tification  num bers correspond  to T able 5-1. E nlarged parts 
o f  the gels are illustrated  in F ig. 5-2 and Fig. 5-3. T he gels show n are representative o f  a single experim ent repeated  three tim es.
1 2 2
Chapter 5
2  m in
iM w( k D a ) 0  m in
6 0  —
5 0  —
s 12 s l O '
5 3
M w
( k D a ) 4  m in
6 0  —
5 0  —
5 3
si Protein disulfide isomerase chain 1
s8-s11 Actin
sl2 40s ribosomal protein
sl8 Mixture of vimentin and tubulin
sl9 Vimentin
s22 Enolase 2, gamma
Figure 5-2 Quantitative changes o f protein phosphorylation in NRK-49F stimulated with 
ET-1. Enlarged parts of the gels shown in Fig. 5-1 are illustrated.
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Spots that showed >20% change between at least two of three experimental conditions 
(untreated cells and cells treated for 2 and 4 mins with ET-1) were selected for analysis 
by mass spectrometry. Approximately 30 spots that satisfied these criteria were cut out 
and digested with trypsin. The resulting peptide mixture was analysed by a MALDI- 
TOF mass spectrometer. The peptide mass spectra analysed with Bruker Data Analysis 
software were searched in sequence databases and 25 proteins were identified (Table 5- 
1). 8 of the identified proteins were folding accessory proteins, with the remaining 17 
belonging to various functional groups, including cytoskeletal proteins (7), metabolic 
enzymes (4) and regulatory proteins/enzymes (4). The majority of the proteins were 
endoplasmic reticulum and cytoplasmic proteins, but a nuclear (interferon regulatory 
factor 1) and an integral plasma membrane (calcium-transporting ATP-ase) protein 
were also identified.
It is also noteworthy that some of the proteins were found in several protein spots. It is 
a characteristic of differentially phosphorylated protein isoforms to form a train-like 
pattern on a two-dimensional gel separation. Indeed, a number of these phosphoprotein 
isoforms showed a different change in intensity compared to the other isoforms of the 
same protein at different experimental conditions (Fig. 5-1 spots si and s8).
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Spot Gene1 Protein Gi2 Accession3 Closest ref,4 Mw theo. Mw5 pi theo. Pi6 No. of pept7 % coverage8 Source9 Comments10 Score11
1. Cytoskeletal proteins
s8 Actb beta-actin 13592133 NP_112406.1 42 48 5.3 5.3 7 20 Rat 76
s8a Actb beta-actin 13592133 NP_112406.1 42 50 5.3 5.2 10 31 Rat 138
s9 Actb beta-actin 13592133 NP_112406.1 42 50 5.2 5.3 13 42 Rat 105
slO Actb put. beta-actin 
(aa 27-375)
49868 CAA27396.1 34856512;
13592133
39 47 5.8 5.5 14 40 Mouse Rat; cytoplasmic 
P-actin
86
s l l  Actg gamma-actin 809561 CAA31455.1 34856512;
13592133
52 48 5.6 5.5 13 45 Mouse Rat; cytoplasmic 
p-actin
103
si 8 Vim vimentin 14389299 NP_112402.1 54 60 5.1 4.8 28 32 Rat mixture 102
Tubal alpha-tubulin 11560133 NP_071634.1 51 60 4.9 4.8 15 46 Rat 71
sl9  Vim vimentin 14389299 NP_112402.1 54 57 5.1 5.0 27 30 Rat 282
2. Enzymes
sl5 Enol Enolase-1, alpha 6978809 NP_036686.1 47 52 5.8 6.2 9 26 Rat 70
sl6  Enol Enolase-1, alpha 6978809 NP_036686.1 47 52 5.8 6.4 12 32 Rat 88
sl7  Enol Enolase-1, alpha 6978809 NP_036686.1 47 52 5.8 6.5 14 38 Rat 113
s22 Eno2 enolase 2, gamma 26023949 NP_647541.1 47 50 5 5.2 14 39 Rat 135
Table 5-1 List of phosphoproteins from NRK-49F cells modified by ET-1 and identified by mass spectrometry. (Continued overleaf)
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Spot Gene1 Protein Gi2 Accession3 Closest ref.4 Mw theo. Mw5 pi theo. Pi6 No. of pept.7 % coverage8 Source9 Comments10 Score11
3. Folding accessory proteins
si P4hb Protein disulfide 
isomerase chain 1
202549 AAA40620.1 55 57 4.9 4.8 11 28 Rat 69
s2 HSPA5 78 kDa glucose-regulated 
protein precursor
25742763 NP_037215.1 72.5 70.5 5 4.9 19 33 Rat 174
s3 HSPA5 78 kDa glucose-regulated 
protein precursor
87528 A29821 25742763 72.2 70.5 5 5 23 39 Human Rat
(97%)
130
s4a FkbplO Similar to 65kDa FK506 
binding protein
34873708 XP_340902.1 6806907 65 46 5.4 5.2 12 29 Rat Mouse;
glycosylated
85
s4 HSPA8 Heat shock cognate 
71 kDa protein
123647 PI9378 13242237 71 75 5.2 5.3 12 31 Hamsterr Rat
(99%)
157
s5 HSPA8 Heat shock cognate 
71 kDa protein
13242237 NP_077327.1 71 75 5.4 5.4 27 50 Rat 70
s7 GRP58 ER-60 protease 8393322 NP_059015.1 57 60 5.8 6 15 30 Rat 141
s7a GRP58 ER-60 protease 8393322 NP_059015.1 57 60 5.8 5.9 20 42 Rat 145
s20 P4hal Prolyl 4-hydroxylase 
alpha-1 subunit
51036657 NP_742059.2 61 65 5.6 5.9 6 14 Rat 92
s21 P4hal Prolyl 4-hydroxylase 
alpha-1 subunit
33859596 NP_035160.1 25453386 61 65 5.6 6 16 33 Mouse Rat
(96%)
126
Table 5-1 (cont’d) List of phosphoproteins from NRK-49F cells modified by ET-1 and identified by mass spectrometry. (Continued overleaf)
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Spot Gene1 Protein Accession3 Closest ref.4 Mw theo. Mw5 pi theo. pF No. of pept.7 % coverage8 Source9 Comments10 Score11
4. Regulatory proteins/enzymes
s6 ARHGDIA RhoGDI-1 21759130 Q99PT1 34875656 24 21 5.1 5 9 50 Mouse Rat 93
si 2 LAMR1 40S Ribosomal protein 
SA (P40)
730681 P38983 33 40 4.8 4.8 8 36 Rat 67
sl3  IRF1 Interferon 
regulatory factor 1 
(IRF-1)
124902 P23570 37 38 5.1 6 10 23 Rat 78
s14 ATP2B2 Plasma membrane 
calcium transporting 
ATP-ase (PMCA2)
14286100 PI 1506 132.5 120 5.7 6 27 25 Rat 85
Table 5-1 (cont’d) List of phosphoproteins from NRK-49F cells modified by ET-1 and identified by mass spectrometry. 1. Name of the gene coding for the 
identified protein; 2. the NCBI sequence identifier; 3. accession number of the database record followed by a dot and a version number; 4. the Gi of the homologous 
rat/mouse sequence in cases where database search output retreived sequences from organisms other than rat (see also 12), or in case where the difference in the 
observed and predicted Mw is too large; 5. Mw estimated from SDS-PAGE; 6. pi estimated from SDS-PAGE; 7. number of MS identified peptides in the database 
search; 8. percentage of protein sequence covered by the identified peptides; 9. organism species that the Gi sequence was retrieved from; 10. sequence homology to 
rat/mouse genome, percentage of homology is indicated where less than 99%; if homology is high, the explanation for the difference in observed mass is given 
where known; 11. the probability based Mowse score taken from Mascot; in Profound search all identified proteins had a P value 1.0e+00 and Est’d Z values were 
between 1.06 and 2.39.
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5.2.2 Phosphorylation kinetics
Phosphorylation of 60% of the proteins identified (15 of 25) was increased after 
treatment with ET-1 (Fig. 5-4) for a brief period of time (0-4 mins). Phosphorylation 
levels of the proteins were examined at time points 2 mins and 4 mins. However, some 
of these increases were transient, with an increase observed after 2 mins of stimulation, 
followed by a return to the phosphorylation level in unstimulated cells at 4 mins (Fig. 5- 
4). 9 of the identified proteins showed an increase in phosphorylation after 4 mins of 
treatment with ET-1 (Fig. 5-4, panels A, B, C, F and H). The rest of the identified 
proteins underwent dephosphorylation after treatment with ET-1. Some of these 
phosphoproteins displayed a biphasic phosphorylation decrease, with an initial 2 mins 
decrease followed by either a return to the level of phosphorylation in the unstimulated 
cells by the 4th minute (Fig. 5-4, sl7) or a further decrease after 4 mins (Fig 5-4, panels 
C, D, F, G and H).
Observation of the kinetic behaviour of cytoskeletal proteins (s8, s8a, s9, slO and si 1) 
revealed that all actin phosphoprotein isoforms are rapidly phosphorylated after 2 mins 
of ET-1 stimulation (Fig. 5-4 panel E). The other cytoskeletal protein, vimentin, 
showed different isoform behaviour. While one of the phospho-isoforms of vimentin 
( s i8) underwent a brief dephosphorylation before returning to the control level after 4 
mins of ET-1 treatment, the other phosphoisoform ( s i9) was further dephosphorylated 
after 4 mins (Fig. 5-4 panel G). This result is not however conclusive, as s l9  was 
identified as a mixture of vimentin and tubulin, so the different phosphokinetic 
behaviour observed could result from either of the proteins.
129
Chapter 5
Folding accessory proteins (78 kDa glucose regulated protein (GRP78), FK506 binding 
protein 10, heat shock cognate 71 kDa protein (Hsc70), protein disulfide isomerase 
(PDI) and ER-60 protease) as a functional group, show variable changes in 
phosphokinetic behaviour, between themselves. In addition changes in the level of 
phosphorylation were observed between phosphoisoforms of a single folding accessory 
protein. The level of phosphorylation increases for all of them after ET-1 treatment, 
apart from FK506 binding protein 10, which is dephosphorylated (Fig. 5-4, panel H, 
s4a). GRP78 is present in the gel with five different phosphoisoforms (Fig 5-3) three of 
which were identified by MALDI-TOF MS (s2, s3 and s3a). s3 and s3a both undergo 
phosphorylation after ET-1 treatment, but the phosphorylation of s3a is transient 
returning to control-level after 4 mins (Fig. 5-4 panel B). The s2 phosphoisoform of 
GRP78 decreases in phosphorylation by approximately 1.4 times in relation to the 
control. ER-60 protease was identified in its two phosphoisoforms (s7 and s7a), with s7 
transiently increasing in phosphorylation and s7a steadily decreasing (Fig. 5-4 panel D). 
Hsc70 phosphoisoforms (s4 and s5) also show opposite phosphokinetic behaviour (Fig. 
5-4 panel C).
Two isoenzymes of enolase were also identified, enolase alpha and enolase gamma 
(Table 5-1). The presence of gamma enolase has been previously reported only in 
nervous tissues. Two phosphoisoforms of alpha izoenzyme (s i6 and s i7) decrease in 
phosphorylation after 2 mins, while sl5  increases after 2 mins (Fig. 5-4 panel F).
Regulatory proteins, IRF-1 and RhoGDI, were also identified. The phosphorylation of 
RhoGDI is increased after 4 mins of ET-treatment, whereas IRF-1 undergoes 
dephosphorylation. The phosphorylation of plasma membrane-associated calcium- 
transporting ATPase was also found to increase after 2 mins of ET-1 treatment (Fig. 5-4
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panel H, sl4) as well as the 40s ribosomal protein ( s i2). This protein was present in the 
gel in several phosphoisoforms (Fig. 5-2) which were not identified in the experiments 
discussed in this thesis.
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5.3 Discussion
The experiments described in this chapter aimed to look at the rapid cellular response to 
ET-1 through monitoring protein phosphorylation and dephosphorylation changes. The 
global “top-down” approach, which followed a large portion of the total 
phosphoproteome of a cell, was used to give an overview of the signalling pathways 
induced in NRK-49F by ET-1. The differential phosphorylation of 25 proteins was 
demonstrated to result from fibroblast treatment with ET-1. The diversity of the protein 
groups in this list indicates that ET signalling takes place on multiple levels that 
together with regulatory proteins and enzymes, involve cytoskeletal proteins, chaperone 
proteins and metabolic enzymes. Within the protein groups, the majority of the 
individual proteins appeared on the gel in several isoelectric isoforms (Figs. 5-1, 5-2 
and 5-3 and Table 5-1). A number of previous studies have interpreted the isoelectric 
shift of an individual protein to be the result of the altered phosphorylation state of that 
protein (Blenis et al., 1984; Rabilloud, 2002). Whilst these studies looked at the level 
of total proteome (with no separation of unphosphorylated and phosphorylated proteins 
being performed), the research conducted in this chapter showed the changes in pre­
enriched phosphorylated proteins (the unphosphorylated proteins were removed by pre­
fractionation). This means that the proteins observed were already phosphorylated and 
that after stimulation with ET-1 the changes in spot intensity of each protein spot 
reflected the changes of a specific “phosphoisoform” of that particular protein. In brief, 
each of these isoforms showed specific changes in phosphorylation state, suggesting 
that each identified protein is composed of differently phosphorylated molecules.
The enrichment of the phosphoproteome of the cell was undertaken with a view to 
simplifying the pattern of spots analysed. In the control (unstimulated) gel there are
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proteins that are phosphorylated already in the resting cell. Ideally a lot of newly 
phosphorylated proteins would be seen appearing in the gels representing stimulated 
phosphoproteome. Observing new spots proved to be difficult, and most of the 
observed proteins were still of low abundance (weakly detected on the gel with 
insufficient material to identify the spot). Pursuing the enrichment and identification of 
low abundance proteins is a very elaborate process but new and more sensitive methods 
that will aid this are on the horizon (Kleiner et al., 2005, in press). In addition, not all 
multi-phosphorylated proteins will appear on the differential display. This will depend 
on the location of different phosphorylation sites in a protein i.e. if the phosphorylation 
is not on the surface of the protein, the probability of it binding to the IMAC column 
will decrease. Using Fe3+ IMAC methodology proteins containing pThr and pSer are 
enriched more than phosphotyrosilated proteins (Ficarro et al., 2002; Ficarro et al.,
2003). As phosphotyrosine-proteome makes up 0.05% of the total phosphoproteome in 
vertebrate cells (Hunter, 1998), IMAC-enriched 2D maps of phosphoproteins will not 
cover this low abundant part of the phosphoproteome. Because of the facts stated above 
the experiments presented in this chapter focused on following the quantitative changes 
in phosphorylation of abundant phosphoproteins after treatment with ET-1.
5.3.1 Cytoskeletal proteins
ET stimulates cytoskeletal rearrangements in fibroblasts via the ETA receptors (Gohla et 
al., 1999). It has been shown that ET can induce the phosphorylation of several 
proteins involved in the formation of focal adhesions (Chrzanowska-Wodnicka and 
Burridge, 1996; Salazar and Rozengurt, 1999; Leopoldt et al., 2000). These results 
demonstrate how the link between ET and the cytoskeleton affects cell growth,
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migration and contraction. In addition to this, actin organization has a role in 
occupancy (ET)-induced receptor internalization (Lunn et al., 2000).
Three cytoskeletal components (actin, vimentin and tubulin) were identified the 
phosphorylation of which was altered in rat kidney fibroblasts after stimulation with 
ET-1. The initial increase in actin phosphorylation (Fig 5-4 panel E) may be the signal 
that leads to the reorganization of the actin-cytoskeleton. This is supported by studies 
from other groups where phosphorylation is implicated as a mechanism of regulation of 
the actin-cytoskeleton in different cells (Reiss et al., 1996; Gu et al., 2003). Another set 
of results (see chapter 6) implicates the reorganization/polymerization of actin in rat 
kidney fibroblasts after 5 mins of ET-1 treatment which is consistent with reports of 
ET-1 induced actin reorganization (Hirshman and Emala, 1999). Additionally, ET 
induced the expression of actin in VSMC (Hahn et al., 1993) and 
phosphorylation/polymerization of actin was shown to be regulated by calcium 
(Constantin et al., 1998). Previous findings demonstrated a Tyr-dephosphorylation of 
actin upon 2 mins ET-treatment of human lung fibroblasts (Stannard et al., 2003 b). 
Experiments in this chapter followed the global phosphorylation state of actin, not 
focusing on specific phosphorylation sites. It may be that different phosphorylation 
sites behave differently after stimulation because actin can be phosphorylated on 
various residues: Tyr (Gauthier et al., 1997), Thr (Furuhashi et al., 2002) and Ser (van 
Delft et al., 1995); or that the regulation of actin is cell type specific. A detailed 
mapping of actin phosphorylation sites would aid understanding of the complex effects 
of actin phosphorylation.
Vimentin is a major cytoskeletal phosphoprotein in fibroblasts that participates in 
building intermediary filaments (IF). Phosphorylation/dephosphorylation of vimentin
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tightly regulates the balance between free vimentin and polymerized IF (Eriksson et al., 
2004). Vimentin was found to be a substrate for various kinases, amongst which are 
Rho-kinase (Inada et al., 1999) and Aurora-B (Yasui et al., 2004) both of which 
regulate the assembly/disassembly of vimentin filaments during cytokinesis. In 
interphase cells the activity of kinases on vimentin is counterbalanced by excessive 
phosphatase activity (Inada et al., 1999; Turowski et al., 1999). In this study, following 
the kinetics of vimentin phosphorylation after brief stimulation with ET-1, a decrease in 
phosphovimentin abundance was observed (Fig. 5-4 panel G) which is in accordance 
with earlier findings from our group (Stannard et al., 2003 b). In addition to vimentin 
dephosphorylation, the report from Stannard et al., suggested the activation of protein 
phosphatase 2A (PP2A) after ET-1 stimulation of a fibroblast cell line. The 
dephosphorylation of vimentin observed in these studies implies the presence of 
phosphatase activity and PP2A being a major interphase phosphatase of vimentin 
(Turowski et al., 1999) could explain the results obtained. Vimentin was identified in 
two phosphoisoforms (sl8  and sl9 , Figs. 5-1 and 5-3): s i 8 transiently dephosphorylated 
after 2 mins of ET-treatment and s l9  steadily dephosphophorylated throughout the 
analysed time-scale (Fig. 5-4 panel G).
The protein in spot s 18 was identified as a mixture between vimentin and tubulin, 
preventing a clear distinction between the signals of the two individual proteins being 
made. Alternatively the signal might be the sum of the intensities of both proteins.
Tubulin is a major constituent of microtubules that regulate cell shape and polarity and 
are involved in cellular transport and mitogenesis. Tubulin isotypes undergo a variety 
of posttranslational modifications including phosphorylation. This process can be 
catalyzed by tyrosine kinases such as Syk in B lymphocytes (Faruki et al., 2000),
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pp60c-src in nerve growth membranes (Matten et a l, 1990) and Ser/Thr kinases like 
GRK2 (Pitcher et al., 1998) and potentially Ca-CaM kinase (Goldenring et al., 1984). 
The general thought is that the phosphorylation of tubulin negatively regulates its 
assembly into microtubules (Wandosell et a l, 1987). So far tubulin 
phosphorylation/dephosphorylation was not reported in ET induced cellular signalling. 
The results presented in this chapter showed tubulin dephosphorylation after ET 
treatment (Fig. 5-4 panel G). Based on the data from literature, this would mean that 
ET promotes tubulin incorporation into microtubules. The biological significance of 
this needs to be further analyzed as microtubules could have different roles in 
fibroblasts: cell motility (Magdalena et al., 2003) mitogenesis (Ball et a l, 1992) and 
receptor mediated endocytosis (Kapeller et a l, 1993).
5.3.2 Folding accessory proteins
Proteins that have a chaperone-like activity and aid in the correct folding of proteins 
into their 2D/3D structure are located mostly in the endoplasmic reticulum. Members 
of this large group of proteins have been implicated in taking part in some cell 
signalling processes (Higuchi et a l, 2004; Guo et a l, 2002; Thulasiraman et a l, 1998), 
but knowledge of their role as potential signalling molecules is scarce. Many proteins 
from this group are phosphorylated. The purpose of such posttranslational modification 
definitely goes beyond serving to stabilize the complex formed between chaperones and 
their interacting proteins and remains to be discovered. There are no reports that show 
the involvement of folding accessory proteins in ET-signalling pathways. The findings 
from this chapter demonstrate for the first time the rapid phosphorylation changes of 
this protein group induced by ET-1. 5 types of proteins were identified that change 
their phosphorylation states after the ET-1 sitmulation of NRK fibroblasts: protein
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disulfide isomerase (PDI), GRP78, immunophillin FKBP65, ER-60 protease and 
HSC71 (Table 5-1). It is interesting to note that the prolyl 4-hydroxylase (P4H) a 
subunit was also identified, which together with PDI (the p subunit) forms a functional 
P4H enzyme. The phosphorylation of PDI, GRP78, HSC71 and FKBP65 was 
previously reported (Quemeneur et a l, 1994; Hendershot et a l, 1988; Coss et a l, 1995; 
Peake et a l, 1998). ER-60 protease can be speculated to be phosphorylated based on 
the sequence similarity it shares with its cognates (from the same protein family) which 
were observed to be posttranslationally modified by phosphorylation (Quemeneur et a l, 
1994).
PDI was located in the 2D gels in three spots, two of which were identfied with 
MALDI-TOF fingerprinting (Fig. 5-2; s i, la), si and s la  increase their phosphorylation 
after 2 mins and increase or remain at the same level of phosphorylation after 4 mins of 
ET-1 stimulation (Fig. 5-4, panel A). Isoelectric isoforms of PDI could be assigned to 
the phosphorylation of several different sites. PDI is phosphorylated by a Src-like 
tyrosine kinase Lyn on a few Tyr residues (Donella-Deana et a l, 1996) but was also 
found to be a substrate for sphingosine-dependent kinases (SDK), implying Ser/Thr 
phosphorylation (Megidish et a l, 1999). The role of PDI phosphorylation in ET 
signalling is unclear, but taking into account the fact that PDI is phosphorylated 
downstream of TNF (Yanagida et a l, 2000); that its phosphorylation is modulated in 
ischemic rats (Sakai et a l, 2003); that it regulates negatively NF-kappa B signal 
(Higuchi et a l, 2004); and is generally a multifunctional enzyme, forming complexes 
with different partners and being localized in different cell compartments (reviewed in 
Noiva, 1999); the participation of PDI in signalling processes becomes imminent.
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ER-60 protease is another PDI, also known as GRP58. Spots s7 and s7a indicate ER-60 
protease on the gel (Fig. 5-1). There are no reports on the phosphorylation of GRP58 or 
its involvement in ET signal transduction, but as it is a PDI, the likelihood of 
phosphorylation of ER-60 is increased. ER-60 is an important factor in cell signalling 
as demonstrated by: its association with interleukine activated Stat3 (Guo et a l, 2002); 
its ability to regulate sarco endoplasmic reticulum calcium ATPase (SERCA) (Li et al.,
2004); its role in the MHC class I assembly (Lindquist et al., 2001); and the role it has 
in the degradation of proteins (Otsu et a l, 1995). In addition to these signalling 
processes, GRP58 could have a role in cancer (Celli et a l, 2003).
GRP78 is a member of the heat shock 70kDa protein family and is resolved on 2D gel 
in several charge isoforms (Fig. 5-1 s2, s3 and s3a) as demonstrated also by others 
(Leustek et a l, 1991; Witzman et a l, 1994). Spots s3 and s3a show dynamic kinetic 
behaviour, increasing in phosphorylation after ET-1 treatment (Fig. 5-4 panel B). 
GRP78 is phosphorylated on Ser and Thr (Hendershot et a l, 1988) and additionally is 
an in vitro substrate of Src kinase (Carlino et a l, 1994). It is also found to undergo 
Ca2+-induced autophosphorylation (Leustek et a l, 1991). As demonstrated in chapter 4, 
ET-1 induces a strong calcium signal that could modify the phosphorylation of GRP78. 
GRP78 is usually phosphorylated when forming oligomers, and it is thought that 
monomeric protein is the unmodified and biologically active form of GRP (Freiden et 
a l, 1992). The results in this thesis are the first report of ET induced phenotypical 
change of GRP78. Which signalling role, if any, this change might have is yet to be 
elucidated.
FK506 binding protein 10 (FKBP65) (Fig 5-1, s4a; Fig. 5-4, panel H) is a peptidylprolyl 
isomerase, that accelerates the rate of the folding of proteins during protein synthesis.
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This protein is a member of a multigene family of FK506 binding proteins, originally 
discovered because of their binding of the immunosuppressant drug FK506 (Harding et 
a l, 1989). FKBP65 is posttranslationally modified with glycosylation and 
phosphorylation (Coss et al., 1995). This explains why this protein migrates on an 
SDS-PAGE gel at a higher Mw (75kDa) than expected (65kDa) (Fig. 5-1 and Table 5- 
1). ET-1 stimulation of NRK cells induced a 2-fold decrease in phosphorylation of 
FKBP65 (Fig. 5-4 panel H). This result implies an activity of a protein phosphatase. 
The biological role of the ET-induced dephosphorylation is not known. It may be that 
in this way the binding to different ligands/partners is regulated. FKBP65 binds to 
tropoelastin (Davis et a l, 1998) but is also found in tissues where this protein is not 
expressed (Patterson et al., 2000) suggesting the presence of other binding partners.
Heat shock cognate 71 kDa protein, a member of HSP70 proteins, was identified in spots 
s4 and s5 (Fig 5-1). After 4 mins of ET-1 stimulation, the more acidic s4 increased in 
phosphorylation by 1.3 times when compared to the control, while the intensity of s5 
decreased by 1.3 times (Fig. 5-4 panel C). An assumption can be made that additional 
phosphorylation of the protein is shifting the abundance of molecules towards the left. 
Again the biological role of this event is unclear. HSP70 proteins were found to be 
phosphorylated on Tyr residues (Otto et al., 2001), Thr (Peake et al., 1998) and in 
modest amounts by casein kinase II (Shi et a l, 1994). Generally the processes of 
protein phosphorylation/dephosphorylation were frequently associated with studies 
involving HSP70 (Chu et a l, 2001; Polanowska-Grabowska et a l, 1997). In addition, 
HSP70 are often shown to regulate some signalling mechanisms (Carter et a l, 1997; 
Thulasiraman et a l, 1998) indicating that their role in cellular signalling is not 
insignificant.
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5.3.3 Enzymes
ET-1 stimulation of rat kidney fibroblasts in these experiments resulted also in 
phosphorylation changes of two enzymes: prolyl 4-hydroxylase (P4H) and enolase. 
There are no previous reports of ET-induced phosphorylation of these enzymes. In 
addition, P4H and enolase-gamma were not reported to be phosphorylated by anything 
else. P4H is listed in the folding accessory protein group (Table 5-1) because it is a 
subunit of PDI.
Enolase was identified in these studies in 4 spots, three of which represent isoelectric 
(phospho) isoforms of alpha-enolase (sl5, s l6  and sl7 ) and s22 which is gamma- 
enolase, also known as neural specific enolase (NSE). This glycolytic enzyme was 
found to be phosphorylated in cells transformed by the Rous sarcoma virus (Cooper et 
al., 1983). Later reports showed that enolase is a substrate for the insulin receptor 
kinase (Sale et al., 1987) and EGFR kinase (Reiss et al., 1986) but mostly it is used as a 
marker of kinase activity for pp60c-src kinase (Cartwright et al., 1993). The three 
isoelectric isoforms of alpha-enolase, show different phosphorylation kinetics (Fig. 5-4 
panel F) with s 15 increasing, s l6  constant and s 17 decreasing in phosphorylation states 
after ET-treatment. As these spots represent the differentially phosphorylated forms of 
the same protein, it is possible that the decrease observed for sl7  accounts for the 
increase in phosphorylation of s 15 ( s i6 could be an intermediate phosphoisoform). It 
can be speculated that the ET-1 induced change in phosphorylation of alpha enolase is a 
result of the activity of Src kinase or ET-induced EGFR transactivation (Bisotto et al., 
2001; Daub et al., 1996) and that its potential biological significance is related to the 
increased rate of cell growth, proliferation and transformation (Simonson et al., 1996; 
Lahaye et al., 1999) of NRK cells.
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The appearance of NSE in rat kidney fibroblasts is an interesting finding, because this 
enzyme is used as a neuronal tissue marker (Sakimura et al., 1987). It is also found in 
platelets so the possibility of this enzyme isoform appearing in cells other than neuronal 
cells is not excluded (Kato et al., 1983). Another explanation for this result could be 
that rat fibroblasts express a homologue of gamma-enolase that has not yet been 
described and could be generated by protein splicing (Shakib et al., 2005).
5.3.4 Regulatory enzymes/proteins
Several regulatory proteins were identified in this study to modify their phosphorylation 
state after a signal trigger by ET-1. These proteins are: IRF-1, 40s ribosomal protein, 
PMCA2 and RhoGDI-1. All of the regulatory proteins were reported previously for 
phosphorylation with greater or lower confidence (RhoGDI-1). For most of them the 
role of phosphorylation was implied in the regulation of their protein function, but there 
are still no clear views on this aspect. 40s ribosomal protein, PMCA2 and RhoGDI-1 
can be directly and indirectly linked to ET signalling although no reports on the 
participation of these particular proteins in the signalling cascade were published (apart 
from one in respect of 40s ribosomal protein (Wang and Proud, 2002)). IRF-1, on the 
other hand, is a completely new target of ET-1. Together the results obtained in this 
chapter could provide insights into the previously unknown effects of ET.
Phosphorylation of 40s ribosomal protein has been implied in the up-regulation of 
protein synthesis in interphase cells (Thomas, 2002), in tumour growth (Comolli and 
Albert, 1988) and cell growth (Volarevic and Thomas, 2001). 40s ribosomal protein is 
phosphorylated by a Ser/Thr kinase S6 kinase that is activated by various mitogens and 
growth factors. It was reported that ET-1 activates S6K and consequently the
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phosphorylation of 40S ribosomal protein in a signal regulating ET-induced cell growth 
(Iwasaki et al., 1999; Wang and Proud, 2002). The signal upstream of S6K could 
involve ETAR and Ca2+ dependent EGFR transactivation (Iwasaki et a l, 1999); Ras and 
MEK-1 (Wang and Proud, 2002); and ETbR, PKC, Raf-1 and MAP kinase (Terada et 
al., 1995). In the experiments presented in this chapter ET-1 induced an increase in 
phosphorylation of 40s ribosomal protein immediately after 2 mins and this increase 
remained strong after 4 mins (Fig. 5-1 and Fig. 5-4 panel H) These findings agree with 
the previous reports and imply the stimulation of a pathway leading to S6K activation 
which would suggest that ET-1 triggers signals that regulate protein synthesis and cell 
growth in rat fibroblasts. The regulation of protein synthesis by ET-1 accords with the 
results from chapter 3.
Although only one phosphoisoform of 40s ribosomal protein was identified ( s i2, Fig. 5- 
1 and Fig. 5-4 panel H) there are two additional spots left (more acidic) of s i 2, which 
very probably correspond to the same protein. In support of this assumption is the 
observed differential phosphorylation of 40s ribosomal protein resolved on a 2D PAGE 
reported by others (Leader et al., 1980; Blenis et al., 1984) and the fact that this protein 
was demonstrated to have multiple phosphorylated sites (Katahira et al., 1996).
Phosphorylation of IRF-1 was observed to decrease slightly after 4 mins of ET 
treatment (Fig. 5-1, s i3; Fig. 5-4 panel H). IRF-1 is a transcription factor, the activation 
of which was implied in different cellular responses: antiviral/antibacterial; anti­
proliferative; pro- and anti-apoptotic; inhibition of cell transformation; and immune 
responses (Kroger et al., 2002). Both Ser and Tyr phosphorylation of IRF-1 were 
detected (Lin and Hiscott, 1999; Kautz et al., 2001) but it is not clear in what respect 
this regulates IRF-1 activity (whether it affects the protein-protein interactions or the
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binding of IRF-1 to DNA). In ET biology, the release of ET from vascular smooth 
muscle cells is regulated by cytokine induced IRF-1 activation (Woods et al., 2003). 
Based on the current knowledge of ET-induced biological effects and the biological 
effects caused by IRF-1 activation, there are several possible signalling events that can 
link these two molecules:
• IRF-1 up-regulation of nitric oxide synthase (Kamijo et al., 1994), which causes 
the production of NO, the partner of ET in the regulation of vascular 
homeostasis;
• Inhibition of apoptosis demonstrated individually for both molecules (Chapman 
et al., 2000; Shichiri et a l, 1998). IRF-1 also has pro-apoptotic effects (Tamura 
et al., 1995); and
• Regulation of cancer development; IRF-1 acts as a tumour suppressor (Tanaka 
et al., 1994), whilst ET promotes tumour development (Nelson et al., 2003).
The outcome of any of the possible connections between ET and IRF-1 highly depends 
on the way in which ET regulates the activity of IRF-1 (activation/inhibition). 
Unfortunately, no conclusions can be drawn as to what effect the ET-induced 
dephosphorylation of IRF-1 observed in these studies might have on the transcriptional 
activity of this transcription modulator.
Plasma membrane calcium transporting ATPase (PMCA) is a key enzyme that regulates 
intracellular calcium concentration. There are four different isoforms of this enzyme: 
PMCA1, PMCA2, PMCA3 and PMCA4. Additional diversity of the enzyme isoforms 
is achieved through alternative splicing (Strehler and Zacharias, 2001). PMCA is a 
phosphoprotein which could have Ser, Thr and Tyr phosphorylation (James et al., 1989; 
Wang et al., 1991; Dean et a l, 1997). In the experiments presented in this chapter the
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PMCA2 isoform of the protein was identified. The phosphorylation of PMCA2 was up- 
regulated after 2 mins of ET-1 treatment (Fig. 5-4 panel H) and returned to slightly 
above the basal level of phosphorylation, after 4 mins of ET-1 treatment. As ET 
induces a strong calcium signal (chapter 4) it would be logical to assume that it 
negatively regulates the activity of PMCA at least in the first instance, in order to 
maintain a high intracellular calcium level to transduce the signal further. Many papers 
support this assumption (Jouneaux et al., 1993; Jouneaux et al., 1994; Yokomori et al., 
2003). In addition to this, a report on phosphorylation induced down-regulation of 
PMCA activity strengthens this hypothesis (Dean et al., 1997).
What is interesting is that a specific isoform of the enzyme was identified to be 
regulated by ET-1 in NRK cells. PMCA2 is predominantly expressed in the brain, but 
certain splice variants are found in specific tissues (Strehler and Zacharias, 2001). 
These are for PMCA2 expressed in kidneys: 2w, 2x and 2b. It is likely that the 
alternative splice isoform of PMCA2 observed here is one of these three. During 
peptide mass fingerprinting, several different databases were searched and all of them 
identified the spot s l4  as PMCA2. Only the SwissProt database specified alternative 
splice-variants, out of which the highest probability score was for the PMCA2 xb splice 
isoform (SwissProt accession number PI 1506-6) with 30% of sequence coverage. In 
addition, only the xb splice variant contains Arg1142 and the peptide containing this Arg 
was identified with peptide mass fingerprinting (see Appendix 2). Most probably this is 
the variant observed in this chapter as it agrees with tissue specific distribution of 
PMCA2 splice variants, but these results need to be confirmed by sequencing, xb splice 
variant is a result of a combination of two alternatively spliced domains at N-terminal 
site A (x) and at C-terminal site C (b). So far the splice sites have only been studied 
independently (Adamo and Peniston, 1992; Keeton et al., 1993). The existence of
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different isoforms of PMCA suggests that their activity can be differentially regulated: 
they bind calmodulin with different affinities and they have distinctive kinase consensus 
sequences (Guerini, 1998). The results in this chapter emphasize that ET could regulate 
different isoforms of PMCA, which could involve specific signalling pathways and this 
creates an extremely interesting new field to investigate.
Another regulatory protein the phosphorylation of which was up-regulated upon ET 
stimulation, is RhoGDI-1 (s6, Fig. 5-1 and Fig. 5-4 panel H). This protein negatively 
regulates the activity of Rho/Rac small GTPases, by forming a complex with them and 
inhibiting the GDP/GTP exchange. The activity of Rho GTPases is regulated by the 
GTPase-GDI complex dissociation, which in turn is tightly controlled by an as yet 
unknown signal input. One of the proposed mechanisms of the regulation of complex 
dissociation is the phosphorylation of GDI proteins (Bourmeyster et al., 1996; Gorvel et 
al., 1998, Mehta et al., 2001). In this way, potentially steric hinderance of residues 
important for complex formation would cause it to disassemble. The results obtained in 
this chapter, encourage the validity of this hypothesis. They also prompted further 
study of the phosphorylation of RhoGDI (see Chapter 6).
As RhoGDI-1 is a guanine dissociation inhibitor with a general binding specificity (it 
can bind RhoA, RhoB, Racl, Rac2 and Cdc42) it is difficult to tell which of these 
molecules is activated by an ET generated stimulus. ET can stimulate the activation of 
RhoA, Racl and Cdc42 (Fleming et al., 1996; Shi-Wen et al., 2004; Miyamoto et al., 
2003) and signalling pathways engaging these GTPases may lead to cell growth, cell 
proliferation, cell migration and contractility (Cazaubon et al., 1997; Kim et al., 1997; 
Miyamoto et al., 2003; Chrzanowska-Wodnicka and Burridge, 1996).
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5.4 Conclusions
• ET-1 induced rapid quantitative phosphorylation changes in NRK-49F cells.
• 25 abundant proteins that showed >20% change after ET-1 stimulation were 
identified.
• Phosphoproteins influenced by ET-1 belong to distinct protein groups
(regulatory enzymes/proteins, cytoskeleton, metabolic enzymes, folding 
accessory proteins) demonstrating that the ET-1 signal occurs on various levels, 
from the modulation of cytoskeleton activity to calcium signalling, protein 
synthesis and gene expression. Again, these results suggest that the activation of 
parallel signalling pathways occurs downstream of ET receptors.
• The majority of the identified proteins exist in the cell as multiply-
phosphorylated forms and it is the phosphorylation state of these isoforms that
ET-1 alters.
• Within a group of isoforms of one protein, phosphorylation changes were quite 
different indicating different regulation of the same group of molecules. This is 
in line with the idea that different protein isoforms may be sequestered within a 
cell and targeted for a different fate (Godovac-Zimmermann et al., 2005).
• Amongst the phosphoproteins modified by ET-1, RhoGDI was selected to be 
analyzed further (Chapter 6) for the following reasons:
1. it is a new phospho-target of ET-1;
2. its phosphorylation was hinted at by other groups but phosphorylation 
sites are not known; and
3. determining phosphorylation site(s) could provide clues to the regulation 
of the stability of Rho-RhoGDI complex, a key signalling point in many 
signalling pathways.
149
Chapter 6
CHAPTER 6. ET-1 INDUCED CHANGES OF RhoGDI 
PHOSPHORYLATION STATES
6.1 Introduction
Several reports have demonstrated that ET induced cellular signalling involves the 
activation of Rho proteins in a range of different cells (Fujihara et a l, 1997; Sakurada et 
a l, 2001; Kim et a l, 1997; Teixeira et a l, 1999; Cazaubon et a l, 1997). These results 
suggest that Rho GTPases are important regulators in the biological effects of ET such 
as: cell contraction, cell migration and adhesion, and cell proliferation.
In fibroblasts ET-Rho connection enables the generation of contractile force (through 
myosin light chain (MLC) phosphorylation) (Yee et a l, 2001), nuclear signalling (Kim 
et a l, 1997), and stress fibre formation (through the FAK pathway) (Gohla et a l, 1999). 
Some data even propose that Rho may play a role in ET-mediated receptor endocytosis 
(Lunn et a l, 2000).
The Rho-GDP guanine nucleotide dissociation inhibitor (GDI) is a protein that controls 
the activity of Rho GTPases which are key signalling molecules in a multitude of 
biological processes (Bishop and Hall, 2000). Rho proteins have a lipid modification on 
their C-terminus and as such cannot remain soluble in the cytosol. They use RhoGDI as 
a mask that protects their vulnerable hydrophobic surface from the aqueous 
surroundings (see Fig. 6-1). In this GDP-bound form as a sort of a heterodimer (Rho- 
RhoGDI) they rest inactively in the cell. When Rho is activated it translocates from the 
cytosol to the plasma membrane where it no longer needs the protection of GDI. The 
heterodimer dissociates and the active GTP-bound form of Rho activates its specific
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downstream effectors. The cycle of Rho is complete when it turns into its inactive 
GDP-bound state that associates with RhoGDI and returns to the cytosol.
The main regulatory features of GDIs would be:
• keeping the Rho GTPases soluble; and
• keeping the Rho GTPases inactive, by inhibiting their otherwise spontaneous
exchange of GDP«->GTP.
Phosphorylation?
Activates downstream effectors
P
Figure 6-1 Cartoon show ing the role o f  R hoG D I in the  R hoG TP ase activation cycle. See 
text for explanation o f the processes illustrated in this figure.
The precise mechanism that causes the dissociation of the complex and therefore 
regulates the activation of Rho is still poorly understood. As RhoGDI has several 
motifs that are potential targets for different Ser/Thr kinases (see Fig. 6-11), it was 
proposed that phosphorylation may be one of the mechanisms that controls the stability 
of the Rho-RhoGDI complex. Previous reports gave indications of the possible 
phosphorylation of different RhoGDI isoforms (Bourmeyster et a l, 1996; Gorvel et al., 
1998, Mehta et al., 2001) in different tissues.
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Results from chapter 5 showed that the phosphorylation of RhoGDI increases after 4 
mins of treatment with ET in rat kidney fibroblasts. To get a better understanding of the 
process of regulation of Rho GTPases, the phosphorylation of RhoGDI induced by ET-1 
was analysed.
The studies of the phosphorylation of RhoGDI were extended by immunoprecipitating 
the RhoGDI and analysing the phosphorylation further by SILAC (stable isotope 
labelling by amino acids in cell culture) methodology and mass spectrometry. A 
phosphorylated RhoGDI peptide was detected in the MALDI-TOF mass spectrum after 
treatment with ET-1. This peptide was sequenced with ESI ion trap mass spectrometry, 
and the phosphorylation of Tyr144 and Ser148 was detected. This finding indicates that 
RhoGDI phosphorylation may have a role in regulating the stability of GDI-GTPase 
complex and consequently the activity of some small GTPases as downstream effectors 
of ET-1 signalling.
6.2 Results
6.2.1 Immunoprecipitation o f RhoGDI
In the initial experiments NRK-49F cells were stimulated with ET-1 (lOOnM) for 2 and 
5 mins and RhoGDI was immunoprecipitated from the cell lysate. The protein extract 
obtained after immunoprecipitation was resolved on SDS-PAGE and the RhoGDI was 
immunodetected with anti-RhoGDI antibody (Fig. 6-2 A). RhoGDI was resolved as a 
strong band at Mw~30kDa. The antibody detected another band (Mw~80kDa) that co­
precipitated with RhoGDI after stimulation with ET-1.
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<4— RhoGDI
Figure 6-2 Immunodetection of RhoGDI after ET-1 stimulation. Quiescent NRK cells 
were treated with or without ET-1 (lOOnM) for the indicated period of time. RhoGDI was 
immunoprecipitated and the obtained protein extract was separated on SDS-PAGE. Gel 
separated proteins were transferred onto a nitrocellulose membrane and incubated with either 
anti-RhoGDI (A) or phospho(Ser)-PKC substrate (B) antibodies. After the incubation with the 
primary antibody membranes were incubated with secondary anti rabbit antibody and protein 
bands were detected with a chemiluminescence detection kit. The arrows indicate RhoGDI and 
the unknown protein (see text). The last column in both images represents the ‘PA control’ (the 
cell lysate proteins bound to protein A sepharose).
The same immunoblot was reprobed with phospho-(Ser) PKC substrate antibody (Fig. 
6-2 B). Phospho-(Ser) PKC substrate antibody detected RhoGDI in both unstimulated 
and stimulated cell extract. Although it seems that there is dephosphorylation of 
RhoGDI after ET-1 stimulation, normalized values of the signal suggested that the
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dephosphorylation was not significant. In addition the same antibody detected the 
protein co-precipitating with RhoGDI in a stimulation-dependent manner.
An interesting result came unexpectedly from the immunoprecipitation experiment: 
ponceau staining of the nitrocellulose membranes showed that there is a protein band 
(Mw~ 45kDa) that increased in abundance after cells were stimulated with ET-1 (Fig. 6 - 
3 A). However, this protein could not be detected on the blot or its signal was covered 
by the signal from the heavy chain of immunoglobulin. In addition, silver staining of 
the gel with protein extract obtained after immunoprecipitation also showed a protein 
(Mw~ 45kDa) whose abundance increased 5 mins after ET-1 stimulation. However, the 
same protein was detected in the ‘PA control’ (used to monitor non-specific binding of 
proteins to the sepharose) (Fig. 6-3 B). Protein extract from cells stimulated for 5 mins 
with ET-1 was used for the ‘PA control’ and the protein was binding more strongly to 
the sepharose after stimulation. MALDI-TOF analysis of the protein band identified it 
as actin.
Time (min)
Figure 6-3 E T-1  induced actin polym erization . T he experim ent was perform ed as 
described in Fig. 6-1. (A) The nitrocellulose m em brane stained with ponceau-S. (B) Gel 
separated proteins stained with silver. IP -  im m unoprecipitation; PA -  control for the non­
specific binding.
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6.2.2 MALDI-TOF analysis o f immunoprecipitated RhoGDI
To analyse the appearance of novel phosphorylated peptides in the RhoGDI molecule 
by mass spectrometry SILAC methodology was used. This novel method was described 
in studies of functional protein-protein interactions (Blagoev et al., 2003) and 
quantitative estimation of protein abundance in cells (Ong et al., 2002). The essence of 
the method lies in the application of two isotopes of the same element 12C and 13C 
(hydrogen and deuterium have also been used in SILAC experiments) (Ong et a l, 
2002). 13C is incorporated in arginine, an essential amino acid in cell culture (Scott et 
a l,  2000) which is then used to label proteins in the cell. The l3C6-Arg has a molecular 
weight 6 Da higher (because Arg has 6 carbon atoms in its structure) than the normal 
12C-Arg, and this property (the mass difference) is later used in mass spectrometric 
analysis to distinguish peptides obtained from two differently treated cell pools 
(unstimulated and stimulated) (Fig. 6-6). The principle of the method used in the 
experiments in this chapter is as follows (Fig. 6-4):
• one cell pool (unstimulated) is grown on the medium containing normal 12C 
arginine;
• the other cell pool (stimulated) is labelled with 13C6-Arg;
• cells are grown in culture, as usual;
• a stimulation experiment is performed (ET-1, lOOnM), cells are lysed and the 
protein concentration is determined from both cell pools. Equal amounts of 
proteins from unstimulated and stimulated cell lysates are mixed together (1:1);
• from the mixed lysates, RhoGDI is immunoprecipitated and separated on a 2D 
PAGE (Fig. 6-5); and
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• RhoGDI spots are digested with trypsin and analysed with MALDI-TOF mass 
spectrometry to produce a characteristic peptide spectrum (Fig. 6 -6 ); this 
spectrum contains doublet peak-pairs separated by 6  Da.
The aim of the experiments described in this chapter was to look for RhoGDI peptides 
phosphorylated after ET-1 stimulation. The SILAC methodology was applied with a 
view to detecting new peaks in the MS spectrum that represent phosphorylated RhoGDI 
peptides purified from the stimulated cell pool.
[1JC]Arg [”C]Arg
No stimulation ET-1 stimulation
Mix lysates 1:1 and 
immunoprecipitate RhoGDI
Separate on 2D PAGE;
Cut RhoGDI and digest with trypsin; 
Analyse with MALDITOF MS
1
m/z
Figure 6-4 A  diagram  o f  the S IL A C  m ethod  applied  in th is chapter. In the mass spectrum  
peptide peaks from the control cell pool are blue; peptide peaks from  the stim ulated cell pool 
are red; the phosphorylated peptide peak is labelled with P.
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2D gel separation of immunoprecipitated RhoGDI showed several spots in the Mw 25 
kDa pi (4.9-5.3) coordinate range (Fig. 6-5). These spots were not present in either of 
the control gels. Three of them (s2, s3 and s4) were cut out, digested with trypsin and 
analysed with MS. Database searches of the obtained peptide masses identified all three 
spots as RhoGDI. The percentage of coverage of the RhoGDI sequence for spot s2 and 
s4 was 54% and for spot s3 it was 47%. Peptides that were identified for each of the 
spots are represented in Tables 6-1, 6-2 and 6-3.
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protein A
Figure 6-5 2D PAGE separation of RhoGDI IP. Cell lysates from unstimulated and [13C] Arg labelled NRK-49F cells (labelled by Miss C. Guerrera), 
stimulated for 5 mins with ET-1 (lOOnM), were mixed 1:1 and incubated with anti-RhoGDI antibody. The yellow-labelled arrows show protein spots identified as 
RhoGDI with MALDI-TOF mass fingerprinting (Fig. 6 -6 ). ‘PA control’ represents the cell lysate proteins bound to protein A sepharose. ‘Ab+protein A control’ 
illustrates the 2D PAGE separation of anti-RhoGDI antibody and protein A sepharose with no added cell lysate.
158
Chapter 6
Intens.
987
2500
2000
1657
1500
17841524
1000
1924
500 2052
23 54
2500 30002000 m /z1500
Intens.
1657
1500-
17841608
1524
1000 '
500-
1736
1650 1700 1750 18001550 1600 m/z
Figure 6-6 RhoGDI mass spectrum. MALDI-TOF spectrum from spot s2 (see Fig. 6-5). 
A full range spectrum (A); a close up of one area of interest (B). Duplicate peaks differ in mass 
by 6 Da, which corresponds to [13C Arg], of the stimulated peptide variant. Observation of 
phosphorylated peptides is marginal (see Discussion for explanation).
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Obs mass Exp mass A Peptide
948.587 948.539 0.048 51-58
979.509 979.487 0.02 128-134
985.524 985.534 -0.010 128-134 + [ IJC] Arg
1244.570 1244.549 0.021 142-152
1250.606 1250.596 0.01 142-152+ [I3C] Arg
1426.688 1426.523 0.165 142-152+ 2P + 1 Ox Met + [|3C] Arg
1600.766 1600.755 0.011 139-152
1606.784 1606.802 -0.08 139-152 + [UC] Arg
1649.900 1649.909 -0.009 59-74
1655.919 1655.956 -0.037 59-74+ [1JC] Arg
1782.808 1782.729 0.079 139-152 + 2P + 1 Ox Met + [13C] Arg
1782.808 1782.801 0.007 153-167
1916.929 1916.932 -0.03 34-49
1922.898 1922.979 -0.081 34-49+ [UC] Arg
1985.956 1986.812 0.144 121-134+ 3P + 1 Ox Met + [IJC| Arg
2363.125 2363.106 0.019 181-199
2575.239 2575.308 -0.069 75-98
Table 6-1 Table of RhoGDI peptides recovered from spot s2. Masses observed from the 
spectrum correspond to the theoretical tryptic-digests of RhoGDI. Peptides are represented as 
amino acid numbers in the sequence of the protein, with observed modifications: [13C] Arg- 
arginine residue labelled with I3C; Ox Met-oxidized methionine; P-phosphate group; A-the 
difference between the mass observed and the mass expected..
From spot s2 in total 17 peptides were identified, 14 of which trypsin had cleaved after 
Arg residue and 3 had Lys as the peptide-end residue. Out of the 14 residues with Arg- 
endings, 6  peptides were identified that belong to the unstimulated form of Rho GDI 
and 8  peptides that belong to the stimulated RhoGDI (they contained 13C-Arg) (Table 6 - 
1). Only 2 arginine-ending peptides (peptide 51-58 and peptide 121-134, Table 6-1) 
were not paired - their stimulated [13C-Arg]/unstimulated [12C-Arg] counterparts were 
not identified from the spectrum. 2 [13C-Arg] peptides (142-152 and 139-152) were 
identified with two phosphorylations in the peptides. This is essentially the same 
peptide in its shorter and longer form. The unphosphorylated forms of these peptides 
were also identified, both as unstimulated [12C-Arg] and stimulated [ l3C-Arg] variants.
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Peptide (121-134) was also observed as a [13C-Arg] form with three phosphorylations, 
but unphosphorylated forms of this peptide were not observed.
Obs mass Exp mass A Peptide
979.574 979.487 0.087 128-134
985.507 985.534 -0.027 128-134 + [l3C] Arg
1244.503 1244.549 -0.046 142-152
1250.531 1250.596 -0.065 142-152+ [I3C] Arg
1426.684 1426.523 0.161 142-152+ 2P + 1 Ox Met + [ l3C] Arg
1600.687 1600.755 -0.068 139-152
1606.704 1606.802 0.087 139-152 + [13C] Arg
1649.850 1649.909 -0.027 59-74
1655.877 1655.956 -0.046 59-74 + [13C] Arg
1782.738 1782.729 0.009 139-152 + 2P + 1 Ox Met + [,3C] Arg
1782.738 1782.801 -0.063 153-167
1916.899 1916.932 0.087 34-49
1922.915 1922.979 -0.027 34-49 + [UC] Arg
2363.084 2363.106 -0.046 181-199
2575.561 2575.308 0.253 75-98
Table 6-2 Table of RhoGDI peptides recovered from spot s3. Masses observed from the 
spectrum correspond to the theoretical tryptic-digests of RhoGDI. Peptides are represented as 
amino acid numbers in the sequence of the protein, with observed modifications: [13C] Arg- 
arginine residue labelled with 13C; Ox Met- oxidized methionine; P-phosphate group; A-the 
difference between the mass observed and the mass expected.
Spot s3 had in total 15 peptides identified as RhoGDI peptides (Table 6-2), 3 with Lys 
residues and 12 as peptides with Arg at the end of the amino acid sequence. 5 [t2C- 
Arg]-peptides have their [13C-Arg]-peptide pairs and 2 additional [13C-Arg]-peptide 
pairs in their phosphorylated form (139-152 and 142-152). All of the identified 
peptides were also identified in spot s2 .
From spot s4, 19 RhoGDI peptides were identified: 4 with Lys-ending and 15 with Arg 
ending (Table 6-3). In addition to the peptides identified in spots s2 and s3, 2 peptides
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that were identified solely in s4 had phosphorylation sites. Peptide 187-199 observed 
with one phosphate group had a Lys at the end of the amino acid sequence, therefore it 
was not possible to distinguish whether this peptide belonged to the stimulated or 
unstimulated form of RhoGDI. Peptide 121-134, observed as a [13C-Arg] peptide with 
2  phosphate groups, was also identified in spot s2  where it was observed with 3  
phosphate groups.
In all three RhoGDI spots the consistent change was the dually-phosphorylated peptide 
(139-152) M+H+ = 1782.7 (Tables 6-1, 6-2 and 6-3 and Fig. 6 -6 )
IDKTDYMVGSYGPR that appeared after treatment with ET. This peptide has four 
potential amino acid residues as candidates for phosphorylation: Thr142, Tyr144, Ser148 
and Tyr149.
The unphosphorylated form of the peptide was also observed in both unstimulated 
(M+H+ = 1600.7) and stimulated (M+H+ = 1606.8) RhoGDI. In addition to this the 
shorter version of the peptide (TDYMVGSYGPR) was present in the spectrum with all 
three peaks: M+H+ = 1244.5 representing the unphosphorylated peptide obtained from 
unstimulated cells; M+H+ = 1250.6 representing the unphosphorylated peptide obtained 
from stimulated cells; and M+H+ = 1426.5 representing the dually phosphorylated 
RhoGDI peptide from stimulated cells.
The mass of M+H+ = 1782.8 also covers another peptide from RhoGDI (153-167) 
(AEEYEFLTPMEEAPK) (Tables 6-1, 6-2 and 6-3). Both peptides (139-152 and 153- 
167) could therefore be giving rise to the peak with such high intensity (Fig. 6 -6 ).
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Obs mass Exp mass A Peptide
948.508 948.539 -0.031 51-58
979.442 979.487 -0.045 128-134
985.461 985.534 -0.073 128-134+ [UC] Arg
1244.462 1244.549 -0.087 142-152
1250.471 1250.596 -0.125 142-152 + [13C] Arg
1426.396 1426.523 -0.127 142-152+ 2P + 1 Ox Met + [l3C] Arg
1600.641 1600.755 -0.114 139-152
1606.659 1606.802 -0.143 139-152 + [,3C] Arg
1641.699 1641.814 -0.115 187-199
1649.798 1649.909 -0.111 59-74
1655.817 1655.956 -0.139 59-74+ [13C] Arg
1721.590 1721.781 0.191 187-199 + P
1782.685 1782.729 -0.044 139-152 + 2P + 1 Ox Met + [13C] Arg
1782.685 1782.801 -0.116 153-167
1889.835 1889.850 -0.015 121-134+ 2P + [13C] Arg
1916.861 1916.932 -0.071 34-49
1922.876 1922.979 -0.103 34-49 + [13C] Arg
2363.163 2363.106 0.057 181-199
2575.329 2575.308 0.021 75-98
Table 6-3 Table of RhoGDI peptides recovered from spot s4. Masses observed from the 
spectrum correspond to the theoretical masses of tryptic-digests of RhoGDI. Peptides are 
represented as amino acid numbers in the sequence of the protein, with observed modifications: 
[l3C] Arg-arginine residue labelled with 13C; Ox Met- oxidized methionine; P-phosphate group; 
A-the difference between the mass observed and the mass expected.
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Mass
observed Mass expected Obs.-Exp. Ion
289.9 290.15 0.25 y5+2
346.1 346.17 0.07 a6-NH3+2
420.7 420.2 0.5 a7+2
492.4 492.26 -0.14 y4
502.9 503.24 -0.34 b9-H20 +2
620 619.8 0.2 y6-NH3
628.1 628.29 -0.19 b ll-H 20 +2
636.5 636.31 0.19 y6
637.6 637.29 0.31 b i i +2
651.6 651.81 -0.21 a l2+2
562 562.26 -0.26 y5-NH3
687.3 687.33 -0.03 y l2 +2
691.8 691.33 0.47 a6-NH3
705.6 705.32 0.28 bl3-H20
708.6 708.36 0.24 a6
714.7 714.33 0.37 b l3+2
717 717.37 -0.37 y7-H20
718.2 718.34 -0.14 b6-H20
719.6 719.33 0.28 b6-NH3
735.5 735.38 0.12 y7
736.4 736.35 0.15 b6
850.2 850.37 -0.17 b7-H20
938.9 938.47 0.43 a8
949.2 949.43 -0.13 b8-NH3
966.2 966.46 -0.26 b8
1012.3 1012.46 -0.16 y9-NH3
1023.7 1023.48 0.22 b9
1093.4 1094.43 -0.03 bl0-NH3
1127.1 1127.48 -0.17 yl0-NH3
1228.6 1228.53 0.43 yll-N H 3
Table 6-4 Table of masses observed for the ion 801+2. Peptide observed in the MALDI-
TOF spectrum of trypsin-digested RhoGDI, m/z 1600, was sequenced by nanospray MS/MS. 
The masses observed in the spectrum are shown with their deviation from theoretical values. 
‘b \ ‘y’ and ‘a’ ions shown are most useful for sequencing and were used to determine the 
sequence of the peptide illustrated in Fig. 6-7.
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Figure 6-7 Sequence analysis of ion 801+2 by MS/MS analysis. The unstimulated 
RhoGDI peptide m+H+ = 1600, identified in MALDI-TOF analysis, was sequenced by 
nanospray ion trap mass spectrometry. The figure illustrates the sequence generated from the 
ions recovered from the spectrum.
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Mass
observed Mass expected Obs.-Exp. Ion
287.3 287.15 0.15 b5+2
357.4 357.21 0.2 b3
360.1 360.21 -0.11 b6-NH3+2
413.2 413.24 -0.04 a4-NH3
441.0 441.23 -0.23 b4-NH3
461 461.22 -0.22 a8-NH3+2
469.9 469.74 0.16 a8+2
474.1 474.73 -0.63 b8-H20 +2
483.4 483.7 -0.3 cr 00 +
489.2 489.73 -0.53 a9-NH3+2
503.4 503.24 0.16 b9-H20 +2
512.1 512.24 -0.14 b9+2
528.4 528.27 0.13 a5-NH3
533.1 533.25 -0.15 al0-NH3+2
545.3 545.29 0.01 a5
546.2 546.76 -0.56 bl0-H2O+2
555.8 555.76 0.04 blO+2
556.6 556.26 0.34 b5-NH3
573.3 573.29 0.01 b5
623.3 623.4 -0.1 a l l +2
651.81 651.8 0.01 al2+2
656.7 656.8 -0.1 bl2-H20 +2
657.4 657.29 0.11 b 12-NH3+2
665.7 665.8 -0.1 b l2+2
674.7 674.8 -0.1 bl2+H20 +2
691.2 691.33 -0.13 a6-NH3
691.7 691.82 -0.12 al3-NH3+2
700.8 700.33 0.47 al3+2
705.2 705.32 -0.12 bl3-H20 +2
708.9 708.36 0.54 a6
714.6 714.33 0.27 b l3+2
718.3 718.34 -0.04 b6-H20
719.6 719.33 0.27 b6-NH3
723.4 723.34 0.06 bl3+H20 +2
736.5 736.35 0.15 b6
839.9 839.4 0.5 a7
850.4 850.37 0.03 b7-NH3
867.7 867.39 0.31 b7
948.4 948.45 -0.05 b8- HzO
966.6 966.48 0.12 b8
978.1 978.46 -0.36 a9- NH3
1005 1005.47 -0.47 b9- H20
Table 6-5 Table of masses observed for the ion 804+2. (Continued overleaf)
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Mass
observed Mass expected Obs.-Exp. Ion
1024.4 1023.48 -0.08 b9
1082.5 1082.52 -0.02 alO
1110 1110.5 -0.5 blO
1255.4 1255.57 -0.13 b l 1- HzO
1256.4 1256.55 -0.15 b ll-N H 3
1273.5 1273.58 -0.08 bl 1
1302.5 1302.6 -0.1 al2
1313.1 1313.57 -0.47 bl2- NH3
1330.8 1330.6 0.2 bl2
1400.1 1399.6 0.5 al3
585.9 585.29 0.61 y5
642.2 642.31 -0.11 y6
741.1 741.38 -0.28 y7
1251.7 1251.56 0.14 y l l
252.7 252.63 0.07 y4+2
521.1 521.25 -0.15 y9+2
750.9 750.84 0.06 y l3 +2
578.7 578.76 0.04 y l0+2
693.1 693.33 -0.23 y l2 +2
Table 6-5 (cont’d) Table of masses observed for the ion 804*2. Peptide observed in the 
MALDI-TOF spectrum of trypsin-digested RhoGDI, m/z 1606, was sequenced by nanospray 
MS/MS. The masses observed in the spectrum are shown with their deviation from theoretical 
values, ‘b’, ‘y’ and ‘a’ ions shown are the most useful for sequencing and were used to 
determine the sequence of the peptide illustrated in Fig. 6 -8 .
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Figure 6 - 8  Sequence analysis of the ion 804¥2 by MS/MS analysis. The stimulated 
RhoGDI peptide m+H+ = 1606, identified in MALDI-TOF analysis, was sequenced by 
nanospray ion trap mass spectrometry. The figure illustrates the sequence generated from the 
ions recovered from 
the spectrum.
168
Chapter 6
In order to confirm that the peptide (139-152) in its dually phosphorylated stimulated 
form is below the peak M+H+ = 1782.8, the peptide was sequenced using a nanospray 
ion trap mass spectrometer (Table 6 - 6  and Figs. 6-9 and 6-10). The spectrum obtained 
from MS/MS of the peak at m/z = 892+2, corresponding to M+H+ = 1782.8 is given in 
Fig. 6-9. y, b and a ions are labelled. These ions correspond to the masses of pieces of 
peptide sequence which include either the N-terminus (a, b) or the C-terminus (y). 
These ions are therefore the most useful for sequencing peptides, as compared to 
internal fragment ions, which can come from anywhere in the peptide and do not 
include either terminus. In addition to the y, a and b ions, many internal fragments were 
also identified, but these were not included in the table. For the complete list of ions 
used in the identification of the sequence see Table 6 -6 .
The fragmentation spectrum shown in Fig. 6-9 contains ion signals corresponding to the 
neutral loss of one (m/z = 843.4, ((1782.8 + 2H+ -98)/2)) and two (m/z = 794.4, 
((1782.8 + 2H+ -98*2)/2)) molecules of phosphoric acid (H3PO4, 98 Da) from the 
parent ion. These signals indicate the presence of two phosphorylated residues in the 
peptide. From the series of b and y fragment ions (indicated in Table 6 -6 ) the sequence 
of the peptide was revealed (Fig 6 - 10a) with Tyr144 and Ser148 as the two 
phosphorylation sites.
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1
Figure 6-9 The spectrum obtained from MS/MS analysis of the peak m/z = 892+2 (M+H+ 
= 1782). (Continued overleaf)
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Figure 6-9 (cont’d) The spectrum obtained from  MS/MS analysis o f the peak m/z = 
892+2 (M+H* = 1782). The ions identified in the spectrum and the sequence generated 
from them are represented in Table 6-6 and Fig. 6-10. B and D show details from the 
dense section in A and C (red rectangle). Backbone sequence ions (y, a, b) are labelled 
above the spectra. Ion signals obtained from the neutral loss of one (m/z = 843.4) and 
two (m/z = 794.4) molecules of phosphoric acid are indicated. MALDI data on RhoGDI 
phosphorylation were marginal (Fig 6-6) (see Discussion for explanation).
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Mass
observed Mass expected Obs.-Exp. Ion
474.9 475.6 0.7 y8-NH3+2
531.4 531.7 -0.3 b8+2
613.8 614.2 0.4 ylO-H3P 0 4+2
635.4 635.2 0.2 blO -N lV 2
647.9 648.23 -0.3 y5-NH,
654.2 654.9 0.7 ylO-H20 +2
654.9 654.7 0.2 yl0-NH3+2
704.7 704.8 0.1 yl 1-H20 +2
704.8 704.78 0.02 bl2-H3P 0 4+2
704.8 705.2 0.4 y6-NH3
705.2 704.8 0.5 y ll-N H 3+2
716.5 716.75 -0.25 bl 1-NH3+2
722.1 722.28 -0.18 y6
723.5 723.37 0.13 y7-H3P 04
725.3 725.26 0.04 b l l +2
731.1 731.26 -0.16 a12-NH3+2
745.6 745.25 0.35 b12-NH3+2
753.8 753.77 0.03 b l2+2
768.7 768.8 0.1 yl2-H20 +2
768.8 769.2 0.4 yl2-NH3+2
798 798.31 -0.31 b6-H20
799.8 799.29 0.51 b6- NH3
802.4 802.29 0.11 b l3+2
804.7 804.32 0.38 y7- NH3
811.6 811.3 0.3 bl3+H20 +2
816.3 816.32 -0.02 b6
821.5 821,35 0.15 y7
826.7 826.3 0.4 yl3-H20 +2
826.8 826.7 0.1 yl3-NH3+2
835.3 835.3 0 y l3+2
1090.9 1091.45 -0.55 a9
1113.1 1113.43 -0.33 y9- H3P 0 4
1410.5 1411.1 0.5 y ll-N H 3
1432.1 1432.48 -0.38 b,|-NH3
1457.7 1457.6 0.1 y 12- h 3p o 4
1461.6 1461.51 0.09 a,2-NH3
1488.7 1488.52 0.18 bl2-H20
1524.4 1524.54 -0.14 bl2+H20
1572.4 1572.63 -0.23 y 13- H3P 04
1652.6 1652.6 0.00 y 13-H20
Table 6-6 Table of masses observed for the ion 892+2. The peptide observed in the 
MALDI-TOF spectrum of trypsin-digested RhoGDI, m/z 1782, was subjected to nanospray 
sequencing. The masses observed in the spectrum are shown with their deviation from 
theoretical values. ‘b \ ‘y’ and ‘a’ ions shown are the most useful for sequencing and were used 
to determine the sequence of the peptide illustrated in Fig. 6-10.
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F ig u re  6-10 Sequence analysis o f  the ion 892+2 by M S /M S  analysis. (Continued overleaf)
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a3
b4
b6
a7
b8
b9 
b!4 -
A E E F M E E A P K
yl4
yi3
- y l 2
y9
y»
y7
y«
Mass
obs.
Mass
expected
Obs.-
Exp.
Ion
301.8 302.14 -0.24 a3
741.4 741.3 0.1 a6
854.9 854.39 0.5 a7
955.8 955.4 0.4 a8
1052.49 1052.8 0.31 a9
474.9 475.18 -0.28 b4-H20
1062.1 1062.48 -0.38 b9-H20
769.8 769.3 -0.5 b6
983.5 983.44 0.1 b8
1637.9 1637.7 0.2 b l4
704.3 704.8 -0.5 y6
1015.1 1015.1 0 y9
508.3 508.26 0.04 y9+2
784.5 784.36 0.24 y7-NH3
885.1 885.4 -0.3 y8-NH3
1565.5 1565.72 -0.22 yl3-H20
718.7 718.84 -0.14 yl2-H20
847.7 847.89 -0.29 yl4-H20
Figure 6-10 (cont’d) Sequence analysis of the ion 892+2 by MS/MS analysis. (A) The 
stimulated RhoGDI peptide m+H+ = 1782, identified in MALDI-TOF analysis, was sequenced 
by nanospray ion trap mass spectrometry. The figure illustrates the sequence generated from 
the ions recovered from the spectrum, ‘P’ represents a phosphate group. (B) A schematic 
representation of the ions generated by collision-induced dissociation (CID). The coloured 
circles represent phosphorylated Ser/Tyr residues. (C) Fragment ions obtained by MS/MS of 
the ion 8922+ that correspond to the RhoGDI peptide 153-167.
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GDIR_MOUSE MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVA 60
GDIR_RAT MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVA 60
GDIRjyiOUSE VSADPNVPNVIVTRLTLVCSTAPGPLELDLTGDLESFKKQSFVLKEGVEYRIKISFRVNR 120
GDIR_RAT VSADPNVPNVIVTRLTLVCSTAPGPLELDLTGDLESFKKQSFVLKEGVEYRIKISFRVNR 120
GDIR_MOUSE EIVSGMKYIQHTYRKGVKIDKTDYMVGSYGPRAEEYEFLTPMEEAPKGMLARGSYNIKSR 180
GDIR_RAT EIVSGMKYIQHTYRKGVKIDKTDYMVGSYGPRAEEYEFLTPMEEAPKGMLARGSYNIKSR 180
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GDIR_MOUSE FTDDDKTDHLSWEWNLTIKKEWKD 204
GDIR_RAT FTDDDKTDHLSWEWNLTIKKEWKD 204
F ig u re  6-11 C om parison o f  ra t an d  m ouse R hoG D I. Sequences w ere aligned w ith 
ClustalW . The peptide identified with mass spectrom etry is labelled in red with phosphorylated 
residues in blue. Sequence patterns recognized usually by Ser/Thr kinases are highlighted in 
light-blue. The consensus sequence is labelled w ith stars. Gi num bers are: m ouse - R hoG D I-1, 
31982030; rat - sim ilar to R hoG D I-1, 34875656.
G D I-S 2  MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVA 60
G D I-S 3  MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVA 60
G D I-S 4  MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRKYKEALLGRVA 60
G D I-S 2  VSADPNVPNVIVTRLTLVCSTAPGPLELDLTGDIESFKKQSFVLKEGVEYRIKISFRVNR 120
G D I-S 3  VSADPNVPNVIVTRLTLVCSTAPGPLELDLTGDLESFKKQSFVLKEGVEYRIKISFRVNR 120
G D I-S 4  VSADPNVPNVIVTRLTLVCSTAPGPLELDLTGDLESFKKQSFVLKEGVEYRIKISFRVNR 120
G D I-S 2  E I  VlGMKl I QHBYRKG VKIDKT dBmVGIY GP RAEE YEF LTPMEE AP KGMLARGS YNIKS R 180
G D I-S 3  E Iv J g MKIIQHBYRKGVKIDKTdI mVgI y GPRAEEYEFLTPMEEAPKGMLARGSYNIKSR 180
G D I-S 4  e iv s g m k | iq h | y r k g v k id k t d | mvg| y g p r a e e y e f l t p m e e a p k g m l a r g s y n ik s r  180
G D I-S 2  FTDDDKTDHLSWEWNLTIKKEWKD 2 0 4
G D I-S 3  FTDDDKTDHLSWEWNLTIKKEWKD 2 0 4
G D I-S 4  FTDDDKTDHLSWEWNLTIKKEWKD 2 0 4
F ig u re  6-12 D ifferences in R hoG D I isoelectric iso form s. T he peptides identified w ith 
mass spectrom etry in three different isoelectric (phospho)isoform s (see Fig. 6-5 and Tables 6-1, 
6-2 and 6-3) are labelled in yellow. Residues labelled in red are phosphorylated in stim ulated 
RhoGDI. Residues labelled in light blue are also potentially phosphorylated in stim ulated 
RhoGDI.
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6.3 Discussion
The results from the previous chapter showed that RhoGDI is purified in the enriched 
phosphoprotein fraction in rat fibroblasts, and that the phosphorylation level of this 
protein increased 4 mins after cells were stimulated with ET-1. In the experiments 
described in this chapter the goal was to further examine the phosphorylation changes of 
RhoGDI induced by ET-1. The results reported in this section indicate the identity of 
the RhoGDI peptide that is phosphorylated after ET-treatment. In addition, the 
sequencing of this peptide revealed previously unknown sites of in vivo phosphorylation 
of RhoGDI.
Initially immunoprecipitated RhoGDI was resolved on a SDS-PAGE gel (Fig. 6-2). 
Succesful immunoprecipitation of RhoGDI was verified. In addition a protein band 
(Mw~80kDa) was observed to co-precipitate with RhoGDI after ET-1 stimulation. The 
efforts to identify this protein during the course of this PhD project were unsuccsessful 
due to the following reasons:
• the separation of the proteins in SDS-PAGE was not good enough to identify the 
protein with MALDI-TOF MS; and
• the protein was not observed in 2D gels of the same experiment. The pi value of 
the protein may have been outside the pH strip range used for the first dimension 
(pH 4-7 and pH 3-10 strips were tried).
The phosphorylation of RhoGDI was immunodetected with phospho-(Ser) PKC 
substrate antibody (Fig. 6-2 B). This antibody detects proteins phosphorylated at serine, 
surrounded by arginine or lysine in -2 and +2 positions and a hydrophobic amino acid at 
the +1 position. RhoGDI was phosphorylated in unstimulated as well as ET-1
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stimulated cells. In chapter 5 phosphorylation of RhoGDI was also observed in 
unstimulated cells (Fig. 5-1). However, the level of phosphorylation of RhoGDI 
(observed with phospho-(Ser) PKC substrate antibody) after ET-1 stimulation did not 
change significantly. RhoGDI could have multiple phosphorylation sites and not all of 
them modified by stimulation in the same way. There are four possible Ser residues in 
RhopGDI that fit in the sequence motif recognized by the anti-phospho PKC substrate 
antibody: Ser47, Ser96, Ser101 and Ser115 (see Fig. 6-9 for location).
The unknown protein co-precipitating with RhoGDI was also detected with this 
antibody suggesting that it is phosphorylated on Ser. From the results obtained, it can 
not be ascertained whether this protein is phosphorylated as a result of ET-1 
stimulation. The stronger signal which was observed could come from the higher 
abundance of this protein in the stimulated cell extract (Fig. 6-2 A).
Incidentally the immunoprecipitation experiments revealed that ET-1 induces actin 
reorganization/polymerization in NRK-49F cells (Fig. 6-3). Namely, actin was binding 
with high affinity to sepharose and was purified in the control for non-specific binding. 
ET-1 was previously reported to induce actin reorganization and stress fibre formation 
in different cells, for example:
• ET-1 induced actin polymerization in airway smooth muscle cells and this 
process involved the activation of Rho (Hirshman and Emala, 1999); and
• in astrocytes ET-1 stimulated FAK/Src pathway activation and the formation of 
stress fibres (Cazaubon et al., 1997).
The phosphorylation of actin observed in chapter 5 may regulate the reorganization of 
actin observed here. In NRK-49F cells ET-1 induces anchorage-independent growth
177
Chapter 6
and on the other hand actin polymerization is important for cell adhesion (Lahaye et al., 
1999; Cazaubon et al., 1997). In this view it would be interesting to define the kind of 
cytoskeletal reorganization that ET-1 induces and how that is related to anchorage- 
independent cell growth.
2D gel separation of the immunoprecipitated RhoGDI revealed an array of spots 
forming a train-like pattern in the region corresponding to RhoGDI (Fig. 6-5). This 
pattern stems from the shift in pi of the protein, indicating the existence of additional 
charge. Additional charge is often due to protein phosphorylation (Smith et al., 1984; 
Choudhary et al,  2000) which adds negative charge to the net protein charge rendering 
the molecule movement closer to the acidic end. Additional charge can also be 
attributed to protein glycosylation but this is usually accompanied by an increase in 
molecular weight, so it was not considered as a possibility in the situation presented in 
Fig. 6-5. The results therefore suggest that RhoGDI is resolved on a 2D gel in several 
differentially phosphorylated forms. The most acidic isoelectric form (pH~5.0) of Rho 
GDI was predominant (s4, Fig. 6-5), and this one is likely to have the highest proportion 
of phosphorylation. Based on relative spot-intensity comparisons, the order of relative 
abundance of RhoGDI isoelectric isoforms is : s4>s2>s3. It could be speculated that s2 
and s4 are major isoforms and s3 is a transient one, which the protein assumes in 
between the other two isoforms. There is an additional spot at pH~4.9 more acidic than 
s4, highly likely to be another GDI isoform, which was not identified in the course of 
these experiments.
All three spots were identified by peptide mass fingerprinting to be RhoGDI-1 
(gil31982030) from the house mouse. Fibroblasts used for the studies were from rat but 
the fact that the top score in database searches was a mouse form of GDI protein is not
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significant as this protein is identical in sequence to its rat homologue, similar to 
RhoGDI-1 (gil34875656) (Fig. 6-11). In addition to this the molecular weight of the 
identified protein corresponds to the Mw of non-truncated RhoGDI-1, confirming that 
we are not looking at a different splice-variant. The protein sequence of rat homologue 
of GDI-1 was generated by computational translation of a genomic sequence and is 
supported by mRNA and EST evidence.
MALDI-TOF analysis of the three protein spots demonstrated that the majority of peaks 
identified were the same, but there were some peaks that were different among the 
spectra of the three different RhoGDI forms. Some of the different peaks were 
identified as phosphorylated peptides, agreeing with the observation of the pattern the 
protein forms on a 2D gel (Tables 6-1, 6-2 and 6-3). The most acidic spot s4 was 
shown to be the one with the most phosphorylation sites. The second most 
phosphorylated form is spot s2, which out of the three identified RhoGDI spots, was the 
most basic spot. The explanation of this result lies in the fact that phosphopeptides 
often give low-intensity signals or even no signals in MALDI-TOF spectra (Liao et al., 
1994), therefore spot s3 may have additional phosphorylation that was not detected. 
Additional experiments with the detailed sequence analysis of all potential RhoGDI 
phosphoisoforms are needed to evaluate the results observed in the experiments 
presented in this chapter.
SILAC methodology enabled the comparison of the unstimulated (12C-Arg containing 
peptides) and stimulated (13C-Arg containing peptides) RhoGDI in the same mass 
spectrum. The doublet peak-pair is the main feature of SILAC generated mass spectra 
of protein digests (Figs. 6-4 and 6-6). It consists of the first peak being the peptide that 
comes from the unstimulated cell pool (with normal Arg), and the second peak (6 Da to
179
Chapter 6
the right of the first peak) which comes from the 13C6-Arg labelled stimulated cell pool. 
Because protein extracts are mixed in equal proportion at the beginning of the 
experiment, the difference in peak intensities would correspond to the quantitative 
difference in the abundance of peptide from the unstimulated cell pool compared to the 
abundance of the same peptide in the stimulated cell pool.
A dually phosphorylated IDKTDYMVGSYGPR peptide (139-152) was observed to be 
consistently phosphorylated after treatment with ET in mass spectra of all RhoGDI 
spots (Tables 6-1, 6-2 and 6-3). The mass of this peptide coincides with the mass of the 
peptide AEEYEFLTPMEEAPK (153-167), also observed in all mass spectra. Both 
peptides could be present in the trypsin digest and give rise to the high intensity signal 
at M+H+ = 1782.8. Observation of the short form of peptide TDYMVGSYGPR (142- 
152) again as a dually phosphorylated peptide (M+H+ = 1426.3) in stimulated RhoGDI 
gave a more clear indication that the dual phosphorylation of this peptide is indeed 
present in the stimulated RhoGDI. In addition to the novel phosphorylation observed in 
the stimulated RhoGDI, unphosphorylated forms of the peptide were also identified 
through analysing spectra of both unstimulated (M+H+ = 1244.4) and stimulated (M+H+ 
= 1250.4) RhoGDI. Quantification of phosphopeptides is difficult in MALDI-TOF MS 
because the energies applied often cause dephosphorylation and this process is not 
quantitative which enables the detection of the same peptide in phosphorylated and 
unphosphorylated forms in the same spectrum (Liao et al., 1994).
Therefore the observed unphosphorylated IDKTDYMVGSYGPR peptide obtained from 
the stimulated cell pool could in fact have been dephosphorylated during spectrum 
acquisition. Because quantification of phosphorylation was not possible, the 
reproducibility of the spectra and the presence of all but one species of a single peptide
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(unphosphorylated-unstimulated, phosphorylated-unstimulated, unphosphorylated- 
stimulated and phosphorylated-stimulated) were the criteria for the selection of peaks 
for electrospray analysis.
MALDI-TOF analysis just partially helped in evaluating potential RhoGDI peptides that 
undergo phosphorylation after ET-1 stimulation. A much clearer picture would be 
formed if the phosphorylated peptides of RhoGDI were enriched prior to MS analysis.
It should be noted here that the observation of phosphorylated peptides in MALDI-TOF 
MS is difficult and the peptides observed in this chapter (Fig. 6-1) were of very low 
intensity or masked by a high signal from a different unphosphorylated peptide. This 
could also explain a dense peak MS/MS spectrum (Fig. 6-9). The data based on shown 
spectra should therefore be taken with caution. However, repeated MS/MS analysis of 
RhoGDI from several different experiments in our group confirmed the pattern of 
phosphorylation observed in this chapter.
The peptide IDKTDYMVGSYGPR has four potential phosphorylation sites, but only 
two of them have the very high probability score for phosphorylation: Tyr144 and Ser148 
based on database predictions (Scansite at http://scansite.mit.edu/ and Phosphobase at 
http://www.cbs.dtu.dk/databases/PhosphoBase/). In order to confirm the existence and 
establish the phosphorylation sites of this peptide it was sequenced with nanospray 
MS/MS. The results of the sequencing confirmed that this peptide is present in its 
dually phosphorylated form in the tryptic digest of ET-stimulated RhoGDI. Sequencing 
also revealed Tyr144 and Ser148 as the sites of modification. In the literature there are no 
reports on the phosphorylation of RhoGDI in fibroblasts. The phosphorylation of Thr 
residues of Ly-GDI, a hematopoietic cell homologue of RhoGDI-2, is the sole work
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reported on phosphorylation sites of RhoGDI (Scherle et a l,  1993). In addition to this 
RhoGDI was shown to be a substrate for PKCa in response to thrombin induced 
activation of endothelial cells (Mehta et a l,  2001).
Phosphorylation of a Ser and a Tyr residue in the same molecule suggests participation 
of at least two kinases in this process. It is not uncommon that a protein is regulated by 
dual phosphorylation, examples being ERK1/2 and Gab2 (Her et a l ,  1993; Momose et 
al,  2003). Three families of protein kinases, namely the Ser/Thr kinases, the Tyr 
kinases and the dual specificity Ser/Thr/Tyr kinases are contenders for the regulation of 
RhoGDI function. On the other hand, negative regulation of GDI phosphorylation 
would be controlled by the activity of different phosphatases. Increasing evidence of 
RhoGDI-1 being found in various multi-protein signalling complexes (Tolias et 
a l ,  1998; Hirao et a l ,  1996; Abo et al,  1994) support the view of a complex regulation 
of RhoGDI function.
The amino acid residues the phosphorylation of which was discovered in these studies 
do not fall within a consensus sequence for common kinases, although the Ser148 is 
within the binding motif for 3-phosphoinositide dependent protein kinase-1 (PDK1). 
This is a Ser/Thr protein kinase that translocates from the cytosol to the membrane after 
stimulation (Anderson et al,  1998), and this process could potentially closely follow the 
process of translocation of Rho to the membrane and its dissociation from RhoGDI. 
Substrates of PDK1 include fundamental signalling proteins: PKB, PKA, PKC zeta and 
ribosomal S6 kinase (Biondi, 2004). These kinases are also known to take part in ET- 
induced signalling pathways.
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A comparison of the sequence of different RhoGDI proteins (Fig. 6-13) shows that the 
motif is evolutionary conserved among different species and also between different 
GDI isoforms, with Ser148 being entirely conserved from yeast to human, while Tyr144 is 
present only in mammalian RhoGDI-1 and in human RhoGDI-3. In other isoforms of 
RhoGDI, Tyr is substituted by Phe (with the exception of yeast RhoGDI-1), an aromatic 
amino acid of the same size and hydropathy. It is also interesting to note that this 
segment of RhoGDI sequence forms the loop connecting p strands p6 and P7, which 
would suggest that it is more likely to evolve. The high level of conservation of this 
particular portion of the protein indicates that it may have an important function.
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G D I—1_M 0USE IDKTDYMVGSYGPRAE 1 5 4
G D I- 1_HUMAN 
G D I- 1 _ B 0 V IN  
G D I-2_M 0U SE  
GDI-2_HUM AN  
G D I-2 _ B 0 V IN  
G D I-3_M 0U SE  
G D I- 3_HUMAN 
G D I—1_C A V P0  
G D I- 1_CAEEL  
G D I-1_Y E A ST
IDKTDYMVGSYGPRAE 1 5 4  
IDKTDYMVGSYGPRAE 1 5 4  
VDKATFMVGSYGPRPE 1 5 0  
VDKATFMVGSYGPRPE 1 5 1  
VDKATFMVGSYGPRPE 1 5 0  
VDKAIFMVGSYGPRAQ 1 7 5  
VDKTVYMVGS YGP SAQ 1 7 5  
IDKTDYMVGSYGPRAE 7 3  
VENEKYMMGSYAPKLE 1 4 4  
VDKIDDHLGSYAPNTK 1 5 2
• *
Figure 6-13 Evolutionary conservation o f IDKTDYMVGSYGPRAE motif in RhoGDI 
proteins. Part of the sequence alignment, containing the peptide of interest, between different 
species is illustrated. Residues identical for all RhoGDI proteins are indicated by asterisk and 
conservative amino acid substitutions are identified by dots. CAVPO stands for Guinea pig, 
CAEEL for Caenorhabditis elegans. The GI numbers are: mouse GDI-1, 31982030; human 
GDI-1, 1707892; bovine GDI-1, 121107; mouse GDI-2, 2494703; human GDI-2, 1707893; 
bovine GDI-2, 13626951; mouse GDI-3, 2494704; human GDI-3, 4502225; guinea pig GDI-1, 
21759490; Caenorhabditis elegans GDI-1, 2494705; yeast GDI-1 2494706.
The replacement of Tyr residue in RhoGDI isoforms other than RhoGDI-1, may 
account for the differential regulation these proteins have. GDI-1 is able to bind several 
Rho/Rac GTPases: RhoA, RhoB, Racl, Rac2 and Cdc42; GDI-3 binds to RhoB whilst 
the GDI-2 Rho partner is still unidentified (Olofsson, 1999). In addition, GDI-3 is 
speculated not to be a cytosolic protein (Zalcman et al., 1996) perhaps implying a 
different role compared to the other RhoGDI isoforms.
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H isl04!
Cdc42
RhoGDI
Figure 6-14 Structure of the RhoGDI in complex with small GTPases. (A) Space-fill 
representation of the human RhoA-RhoGDI complex. RhoGDI is in blue, RhoA is in purple, 
with the GDP molecule in brick. RhoGDI Ser148, phosphorylated after ET-1 stimulation, is in 
red. YDRLRPL (amino acids 64-70) of RhoA are in green and KHFCP (amino acids 104-108) 
are in yellow. Two more molecules of RhoA (brown) and Rho GDI (turquoise) are presented. 
The image is obtained from Protein Data Bank, PDB entry: 1CC0. (B) A ribbon representation 
of Cdc42 (yellow) and RhoGDI (lilac) complex. Side chain residues of Cdc42 that form 
interactions with Ser148 and Tyr144 of RhoGDI are shown (see text for explanation). This image 
has been obtained from Dr N. Keep (Birkbeck College, London).
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Crystal structure of RhoA in complex with RhoGDI-1 (Fig. 6-11), shows that the closest 
portions of RhoA to be in contact with Ser148 in RhoGDI are the YDRLRPL (switch II) 
and KHFCP regions. Multiple alignment analysis revealed that these sequences are 
conserved between Rho/Rac proteins (Fig. 6-15) and that they are loop sequences, again 
implying their important role. Sequence YDRLRPL contains several negatively 
charged residues and some bulky residues, which would not like the vicinity of a 
negatively charged phosphate. Both regions were found in Racl to form hydrogen 
bonds and hydrophobic interactions with Rho GDI (Grizot et al., 2001). Namely, in the 
switch II region (residues 66-70) of Rac-1, the conserved amino acids Tyr64, Arg66, 
His103 and His104 form hydrogen bonds with GDI. Additionally, hydrophobic 
interactions involving Leu67 and Leu70 contribute to the stability of the Racl-RhoGDI 
complex.
RHOA MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDT 60
RAC MQAI— KCVWGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDT 58
CDC42 MQTI— KCVWGDGAVGKTCLLISYTTNKFPSEYVPTVFDNYAVTVMIGGEPYTLGLFDT 58
*  ; *  *  * * * * * * *  * * * * * * *  * *  * ; * ♦ * * ; * *  * . * ; * *
r h o a agq ed^ H ^ H s y p dtdvi lmcf sidsp dslen ipekw tpev kIfH nvp i i l v g n k k d 120
RAC A G Q E D ^ ^ ^ H sYPQTDVFLICFSLVSPASFENVRAKWYPEVrI hH nTPIILVGTKLD 118
CDC42 agqed^ ^ H s y p q t d v f l v c f s w s p s s f e n v k e k w v p e i t|h| ktp f l l v g t q i d 118
* * * * * * * * * * * * * * * ; * * * ; * ; * * * ;  * *  * ; * * ;  * *  * * ;  * _ * * ; * . . * * * .  *
RHOA LRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQ 180
RAC LRDDKDTIEKLKEKKLTPITYPQGLAMAKEIGAVKYLECSALTQRGLKTVFDEAIRAVLC 178
CDC42 LRDDPSTIEKLAKNKQKPITPETAEKLARDLKAVKYVECSPLTQKGLKNVFDEAILAALE 178
* * ; *  * > : * * * ; _  ; * _  ; * .  * ; ★ * * _  * ;  * . .  * * .  * * *
RHOA ARRGKK-KSGCLIL 193
RAC PPPVKKRKRKCLLL 192
CDC42 PPEPKK—SRRCVLL 191
* *  * •  • *
Figure 6-15 M ultip le a lignm en t o f  R hoG TP ases. R at RhoA , Rac-1 and Cdc42 sequences 
were aligned using ClustalW . The regions suspected to be in contact w ith RhoG D I are m arked 
in red with the conserved residues highlighted in black. The consensus sequence is labelled 
w ith asterisks and the conservative am ino acid substitutions are identified by dots. Gi num bers 
are: RhoA-47605935, Rac-1-40354188 and Cdc42-24637541.
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Phosphorylation of GDI on Ser148 would for this reason destabilize the Rho-RhoGDI 
complex and enable dissociation.
The possible effect of the phosphorylation of Tyr144 is less clear. This residue interacts 
with the C-terminal portion of the GTPase molecule (Fig. 6-14 B). This region contains 
basic side chains and is highly variable between small GTPase family members (Fig. 6- 
15).
6.4 Conclusions
• ET-1 stimulates the reorganization of actin in NRK-49F cells.
• ET-1 stimulates the phosphorylation of Ser148 and Tyr144 of RhoGDI-1 in NRK- 
49F cells.
• These residues appear to be important for the interaction of RhoGDI-1 with 
RhoGTPase proteins (based on their position in the protein (GDI-GTPase 
complex) and their evolutionary conservation).
• Additional phosphorylation of RhoGDI-1 both in resting and in ET-1 stimulated 
cells was observed. The exact position and significance of this remains to be 
discovered.
• An unidentified protein (Mw~80kDa), phosphorylated on Ser, co-precipitates 
with RhoGDI after ET-1 stimulation.
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CHAPTER 7. SUMMARY AND FUTURE DIRECTIONS
7.1 Summary
The main findings presented in this thesis are as follows:
• ET-1 stimulates de novo protein synthesis in human lung fibroblasts;
• ETaR and ETBR are expressed by normal rat kidney fibroblasts and the binding 
of ET-1 to the ETaR stimulates a rise in intracellular calcium levels;
• ET-1 stimulates the phosphorylation of c-Raf, ERK1/2 and p38MAPK;
• ET-1 modulates the phosphorylation of four different protein groups amongst
which are the 5 new downstream phosphoprotein targets of ET-1 and a few 
previously reported phosphoproteins; and
• ET-1 stimulates the phosphorylation of Ser148 and Tyr144 of RhoGDI-1, which
appears to influence the interactions of RhoGDI with small GTPases.
The main objective of this thesis was to generate a map of proteins modified by ET 
through monitoring two signalling effects of ET: gene expression and protein 
phosphorylation. The results obtained give an overview of the cellular processes 
modulated by ET and provide a framework for future studies.
In both proteomics studies (gene expression and protein phosphorylation) the same 
protein groups were affected by ET. These are: the cytoskeleton, chaperones, metabolic 
enzymes and regulatory proteins.
ET affects the cytoskeleton immediately by phosphorylation/dephosphorylation and by 
stimulating it to regroup (actin, chapter 6). These changes regulate mostly the
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organization of the cytoskeleton (see chapter 5 discussion). Ultimately cytoskeletal 
rearrangements result in modulations of processes such as: cell adhesion, migration, 
contraction and vesicular transport. By inducing the synthesis of cytoskeletal proteins 
cells prepare probably for proliferation, in addition to the above mentioned processes.
The regulation of the level of chaperone proteins will have an impact on protein folding, 
assembly, secretion and cell survival pathways. ET alters the phosphorylation levels of 
this protein group and in this way probably affects protein-protein interactions and as 
yet unknown signalling mechanisms.
Cytoskeletal and chaperone proteins are the most abundant cell proteins whose 
members cover wide ranges of pi values and molecular weights. Therefore they are the 
most frequently encountered protein groups in the proteomics studies that use the global 
approach. However, this should not make these proteins less interesting, especially if 
their properties are changed as a result of an extracellular stimulus. On the other hand, 
the most attractive protein group are the regulatory proteins as they can tell us which 
intracellular pathways are activated and consequently which other proteins/molecules 
might be involved in the signal. Regulatory proteins are not abundant enough and in 
addition some of the most interesting ones (kinases) are concentrated in the basic end of 
the pi range. This makes it more difficult to identify them on a 2D gel.
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Figure 7-1 A schematic representation of the proteins and cellular processes regulated by 
ET.
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By influencing the expression and phosphorylation of metabolic enzymes, ET controls 
the cells’ energy supplies and accordingly the biosynthesis and active transport of 
molecules.
The regulatory proteins identified to be modulated by ET-1 in this thesis indicate the 
involvement of the following pathways:
• Ca2+ signalling;
• Small GTPase pathways;
• Ribosomal S6 kinase activity;
• RNA processing;
• Gene transcription; and
• MAPK signalling.
The implicated pathways converge to one or more cellular responses (Fig. 7-1).
The specific use of NRK cells for the studies of transforming growth factors was a 
helpful feature. ET-1 also has been shown to stimulate transformation of this cell type 
(Lahaye et a l ,  1999). With this in mind, probably the majority of the ET stimulated 
events observed in this thesis prompt NRK cells to proliferate and transform.
Data obtained from proteomics experiments is a useful starting point for future studies. 
A more detailed investigation is needed to assign a specific function(s) for each protein 
in the network of ET signalling pathways.
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7.2 Future studies
7.2.1 RhoGDI
ET-1 stimulated the phosporylation of two sites in RhoGDI which were identified by 
nanospray sequencing. However, the results from this thesis suggested that RhoGDI is 
phosphorylated in a resting cell and that perhaps there are more 
phosphorylations/dephosphorylations happening after cell stimulation. A drawback of 
the experiments in this thesis was that the MALDI-TOF peptide analysis did not give a 
complete picture of the phosphorylation events (due to the poorer desorption and 
random dephosphorylation of phosphopeptides during the ionisation process).
A detailed peptide LC/MS/MS analysis of unstimulated and stimulated RhoGDI would 
be needed for the identification of all phosphorylation changes. The functional 
significance of these sites could then be verified by site directed mutagenesis. It would 
be very helpful if a specific antibody was raised against the identified phosphopeptides. 
By using other growth factors to stimulate the cells and using different cells it could be 
confirmed whether the pattern of the observed phosphorylations is a general rule or 
specific for the ET signal or the cell type. The final question is which of the small 
GTPases that the RhoGDI is known to bind to is affected by ET stimulation and GDI 
phosphorylation? Reverse co-immunoprecipitation experiments may be helpful in 
addressing this issue.
The observed reorganization of the actin cytoskeleton could be further verified and 
characterized by immunofluorescence microscopy. In addition specific small GTPase
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inhibitors (like the C3-toxin selective for the RhoA protein) could help to establish the 
possible link between actin reorganization and small GTPase activation.
How can one go about identifying the 80kDa protein that co-precipitates with RhoGDI 
upon stimulation? This could be approached by separating the immunoprecipitated 
protein extract on a gradient ID gel to achieve a better separation of the proteins. After 
immunodetection the protein could be cut directly from the nitrocellulose membrane 
digested with trypsin and the obtained peptides analysed by LC/MS/MS. The protein 
identity and its potential biological role could later be verified by immunodetection with 
the specific antibody if available, reverse co-immunoprecipitation, and additional 
experiments.
7.2.2 MAPK signalling
To help elucidate which ET receptors are responsible for the MAPK activation observed 
in this thesis specific receptor antagonists could be used. In addition an NRK-49F clone 
was generated in our laboratory where the expression of ETaR was suppressed by the 
use of siRNA. This will enable the investigation of cellular responses generated by ET- 
1 binding to ETBR, without the need to pharmacologically block the receptor.
The current information available about the signalling mechanisms that lead from 
GPCRs to p38MAPK is limited. Specific inhibitors of families of kinases and of 
protein phosphatases could be used to identify the enzymes relevant for the activation of 
p38MAPK. Subsequently, specific inhibitors of individual components of the relevant 
pathways could be used to delineate the signalling pathway to p38MAPK.
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Proteins that co-precipitate with p38MAPK after stimulation could be identified by 
MALDI-TOF and LC-ESI mass spectrometry. In addition SILAC methodology could 
be exploited as follows: after labelling and cell stimulation a recombinant ATF-2 (a 
substrate for p38MAPK) could be used as bait to affinity purify activated p38MAPK 
and associated proteins. Proteins that interact with the bait in a stimulation-dependent 
manner would be more abundant and give more intense peaks in MALDI-TOF analysis. 
SILAC would enable the distinction from irrelevant peptides whose abundance would 
not change upon stimulation.
7.2.3 Proteomics
The proteins identified in this thesis are just a small proportion of the proteome 
modified by ET-1 stimulation. Limits of the detection were set by the pH range (pH 4- 
7), percentage of gel (11%) and buffers used for the solubilization of proteins. In 
addition to this, low abundant proteins could not be identified. In the future, the study 
started in this thesis could be broadened by using many different pH ranges in the first 
dimension of protein separation, different types of polyacrylamide gels (gradient gels, 
gels with larger separation distance) and different solubilization cocktails. Low 
abundant proteins would need to be enriched prior to identification. Multi-photon 
detection, which was recently used in our laboratory, should significantly aid the 
sensitive detection of low-abundance proteins (Kleiner et al., 2005 in press).
In order to create statistics and overcome the problem of inter-gel variability several 
gels for one sample need to be run. More gels also means more sample load. This is a 
real issue when working with cultured cells, especially after IMAC phosphoprotein 
enrichment where the yield is 10-20% of the starting protein amount. In the future, it
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would be helpful to work with larger quantities of starting material, such as large scale 
suspension based cell production.
In vivo studies or work with primary culture of cardiac myocytes and endothelial cells 
would be more useful for a better understanding of the physiological roles of ET and for 
clinical application.
The continuation of studies of protein isoforms would require methods that allow for 
the:
• accurate measurement of quantitative data; and
• MS characterization of complete protein molecules.
The former could be achieved easily with MPD. Complete protein analysis is at the 
moment achieved with FTICR, although this method is elaborate and far from 
straightforward. Proteomics still needs to improve methods for the resolution of 
complete proteins and to develop new MS methods for rapid isoform characterization.
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A PPE N D IX
A. Proteins identified with M ALDI-TOF peptide fingerprinting from  
Table 3-1
Amino acid structure of identified proteins is shown with the sequences identified with 
MALDI-TOF highlighted in red.
si: gi 4507877; Vinculin
1  M P V F H T R T IE  S IL E P V A Q Q I SH L V IM H E E G  E V D G K A IP D L  T A PV A A V Q A A
51  V SN L V R VG K E  T V Q T T E D Q IL  K R D M P P A F IK  V E N A C T K L V Q  AAQ M LQ SDPY
101  S V P A R D Y L ID  G S R G IL S G T S  D L L L T F D E A E  V R K IIR V C K G  IL E Y L T V A E V
1 5 1  VETM EDLVTY TKNLGPGMTK M AKMIDERQQ ELTHQEHRVM  LVNSM NTVK E
2 0 1  L L P V L IS A M K  IF V T T K N S K N  Q G IE E A L K N R  N FT L E K M SA E  I N E I IR V L Q L
2 5 1  TSW DEDAW AS KDTEAMKRAL A S ID S K L N Q A  K G W LR D PSA S P G D A G E Q A IR
3 0 1  Q IL D E A G K V G  ELCAG K ERRE ILGTCKM LGQ M TDQ VADLRA R G Q G SSPV A M
3 5 1  QKAQQVSQGL DV LTA K V EN A  ARK LEAM TNS K Q S IA K K ID A  AQNW LADPNG
4 0 1  G P E G E E Q IR G  A L A E A R K IA E  L C DD PK ERD D  I L R S L G E I S A  L T S K L A D L R R
4 5 1  Q G K G D SPEA R  ALAK Q VATAL Q NLQ TK TN R A  V A N SR P A K A A  V H L E G K IE Q A
5 0 1  Q R W IDN PTV D  D R G V G Q A A IR  G LV A EG H RLA  NVMMGPYRQD LLAK CDRVDQ
5 5 1  LTA Q LA D LA A  R G E G E SPQ A R  A L A S Q L Q D S L  KDLKARMQEA M T Q E V SD V F S
601  D T T T P IK L L A  V A A T A P P D A P  N R E E V F D E R A  A N F E N H SG K L  G A TAEK AAAV
651  G TA N K STV EG  IQ A SV K T A R E  L T P Q W S A A R  IL L R N P G N Q A  AYEH FETM K N
7 0 1  QW IDNVEKMT G L V D E A ID T K  S L L D A S E E A I  KKDLDKCKVA M ANIQ PQ M LV
7 5 1  A G A T S IA R R A  N R IL L V A K R E  V E N S E D P K F R  E A V K A A S D E L  SK T ISPM V M D
801  A K A V A G N IS D  P G L Q K S F L D S  G Y R IL G A V A K  V R E A F Q P Q E P  D F P P P P P D L E
8 5 1  Q L R LT D E LA P P K P P L P E G E V  P P P R P P P P E E  K D E E F P E Q K A  GEVINQPMMM
901  A ARQ LH DEAR K W S S K G N D II AAAKRMALLM AEM SRLVRG G  SG T K R A L IQ C
951  A K D IA K A S D E  VTRLAK EVAK  Q C T D K R IR T N  L L Q V C E R IP T  I S T Q L K I L S T
10 0 1  VKATMLGRTN IS D E E S E Q A T  EM LVHNAQNL M Q SV K ETVR E A E A A S I K I R T
10 5 1  DAGFTLRW VR KTPWYQ
sl5: gi 42476296; Tropomyosin 2
1 MDAIKKKMQM L K L D K E N A ID  RAEQ AEADK K  QAEDRCK Q LE EEQQALQKKL
51 KG TEDEVEKY SE SV K E A Q E K  LEQ AEK K ATD A E A D V A S L N R  R IQ L V E E E L D
101  R A Q ERLA TA L QK LEEAEK AA D E SE R G M K V I ENRAM KDEEK MELQEMQLKE
151  A K H IA E D S D R  KYEEVARK LV I L E G E L E R S E  E R A E V A E SK C  G D L E E E L K IV
2 0 1  TN N L K SLE A Q  A D K Y STK E DK  Y E E E IK L L E E  K L K E A E T R A E  FA E R SV A K L E
2 5 1  K T ID D L E D E V  YAQKMKYKAI SE E L D N A L N D  I T S L
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sl7: gi 136085; Tropomyosin 3
1  MEAIKKKMQM LKLDK ENALD RAEQ AEAEQ K  Q A E E R SK Q L E  DELAAMQKKL
51 KG TEDELDKY SEA LK D AQ EK  L ELAEK K AAD AEAEVASLNR RIQLVEEELD
1 0 1  R A Q ERLA T A L  Q K LEEAEK AA D E SE R G M K V I E N R A L K D E E K  M E L Q E IQ LK E
1 51  A K H IA E E A D R  KYEEVARK LV IIEGDLERTE E R A E L A E S K C  SE L E E E L K N V
2 0 1  T N N L K SLE A Q  AEK YSQ K EDK  Y E E E I K IL T D  K L K E A ET R A E  F A E R SV A K L E
2 5 1  KTIDDLEDEL Y AQ K LK YK AI SE E L D H A L N D  M T S I
s29: gi 17986264; Myosin light polypeptide 6
1  M CDFTEDQ TA D L IP S T E F K E  AFQLFDRTGD GKILYSQCGD VMRALGQNPT
51  N A EVLK VLG N PK SDEM NVKV L D FE H FL PM L  QTVAKNKDQG T Y ED Y V E G LR
101  V FD K EG N G TV  MGAEIRHVLV TLG EKM TEEE VEM LVAGHED S N G C IN Y E A F
151  V R H IL S G
s5: gi 6470150; GRP78
1  MEEDKKEDVG T W G ID L G T T  Y SCVG VFK NG  RVEIIANDQG NRITPSYVAF
51  T P E G E R L IG D  A A K N Q L TSN P EN TV F D A K R L  IG R T W N D P S V  Q Q D IK F L P F K
101  W E K K T K P Y I QVDIG G G Q TK  T F A P E E IS A M  VLTKM KETAE AYLG KKVTH A
151  WTVPAYFND AQRQATKDAG TIAGLNVMRI I N E P T A A A I A  YGLDKREGEK
2 0 1  N IL V F D L G G G  T F D V S L L T ID  N G V F E W A T N  G DTH LG G EDF D Q R V M E H FIK
2 5 1  LYKKKTGKDV RKDNRAVQKL RREVEK AK RA L S S Q H Q A R IE  IESFYEGEDF
3 0 1  SETLTRAKFE ELNMDLFRST MKPVQKVLED S D L K K S D ID E  IVLVGGSTRI
3 51  P K IQ Q L V K E F  F N G K E P S R G I N PD EA V A YG A  AVQ A G V LSG D  Q DT G D LV LLD
401  V C P L T L G IE T  V G G V M TK LIP R N T W P T K K S  Q IF S T A S D N Q  P T V T IK V Y E G
4 51  ERPLTKDNHL LGTFDLTGIP PAPRGVPQIE VTFEIDVNGI LRVT A E D K G T
5 0 1  G N K N K IT IT N  D Q N R L T P E E I ERMVNDAEKF A E E D K K L K E R  ID T R N E L E S Y
5 5 1  A Y SL K N Q IG D  K EK L G G K LSS EDKETM EKAV E E K IE W L E S H  Q D A D IE D F K A
601 K K K E L E E IV Q  P I I S K L Y G S A  G P P P T G E E D T  AELHHHHHH
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s3: gi 2274968; Glucosidase
1 MAAVAAVAAR RR R SW A SL V L A F L G V C L G IT  L A V D R S N F K T  C E E S S F C K R Q
51 R S I R P G L S P Y  R A L L D SL Q L G  P D S L T V H L IH  E V T K V L L V L E  LQGLQKNMTR
1 01  F R ID E L E P R R  PR Y R V PD V L V  A D P P IA R L S V  S G R D E N S V E L  T M A E G P Y K II
1 51  L T A R P F R L D L  L E D R S L L L S V  N A R G L L E FE H  Q R A PR V SQ G S KDPAEGDGAQ
2 0 1  PEETPRDGDK PEETQGKAEK DEPGAWEETF K T H SD SK P Y G  P M S V G L D F S L
2 5 1  PG M EH V Y G IP E H ADNLRLK V TEGGEPYRLY N L D V F Q Y E L Y  N PM A LYG SV P
3 0 1  V LLAH NPH RD L G IFW L N A A E  T W V D IS S N T A  GKTLFGKMMD Y L Q G SG E T PQ
3 5 1  TDVRWMSETG IID V F L L L G P  S IS D V F R Q Y A  SLTGTQALPP LFSLGYHQSR
4 01  W NYRDEADVL EVDQ GFDDHN L P C D V IW L D I EH A D G K R Y FT W D P S R F P Q P R
4 51  TM LERLASK R R K L V A IV D P H  IK V D SG Y R V H  E E L R N L G L Y V  K T R D G SD Y EG
5 0 1  WCWPGSAGYP DFTNPTMRAW  W ANMFSYDNY E G SA PN L FV W  N D M N E PSV FN
5 5 1  GPEVTM LKDA QHYGGWEHRD VH N IY G L Y V H  M ATADGLRQR SG G M E R PFV L
601  A R A F F A G S Q R  FGAVWTGDNT AEWDHLKISI PM C L SLG LVG  L SFC G A D V G G
651  F F K N P E P E L L  VRWYQMGAYQ PF FR A H A H L D  TG R R EPW LLP SQHNDIIRDA
7 0 1  L G Q R Y SL L P F  WYTLLYQAHR EG IPV M R PLW  V Q Y PQ D V T T F N ID D Q Y L L G D
7 5 1  A L L V H P V S D S  GAHGVQVYLP GQGEVW YDIQ SYQKH HGPQT L Y L P V T L S S I
801  P V F Q R G G T IV  PRW M RVRRSS E C M K D D P IT L  F V A L S P Q G T A  Q G ELFLD D G Y
851  TFN Y Q T R Q E F L L R R F S F S G N  T L V S S S A D P E  G H F E T P IW IE  R V V IIG A G K P
901  A A W L Q T K G S  P E S R L S F Q H D  P E T S V L V L R K  P G IN V A S D W S  IH L R
s22: gi 189438; Cytochrome P-450-scc
1 HFYWELRQKG SVHHDYRGML YRLLG DSK M S F E D IK A N V T E  M LAGG VDTTS
51 MTLQWHLYEM ARNLKVQDML RAEVLAARHQ AQGDMATMLQ LVPLLKASIK
101  ETLRLHPISV TLQRYLVNDL VLRDYMIPAK TLVQVAIYAL G R E P T F F F D P
151  EN FD PT R W L S K D K N IT Y F R N  LGFGWGVRQC L G R R IA E L E M  T IF L IN M L E N
2 0 1  F R V E IQ H L S D  V G T T F N L IL M  P E K P IS F T F W  PF N Q E A T Q Q
s24: gi 852428; Ornithine decarboxylase antizyme
1  N P P C S G S S I A  T A S P E R R K G I N P A P P S T P A A  PCRSLACTAA AAAAVRVPGS
51 PSTAWTRVR GLGGAPDAPH P P L K IP G G R G  N SQ R D H N L SA  N L F Y S D D R L N
101  VTEELTSNDK T R IL N V Q S R L  TDAK RINW RT V L S G G S L Y IE  IP G G A L P E G S
151  KDSFAVLLEF AEEQ LR A D H V  F IC F H K N R E D  R A A L L R T F S F  L G F E IV R P G H
2 0 1  PL V PK R P D A C  F M A Y T FE R ES SG E E E E
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s2: gi 55749531; Splicing factor 3B subunit 2
1  M ATEH PEPPK  A E L Q L P P P P P  PGHYGAWAAQ E L Q A K L A E IG  A P IQ G N R E E L
51 V E R L Q SY T R Q  TGIVLNRPVL RGEDGDKAAP P P M S A Q L P G I P M P P P P L G L P
101  P L Q P P P P P P P  P P P G L G L G F P  M AH PPNLG PP P P L R V G E P V A  L SE E E R L K L A
151  QQQAALLMQQ EERAKQQGDH SL K E H E L L E Q  QKRAAVLLEQ ERQQEIAKM G
2 0 1  TPV PR PPQ D M  G Q IG V R T P L G  PR V A A P V G P V  G P TP T V L PM G  A P V P R P R G P P
2 5 1  PPPG D EN R EM  DDPSVGPKIP Q A L E K IL Q L K  E SR Q E E M N SQ  Q EEEEM ETDA
3 0 1  R S S L G Q S A S E  T E E D T V S V S K  KEKNRKRRNR KKKKKPQRVR G V S S E S S G D R
3 5 1  E K D S T R S R G S  D S P A A D V E IE  Y V T E E P E IY E  P N F I F F K R I F  EAFKLTDDVK
401  K EK EK EPEK L D K L E N SA A P K  KKGFEEEHKD S D D D S S D D E Q  E K K P E A P K L S
4 5 1  KKKLRRMNRF TVAELK Q LVA R P D W E M H D V  TA Q D PK LL VH  L K A T R N SV P V
5 0 1  PRHWCFKRKY LQ G K R G IEK P P F E L P D F I K R  T G IQ E M R E A L  QEKEEQKTMK
5 5 1  SKM REKVRPK M G K ID ID Y Q K  LHDAFFKW QT K P K L T IH G D L  Y Y EG K EF E T R
601  LK EK K PG DLS DELRISLGMP VGPNAHKVPP PWLIAMQRYG P P P S Y P N L K I
651  P G L N S P I P E S  CSFGYHAGGW G K PPVDETG K  PL Y G D V F G T N  A A EF Q T K T EE
7 0 1  E EID R TP W G E  L E P S D E E S S E  E E E E E E S D E D  K P D E T G F IT P  A D S G L IT P G G
7 5 1  FS SV P A G M E T  P E L IE L R K K K  IE E A M D G SE T  P Q L F T V L P E K  RTATVGGAMM
8 0 1  GSTHIYDMST VM SRK G PAPE L Q G VEVALAP EELELDPM AM  TQKYEEHVRE
851  QQAQVEKEDF SDMVAEHAAK QKQKKRKAQP Q DSRG G SK K Y K EFK F
s4: gi 136652; Nucleolar transcription factor 1 (UBF-1)
1 M NGEADCPTD LEMAAPKGQD RW SQEDMLTL LEC M K N N LPS NDSSKFKTTE
51 SHMDWEKVAF KDFSGDMCKL K W V E ISN E V R  K F R T L T E L IL  DAQEHVKNPY
1 01  KGKKLKKHPD F P K K P L T P Y F  RFFM EKRAKY AKLHPEMSNL DLTKILSKKY
151  KELPEKKKMK Y IQ D F Q R E K Q  E F E R N L A R F R  E D H P D L IQ N A  K K S D IP E K P K
2 0 1  TPQQLWYTHE KKVYLKVRPD E IM R D Y IQ K H  PE LN ISE E G I T K ST L T K A E R
2 5 1  QLKDKFDGRP T K P P P N S Y S L  YCAELMANMK D V PST E R M V L  CSQQWKLLSQ
3 0 1  KEKDAYHKKC DQKKKDYEVE LLRFLESLPE EEQQRVLGEE KM LNINKKQA
3 5 1  T S P A S K K P A Q  EGGKGGSEKP K R P V S A M F IF  SE E K R R Q LQ E  E R P E L S E S E L
401  TRLLARMWND LSEKKKAKYK AREA A LK A Q S ER K PG G E R E E  R G K L P E SP K R
451  A E E IW Q Q S V I GDYLARFKND RVKALKAMEM TWNNMEKKEK LMWIKKAAED
5 0 1  Q K R Y E R ELSE M R APPA A T N S SKKMKFQGEP KKPPMNGYQK F S Q E L L S N G E
5 5 1  LNHLPLKERM  VEIGSRWQRI SQ SQKEHYKK LAEEQQKQYK VHLDLWVKSL
601  SPQDRAAYKE Y ISN K R K SM T  K L R G P N P K SS R T T L Q S K S E S  E ED D E E D E D D
651  E D ED E E EE D D  E N G D SSE D G G  D S S E S S S E D E  SE D G D E N E E D  DEDED D D E DD
701  D E D E D N E SE G  S S S S S S S S G D  S S D S D S N
sl4:gi 1881852 ;SRY (sex determining region Y)-box 5
1 MPALRINSGA G P L K A SV P A A  L A S P S A R V S T  IG Y L N D H D A V  TKAIQEARQM
51 K EQLRREQQV L D G K V A W N S  L G LNNCRTEK  E K T T L E S L T Q  QLAVKQNQEG
101  KFSHAMMDFN L SG D SD G S A G  V S E S R I Y R E S  R G R G S N E P H I KRPMNAFMVW
151  AKDERRKILQ A F P D M H N S N I SK IL G SR W K A  MTNLEKQPYY EEQARLSKQH
2 0 1  LEK YPDYKYK PRPKRTCLVD GKKLRIGEYK AIMRNRRQEM RQYFNVGQQA
2 5 1  Q I P I A T A G W  YPGAIAM AGM  P S P H L P S E H S  S V S S S P E P G M  P V IQ S T Y G V K
301  G E E P H IK E E I  Q A E D IN G E IY  D E Y D E E E D D P D V D Y G SD SE N  H IA G Q A N
199
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s23: gi 20379074; Ras-related protein Rab-14 (long)
1 MATTPYNYSY IFK Y IIIG D M  G VGKSCLLHQ FTEKKFMADC PHTIGVEFGT
51 R I I E V S G Q K I  KLQIWDTAGQ ERFRAVTRSY YRGAAGALMV YDITRRSTYN
1 0 1  H LSSW L TD A R  N L T N P N T V I I  L IG N K A D L E A  Q R D V TY EEA K  QFAEENGLLF
151  LEASAKTGEN V E D A F LE A A K  K IY Q N IQ D G S  L D L N A A E SG V  Q H K PSAPQ G G
2 0 1  R L T S E P Q P Q R  EGCGC
s28: gi 6563200; Ras-related protein Rab-14 (short)
1  M A T |P Y N Y S Y  IFK Y IIIG D M  GVGKSCLLHQ FTEKKFMADC PHTIGVEFGT
51 R IIEV SGQ KI KLQIWDTAGQ ERFRAVTRSY YRGAAGALMV YDITRRSTYN
1 0 1  H LSSW L TD A R  N L T N P N T V I I  L IG N K A D L E A  Q R D V TY EEA K  QFAEENGLLF
1 5 1  LEASAKTGEN VEDAFLEAAK K IY Q N IQ D G S  L D L N A A E SG V  Q H K PSAPQ G G
2 0 1  R L T S E P Q P Q R  EGCGC
s31: gi 4506367 RAB3A, member RAS oncogene family
1 MASATDSRYG QKESSDQNFD YM FKILIIGN SSVGKTSFLF R Y A D D S F T P A
51 F V S T V G ID F K  V K T IY R N D K K  IKLQIWDTAG QERYRTITTA Y Y R G A M G FIL
1 0 1  M Y D IT N E E S F  NAVQ DW STQ I KTYSWDNAQV LLVGNKCDME D E R W S S E R G
1 51  R Q LADH LGFE F F E A S A K D N I N V K Q T FE R LE  D V IC E K M S E S  LD TA D PA V T G
2 0 1  AKQ G PQ LSDQ  QVPPHQDCAC
s33: gi 125969; 40S ribosomal protein SA; laminin-binding protein
1  SGALDVLQMK E E D V L K FL A A  GTHLGGTNLD FQ M E Q Y IY K R  K SDG IYIIN L
51 KRTW EKLLLA ARAIVAIENP ADVSVISSRN TG Q R A V LK FA  AATGATPIAG
1 0 1  RFTPGTFTNQ IQAAFREPRL LWTDPRADH QPLTEASYVN LPTIALCNTD
1 5 1  SPLRYVDIAI PCNNKGAHSV GLMWWMLARE V L R M R G T IS R  EHPW EVM PDL
2 0 1  Y F Y R D P E E IE  KEEQAAAEKA VTKEEFQGEW  T A P A P E F T A T  Q PEVADW SEG
2 5 1  V Q V P S V P IQ Q  FPT ED W SA Q P A TED W SA A PT AQATEW VGAT TDWS
s35: gi 1168873; Cyclin-dependent kinase inhibitor IB
1 M SN V R V SN G S PSLERMDARQ AEHPKPSACR N L F G P V D H E E  LTR D LEK H C R
51 DMEEASQRKW N FD FQ N H K PL EGKYEWQEVE K G S L P E F Y Y R  P P R P P K G A C K
101  V PA Q E SQ D V S G S R P A A P L IG  A P A N S E D T H L  VDPKTDPSDS QTGLAEQCAG
151  IRKRPATDDS STQNKRANRT E E N V S D G S P N  A G SV E Q T PK K  PGLRRRQT
s7: gi 938227; Filamin
1  W G K S A D F W  E A IG T E V G T L  G F S IE G P S Q A  KIECDDKGDG SCDVRYWPTE
51  PGEYAVHVIC DDEDIRDSPF I A H IL P A P P D  C FP D K V K A FG  P G L E P T G C IV
1 01  D K P A E F T ID A  RAAGKGDLKL YAQDADGCPI D IK V IP N G N G  TFRCSYVPTK
151  P IK H T IIIS W  GGVNVPKSPF RVN V G EG SH P ER VK VY G PG V  E K T A S R P M SP
2 0 1  P T F T V D C S E A  G Q G D V S IG IK  C A P G W G P A E  A
2 0 0
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s l l :  gi 1352712 Plasminogen activator inhibitor-2 precursor
l M EDLCVANTL FA L N L FK H L A K A S P T Q N L F L S P W S IS S T M A MVYM GSRGST
51 EDQMAKVLQF NEVG ANAVTP M T P E N F T SC G FM Q Q IQ K G SY P D A IL Q A Q A A
101 D K I H S S F R S L S S A IN A S T G N Y L L E SV N K L F G E K S A S F R E E Y IR L C Q K Y Y S
1 51 SEPQAVDFLE CAEEARKKIN SWVKTQTKGK IPNLLPEGSV DGDTRM VLVN
201 AVYFKGKWKT PFE K K LN G LY P F R V N S A Q R T PVQMMYLREK L N IG Y IE D L K
2 5 1 A Q IL E L P Y A G D V SM FL L LP D E IA D V S T G L E L L E S E IT Y D K LNKWTSKDKM
3 0 1 AEDEVEVYIP Q FK LE EH Y EL R SIL R SM G M E DA FN K G R A N F SG M SE R N D LF
351 LSEVFHQAM V D V N EEG TEAA AGTGGVMTGR TG H G G PQ FVA D H P F L F L IM H
401 K ITNCILFFG R F S S P
s20: gi 1703319; Annexin 4
l MATKGGTVKA ASGFNAMEDA QTLRKAMKGL GTDEDAIISV LAYRNTAQRQ
51 E IR T A Y K S T I G R D L ID D L K S E L S G N F E Q V I VGMMTPTVLY DVQELRRAMK
101 G A G TD EG C LI E IL A S R T P E E IRRISQTYQQ Q Y G R S L E D D I R SD T SF M F Q R
151 V L V SL SA G G R DEGNYLDDAL VRQDAQDLYE AGEKKWGTDE V K F L T V L C S R
2 0 1 NRNHLLHVFD E Y K R IS Q K D I E Q S I K S E T S G S F E D A L L A I V KCM RNKSAYF
2 5 1 AEKLYKSMKG L G T D D N T L IR V M VSR A EID M L D IR A H F K R L Y G K S L Y S F IK
3 01 G DTSGDYRKV LLVLCGGDD
s25: gi 136479; Tumour protein, translationally-controlled 1
1  M I I YRDLISH DEMFSDIYKI REIADGLCLE V EG K M VSRTE G N ID D S L IG G
51 N A SA E G PE G E  G T E S T V IT G V  DIVM NH H LQ E T SF T K E A Y K K  Y IK D Y M K S IK
101  GKLEEQRPER VKPFM TGAAE Q IK H IL A N F K  N Y Q F F IG E N M  NPDGM VALLD
151  YREDGVTPYM  IFFK D G LE M E  KC
s26: gi 4757840; Bcl2-related protein A1
1  M TD C E FG Y IY  RLAQ DYLQCV L Q IP Q P G S G P  SK T SR V L Q N V  A FSV Q K E V E K
51 N L K SC LDN V N  W S V D T A R T L  FNQVMEKEFE DGIINWGRIV T I F A F E G I L I
101  K K L L R Q Q IA P D V D T Y K E IS Y  F V A E F IM N N T  GEWIRQNGGW E N G FV K K F E P
151  KSGW MTFLEV T G K IC E M L SL  LKQYC
s30: gi 825671; Nucleophosmin
1  QNYLFG CELK  ADKDYHFKVD NDENEHQLSL R T V SL G A G A K  D E L H IV E A E A
51 M N Y E G S P IK V  TLATLKMSVQ PTVSLGGFEI TPPW LRLKC G S G P V H IS G Q
1 01  HLVAVEEDAE SE D E E E E D V K  L L S IS G K R S A  PG G G SK V PQ K  KVKLAADEDD
1 51  DDDDEEDDDE DD D D DD FD DE EA EEK A PV K K  S IR D T P A K N A  QKSNQ NG KDS
2 0 1  K P S S T P R S K G  Q ESFK K Q EK T PKTPKGPSSV E D IK A K M Q A S IE K G G S L P K V
2 5 1  E A K F IN Y V K N  CFRMTDQEAI QDLWQWRKSL
2 0 1
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B. Proteins identified with MALDI-TOF peptide fingerprinting from  
Table 5-1
Sequences of proteins from table 5-1 are shown. All sequences are obtained from rat 
unless otherwise specified. The peptides identified by mass spectrometry and database 
searches are displayed in red. If a protein was identified from an organism other than 
rat, closest sequences from rat are also shown. The differences (between the sequence 
from rat and the sequence from other species) if present, are highlighted in black.
s l l  (also slO): gi 809561; gamma-actin [Mus musculus]
1  LVID N G SG M C  KAGFAGDDAP R A V F P S IV G R  PRHQGVMVGM GQKDSYVGDE
51 A Q S K R G IL T L  K Y P IE H G IV T  NWDDMEKIWH HTFYNELRVA PEEHPVLLTE
1 01  APLNPKANRE KM TQ IM FETF N T PA M Y V A IQ  A V L S L Y A S G R  TTGIVMDSGD
151  GVTHTVPIYE GYALPHAILR LDLAGRDLTD YLMKILTERG YSFTTTAERE
2 0 1  IV R D IK E K L C  YVALDFEQEM  A T A A S S S S L E  KSYELPDGQV ITIGNERFRC
2 5 1  P E A L F Q P S F L  G M E SC G IH ET  T F N S IM K C D V  DIRKDLYANT VLSGGTTMYP
3 0 1  GIADRMQKEI TALAPSTMKI KIIAPPERKY S V W IG G S IL A  SLSTFQ Q M W I
3 5 1  SK Q EY D E SG P S IV H R K C F
gi 34856512; similar to gamma actin-like protein [Rattus norvegicus]
1  M E E E IA A L V I DNGSGMCKAG FAGDDAPRAV F P S IV G R P R H  QGVMVGMGQK
51  DSYVGDEAQS K R G IL T L K Y P  IE H G IV T N W D  DMEKIWHHTF YNELRVAPEE
101  HPVLLTEAPL NPKANREKMT Q IM F E T F N T P  A M Y V A IQ A V L  S L Y A SG R T T G
151  IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF
2 0 1  TTTAEREIV R  D IK E K L C Y V A  LDFEQ EM ATA A S S S S L E K S Y  ELPDGQVITI
2 5 1  G N E R FR C PE A  LFQ P SFL G M E  S C G IH E T T F N  SIMKCDVDIR KDLYANTVLS
301  GGTTMYPGIA DRMQKEITAL APSTM K IK II APPERKYSVW I G G S I L A S L S
3 51  TFQQM W ISKQ E Y D E Q A P P L S  TANASRW TEQ V P G IC C M S
gi 13592133; cytoplasmic beta-actin [Rattus norvegicus]
1 M D D D IA A L W  DNGSGMCKAG FAGDDAPRAV F P S IV G R P R H  QGVMVGMGQK
5 1  DSYVGDEAQS K R G IL T L K Y P  IE H G IV T N W D  DM EKIW HHTF YNELRVAPEE
1 0 1  HPVLLTEAPL NPKANREKMT Q IM F E T F N T P  A M Y V A IQ A V L  S L Y A SG R T T G
1 5 1  IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF
2 0 1  TTTAEREIV R  D IK E K L C Y V A  LD FEQ EM A TA  A S S S S L E K S Y  ELPDGQVITI
2 5 1  G N E R FR C PE A  L FQ P SFL G M E  S C G IH E T T F N  S IM K C D V D IR  KDLYANTVLS
3 0 1  GGTTMYPGIA DRMQKEITAL APSTM K IK II APPERKYSVW I G G S I L A S L S
3 5 1  TFQQM W ISKQ E Y D E S G P S I V  HRKCF
2 0 2
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s4:gi 13242237; heat shock protein 8; Heat shock cognate protein 70; heat shock 
70kD protein 8 [Rattus norvegicus]
1  M SK G P A V G ID  LG T TY SC V G V  F Q H G K V E IIA  N D Q G N R T T P S YVAFTDTERL
51  IG DAAK NQ VA MNPTNTVFDA K R L IG R R F D D  AWQSDMKHW PFMWNDAGR
1 0 1  PKVQVEYKGE T K S F Y P E E V S  SM VLTKM KEI A EA Y L G K TV T NAWTVPAYF
151  NDSQ RQ ATK D AGTIAGLNVL RIINEPTAAA IAYGLDKKVG AERNVLIFDL
2 0 1  GGGTFDVSIL TIEDGIFEVK STAGDTHLGG EDFDNRMVNH FIAEFKRKHK
2 5 1  K D IS E N K R A V  R R LR T A C E RA  KRTLSSSTQA SIE ID SL Y E G  ID FY TSIT R A
3 0 1  RFEELNADLF R G TLD PV EK A  LR DA K L D K SQ  IH D IV L V G G S  T R IP K IQ K L L
3 5 1  QDFFNGKELN KSINPDEAVA YGAAVQAAIL SG D K SEN V Q D  L L L L D V T P L S
401  LG IE TA G G V M  T V L IK R N T T I PTKQTQTFTT YSDNQPGVLI QVYEGERAMT
451  KDNNLLGKFE LTGIPPAPRG V P Q I E V T F D I  D A N G IL N V S A  V D K STG K EN K
5 0 1  IT IT N D K G R L  SKEDIERMVQ EAEK YK AEDE KQRDKVSSKN SLESYAFNMK
5 5 1  ATVEDEK LQ G  K IN D E D K Q K I L D K C N E IIS W  LDK NQ TAEK E E FEH Q Q K EL E
601  K V C N P IIT K L  YQSAGGMPGG M PGGFPGGGA P P S G G A S S G P  T IE E V D
gi 123647; Heat shock cognate 71 kDa protein [Cricetulus griseus]
1  M SK G PA V G ID  L G TTY SC V G V  F Q H G K V E IIA  N D Q G N R T T P S YVAFTDTERL
51 IG DAAK NQ VA M N PT N TV FDA  K R L IG R R F D D  A W Q SDM K H W  P F M W N D A G R
101  PKVQVEYKGE AKSFYPEEVS SM VLTKM KEI A E A Y L G K T V T  NAWTVPAYF
151  NDSQRQATKD A G T IA G L N V L  RIINEPTAAA IAYGLDKKVG A E R N V L IF D L
2 0 1  G G G T F D V S IL  T IE D G IF E V K  STAG DTH LG G  EDFDNRM VNH FIAEFKRNDK
2 5 1  K D IS E N K R A V  R R LR TA C ERA  KRTLSSSTQA SIE ID SL Y E G  ID FY TSIT R A
3 0 1  RFEELNADLF R G TLD PV EK A  L RDAK LDK SQ  IH D IV L V G G S  T R IP K IQ K L L
3 5 1  Q D FFN G K ELN  K S INPDEAVA YGAAVQAAIL SG D K SEN V Q D  L L L L D V T P L S
401  LG IETAG G VM  T V L IK R N T T I PT K Q T Q T F T T  YSDNQPGVLI QVYEGERAMT
4 51  K DNNLLG K FE L T G IP P A P R G  V P Q I E V T F D I  D A N G IL N V S A  V D K STG K EN K
5 01  IT IT N D K G R L  SKEDIERMVQ EAEK Y K A ED E  KQRDKVSSKN SLESYAFNMK
5 5 1  ATVEDEK LQ G  K IN D E D K Q K I L D K C N E IIS W  LDK NQ TAEK E E FEH Q Q K E LE
601  K V C N P IIT K L  YQSAGGMPGG M PGGFPGGGA P P S G G A S S G P  T IE E V D
203
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s4a: gi 806907; FK506 binding protein 10; FK506 binding protein 6 (65 kDa); 
FK506 binding protein 10 (65 kDa) [Mus musculus]
1  M F L V G SSS H T  L H R V R IL P L L  L L L Q T L E R G L  G R A SP A G A P L  E D W I E R Y H I
5 1  PRACPREVQM GDFVRYHYNG T F E D G K K F D S S Y D R S T L V A I W G V G R L IT G
1 0 1  MDRGLMGMCV N E R R R L IV P P  H L G Y G SIG V A  G L IP P D A T L Y  F D W L L D V W N
1 5 1  K A D T V Q S T IL  L R PPY C PRM V  Q N SD FV R Y H Y  N G T LL D G T G F DNSYSRGGTY
2 0 1  DTYIGSGWLI KGMDQGLLGM C P G E K R K I I I  PPFLAYGEKG Y G T V IP P Q A S
2 5 1  L V F Y V L L L D V  H NPK DTVQLE T LE L PQ G C V R  RAVAGDFMRY HYNGSLM DGT
3 0 1  L F D S S Y S R N H  TYNTYVGQGY IIP G M D Q G L Q  G A C IG E R R R I T V PPH LA Y G E
3 5 1  N G T G D K IP G S  A V L IF D V H V I D F H N P S D P V E  IK T L S R P P E N  C N E T S K IG D F
4 0 1  IR Y H Y N C S L L  DGTRLFSSHD YEAPQEITLG A N K V IE G L D R  GLQGMCVGER
4 5 1  RQLIVPPHLA HGENGARGVP G S A V L L F E V E  L V S R E D G L P T  GYLFVW YQDP
5 0 1  S T SL F E D M D L  N K D G E V PPE E  F S S F I K A Q V N  EGKGRLMPGQ D P D K T IS D M F
5 5 1  QNQDRNQDGK IT A E E L K L K S  D EDQ ERVH EE L
gi 34873708; similar to 65kDa FK506-binding protein [Rattus norvegicus]
1  M FLV G A PSH T L P R L H IL P L L  L L L Q T L E R G L  GRASPSGAPL E D W I E R Y H I
5 1  PRACPREVQM  GDFVRYHYNG T F E D G K K F D S S Y D R S T L V A I IV G V G R L IT G
1 0 1  MDRGLMGMCV N E R R R L I IP P  H L G Y G S IG L A  G L IP P D A T L Y  F D W L L D V W N
1 5 1  KEDTVQSTIL LRPPYCPRMV R N SD FV R Y H Y  N G T L L D G T A F D S S Y S R G G T Y
2 0 1  DTYIGSGWLI KGMDQGLLGM C P G E K R K I I I  PPFLAYGEKG Y G T V IP P Q A S
2 5 1  L V F Y V L L ID V  HNPKDTVQLE TLELPQDCVR RAVAGDFM RY HYNGSLM DGT
3 0 1  L F D SR SG V H P  E G Y IIP G M D Q  G L Q G A C IG ER  R R IT V P P H L A  Y G EN G TG DK I
3 5 1  P G S A V L IF D V  H V ID F H N P A D  P V E IK T L F R P  P E S C N E T A K I G D FIR Y H Y N C
4 0 1  S L L D G T R L F S  S
204
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Kpe molecular chaperone HSPA5 precursor [Homo sapiens]
B H a EE e d k k e d v g t v  v g i d l g t t y s  c v g v f k n g r v
ITPSYVAFTP EGERLIGDAA KNQLTSNPEN TVFDAKRLIG 
D I K F L P F K W  EKKTKPYIQV DIGGGQTKTF A P E E IS A M V L  
LGKKVTHAW TVPAYFNDAQ RQATKDAGTI AGLNVMRIIN
L D K R EG E K N I LV FD L G G G T F D V S L L T ID N G  V FEV V A TN G D  
RV M E H FIK L Y  KKKTGKDVRK D NRAVQ K LRR E V E K A K A L SS  
F Y E G E D F S E T  LTRAKFEELN MDLFRSTMKP V Q K V L E D SD L  
VGGSTRIPKI QQLVKEFFNG KEPSRGINPD EAVAYGAAVQ  
GDLVLLH VCP L T L G IE T V G G  V M T K L IP S N T  W P T K N S Q I F  
TIKVYEGERP LTKDNHLLGT FDLTGIPPAP RGVPQIEVTF 
TAEDKGTGNK NKITITNDQN R L T P EETERM  V N D A E K FA E E  
RNELESYAYS LK N Q IG D K E K  L G G K ^ g g ^ | H H ^ VEEK  
D IE D FK A K K K  E L E E I V Q P I I  SK L Y G S A G P P  P T G E E D T A E K
gi 25742763; heat shock 70kD protein 5 [Rattus norvegicus]
1  M K F T W A A A L  L LL C A V R A EE  EDK K EDVG TV V G ID L G T T Y S  CVG VFK NG RV
5 1  EIIANDQGNR ITPSYVAFTP EGERLIGDAA KNQLTSNPEN TVFDAKRLIG
1 0 1  RTWNDPSVQQ D IK FLPFK W  EKKTKPYIQV DIGGGQTKTF A P E E IS A M V L
1 5 1  TKMKETAEAY LGKKVTHAW TVPAYFNDAQ RQATKDAGTI AGLNVMRIIN
2 0 1  EPTAAAIAYG L D K R EG E K N I L V FD L G G G T F D V S L L T ID N G  V FE V V A TN G D
2 5 1  THLGGEDFDQ R V M EH FIK L Y  KKKTGKDVRK DNRAVQ K LRR E V EK A K R A L S
3 0 1  SQHQARIEIE SFFEGEDFSE TLTRAKFEEL NMDLFRSTMK PV Q K V L E D SD
3 5 1  LKKSDIDEIV LVGGSTRIPK IQ Q L V K E F F N  G K E P S R G IN P  DEAVAYG AAV
4 0 1  QAGVLSGDQD TG DLVLLDVC P L T L G IE T V G  G V M T K L IPR N  T W P T K K S Q I
4 5 1  F S T A S D N Q P T  V T I KVYEGER PLTKDNHLLG TFDLTGIPPA PRGVPQIEVT
5 0 1  FEIDVNGILR VTAEDKGTGN KNKITITNDQ N R L T P E E I E R  M VNDAEKFAE
5 5 1  E D K K L K E R ID  TRNELESYAY SL K N Q IG D K E  K L G G K L SP ED  KETM EKAVEE
6 0 1  K IEW LESH Q D  A D IE D F K A K K  K E L E E I V Q P I  IS K L Y G S G G P  P P T G E E D T S E
6 5 1  KDEL
gi 31981722; heat shock 70kD protein 5 (glucose-regulated protein); glucose 
regulated protein, 78 kDa; heat shock 70kD protein 5 (glucose-regulated protein, 
78kD) [Mus musculus]
1 MMKFTWAAA LLLL G A V R AE EEDK K EDVG T W G I D L G T T Y  SC V G V FK NG R
5 1  VEIIANDQGN RITPSYVAFT PEGERLIGDA AKNQLTSNPE NTVFDAKRLI
1 0 1  GRTWNDPSVQ QDIKFLPFKV VEKKTKPYIQ VDIGGGQTKT FAPEEISAMV
1 5 1  LTKMKETAEA YLGKKVTHAV VTVPAYFNDA QRQATKDAGT IAGLNVMRII
2 0 1  NEPTAAAIAY GLDKREGEKN IL V F D L G G G T  F D V S L L T ID N  G V F E W A T N G
2 5 1  D TH LG G EDFD Q R V M EH FIK L YKKKTGKDVR KDNRAVQKLR R EVEK AK RAL
3 0 1  SSQHQARIEI ESFFEGEDFS ETLTRAKFEE LNMDLFRSTM K P V Q E V L E D S
3 5 1  DLKKSDIDEI VLVGGSTRIP K IQ Q L V K E F F  NGKEPSRGIN P D E A V A Y G A A
4 0 1  VQ AG VLSG DQ  D T G D L V L L D V  C P L T L G IE T V  G G V M T K L IPR  N T W P T K K S Q
4 5 1  IF S T A S D N Q P  TVTIKVYEGE RPLTKDNHLL GTFDLTGIPP APRGVPQIEV
5 0 1  TFE ID V N G II RVTAEDKGTG NKNKITITND Q N R L T P E E I E  RM VNDAEK FA
5 5 1  E E D K K L K E R I DTRNELESYA YSLKNQIGDK S S 3 2 3 3 2 2 Z 3 2  F
6 0 1  E K IE W L E SH Q  D A D IE D F K A K  K K E L E E IV Q P  I IS K L Y G S G G  P P P T G E E D T S  
6 5 1  EK D EL
s3: gi 87528; dnaK-t
l
5 1 E IIA N D Q G N R
1 0 1 RTWNDPSVQQ
1 5 1 TKMKETAEAY
2 0 1 E P T A A A IA Y G
2 5 1 THLGGEDFDQ
3 0 1 QHQARIEIES
3 5 1 K K S D ID E IV L
4 0 1 AG VLSG DQ DT
4 5 1 S T A S D N Q P T V
5 0 1 E ID V N G IL R V
5 5 1 DKKLKERIDT
6 0 1 IEW L E SH Q D A
6 5 1 D E L
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s21: gi 33859596; procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4- 
hydroxylase), alpha 1 polypeptide [Mus musculus]
1  M IW W L M M A I L L P Q SL A H P G  F F T S IG Q M T D  L IH N E K D L V T  
5 1  DKLEQ IKKW A E K L D R L T ST A  TK D PE G FV G H  PVNAFKLMKR 
1 0 1  L IL K D M SD G F  IS N L T IQ R Q Y  FPNDEDQVGA A K A L FR L Q D T  
1 5 1  GNLPGVQHKS FLTAEDCFEL G K VAYTEADY YHTELWMEQA  
2 0 1  TVDKV SV L D Y  LSYAVYQQGD L D K A LL LTK K  LLELDPEHQR 
2 5 1  T M si T A P K K K G IA V  D Y L P E R Q K Y E
3 0 1  T PR R Q K R L FC  RYHDGNRNPK F I LAPAKQED EWDKPRII R F  
3 5 1  IV K D L A K P R L  SKSAWLSGYE
4 0 1  IQ D L T G L D V S TAEELQ VANY GVGGQYEPHF D FA R K D E PD A  
4 5 1  ATW LFYM SDV SA G G A T V FP E  VGASVW PKKG TA VFW Y N LFA  
5 0 1  A ACPVLVG NK  WVSNKWLHER G Q E F R R P C T L  S E L E
gi 25453386; prolyl 4-hydroxylase alpha subunit [Rattus norvegicus]
1  MIWGVLMMGI LLPQ C SA H PG  F F T S IG Q M T D  L IH N E K D L V T  S L K D Y IK A E E
5 1  DKLEQIKKW A E K L D R L T ST A  TKDPEGFVGH PVNAFKLMKR LNTEWSELEN
1 0 1  L IL K D M SD G F  IS N L T IQ R Q Y  FPNDEDQVGA A K A L FR L Q D T  Y N L D T N T IS K
1 5 1  GNLPGVKHKS FLTAEDCFEL GKVAYTEADY YHTELWMEQA LMQLEEGEM S
2 0 1  T V DK VSV LD Y  LSYAVYQQGD LD K A LLLTK K  LLELDPEHQR A N G N LV Y FE Y
2 5 1  IM SK EK DANK  SA SG ER A D Q K  TTPKKKGIAV DYLPERQKYE M LCRGEGIKM
3 0 1  T PR R Q K R L FC  RYHDGNRNPK FILAPAKQED EWDKPRII R F  H D IISD A E IE
3 5 1  IV K D L A K P R L  SR A T V H D PE T  G K LTTAQ YRV SKSAWLSGYE DPW SRINM R
4 0 1  IQ D L T G L D V S TAEELQ VANY GVGGQYEPHF D F A R K D E P D A  F R E L G T G N R I
4 5 1  ATW LFYM SDV SA G G A T V FP E  VGASVW PKKG T A VFW Y N LFA  SG E G D Y ST R H
5 0 1  A A CPVLVG NK  WVSNKWLHER G Q E F R R P C T L  S E L E
sl: gi 202549; Protein disulfide isomerase chain 1
1  V L V L K K SN F A  EA LA A H N Y LL  VEFYAPW CGH C K A L A P E Y A K  A A A K LK AEG S
51  E I RLAK VDAT EESDLAQQYG V R G Y P T IK F F  K N G D T A SPK E  Y T A G R E A D D I
1 0 1  VNWLKKRTGP A A T T L SD T A A  A E S L V D S S E V  T V IG F F K D A G  S D S A K Q F L L A
1 5 1  A E A V D D IP F G  I T S N S D V F S K  YQLDKDGWL FK K FD E G R N N  F E G E IT K E K L
2 0 1  LDFIKHNQLP LVIEFTEQTA P K IF G G E I K T  H I L L F L P K S V  SD Y D G K L SN F
2 5 1  KKAAEGFKGK IL F IF ID SD H  TDNQRILEFF G L K K E EC P A V  R L IT L E E E M T
3 0 1  K Y K P E SD E L T  AEKITQFCHH FLEGKIKPHL MSQELPEDWD KQPVKVLVGK
3 5 1  NFEEVAFDEK K N V FV E FY A P WCGHCKQLAP IW DK LG ETYK  D H E N IV IA K M
4 0 1  D ST A N E V E A V  K V H SF P T L K F  FPASADRTVI DYNGERTLDG FK K FL ESG G Q
4 5 1  DGAGDNDDLD LEEA LEPD M E EDDDQKAVKD EL
S L K D Y IK A E E
LNTEWSELEN
Y N L D T N T IS K
L T Q L E E G E L S
A N G N LV Y F EY
MLCRGEGIKM
H D IISD A E IE
D P W S R I N M R
F R E L G T G N R I
SG E G D Y ST R H
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s2: gi 25742763; 78 kDa glucose-regulated protein precursor (GRP78)
1  M K F T W A A A L  LL L C A V R A EE  EDK K EDVG TV V G ID L G T T Y S  CVGVFKNGRV
5 1  EIIANDQGNR ITPSYVAFTP E G E R L IG D A A  KNQLTSNPEN TVFDAKRLIG
1 0 1  RTWNDPSVQQ DIK FL PFK W  EKKTKPYIQV DIGGGQTKTF A P E E IS A M V L
1 5 1  TKM KETAEAY LGKKVTHAW TVPAYFNDAQ R Q A T K D A G T I A G L N V M R IIN
2 0 1  EPTAAAIAYG L D K R EG E K N I L V FD L G G G T F D V S L L T ID N G  V F E W A T N G D
2 5 1  THLGGEDFDQ R V M EH FIK L Y  KKKTGKDVRK DNRAVQ K LRR E V E K A K R A L S
3 0 1  S Q H Q A R IE IE  SFFEGEDFSE TLTRAKFEEL NM DLFRSTM K PV Q K V L E D SD
3 5 1  LKKSDIDEIV LVGGSTRIPK IQ Q L V K E F F N  GKEPSRGINP DEAVAYG AAV
4 0 1  QAGVLSGDQD T G DLVLLDVC P L T L G IE T V G  G V M T K LIPR N  T W P T K K S Q I
4 5 1  F S T A S D N Q P T  VTIKVYEGER PLTKDNHLLG TFDLTGIPPA PRGVPQIEVT
5 0 1  FEIDVNGILR VTAEDKGTGN K N K IT IT N D Q  N R L T P E E I E R  M VNDAEKFAE
5 5 1  E D K K L K E R ID  TRNELESYAY SL K N Q IG D K E  K L G G K L SP ED  KETM EKAVEE
6 0 1  K IEW L ESH Q D  A D IE D F K A K K  K E L E E I V Q P I  IS K L Y G S G G P  P P T G E E D T S E
6 5 1  K DEL
s5: gi 13242237; Heat shock cognate 71kDa protein
1  M SK G PA V G ID  L G TTY SC V G V  F Q H G K V E IIA  N D Q G N R T T P S YVAFTDTERL
5 1  IG DAAK NQ VA M N PTN TV FDA  K R L IG R R F D D  A W Q SDM K H W  P F M W N D A G R
1 0 1  PKVQVEYKGE T K S F Y P E E V S  SM VLTKM KEI A EA Y L G K TV T NAWTVPAYF
1 5 1  NDSQRQATKD A G T IA G L N V L  RIINEPTAAA IAYGLDKKVG A E R N V L IF D L
2 0 1  G G G T F D V S IL  T IE D G IF E V K  STAG DTH LG G  EDFDNRM VNH FIAEFKRKHK
2 5 1  K D IS E N K R A V  RR LR TA C ERA  KRTLSSSTQA SIE ID SL Y E G  ID FY TSIT R A
3 0 1  RFEELNADLF R G TLD PV EK A  LRDAK LDK SQ  IH D IV L V G G S  T R IP K IQ K L L
3 5 1  Q D FFN G K ELN  K S INPDEAVA YGAAVQAAIL SG D K SEN V Q D  L L L L D V T P L S
4 0 1  LG IETAG G VM  T V L IK R N T T I  PT K Q T Q T F T T  YSDNQPGVLI QVYEGERAMT
4 5 1  K DNNLLG K FE L T G IP P A P R G  V P Q I E V T F D I  D A N G IL N V S A  VD K STG K EN K
5 0 1  IT IT N D K G R L  SKEDIERMVQ EAEKYKAEDE KQRDKVSSKN SLESYAFNMK
5 5 1  A TVEDEKLQG K IN D E D K Q K I L D K C N E IIS W  LDK NQ TAEK E E FEH Q Q K E LE
6 0 1  K V C N P IIT K L  YQSAGGMPGG M PGGFPGGGA P P S G G A S S G P  T IE E V D
s7: gi 8393322; Protein disulfide isomerase A3 precursor (Disulfide isomerase ER- 
60)
1  M R FSC L A L L P GVALLLASAL L A S A S D V L E L  T D E N F E S R V S  D TG SAG LM LV
5 1  EFFAPW CGHC KRLAPEYEAA A T R L K G IV P L  A K V D C TA N TN  TCNK YG VSG Y
1 0 1  PTLKIFRDGE EAGAYDGPRT A D G IV S H L K K  Q A G P A S V P L R  T E D E F K K F IS
1 5 1  DKDASWGFF RDLFSDGHSE F L K A A SN L R D  N Y R FA H T N V E  SLV K EY DD N G
2 0 1  E G IT I F R P L H  L A N K F E D K IV  AYTEKKM TSG K I K K F I Q E S I  FG LCPH M TED
2 5 1  N K D L IQ G K D L  LTAYYDVDYE KNTKGSNYW R NRVMMVAKTF LDAGHKLNFA
3 0 1  VASRKTFSHE LSDFGLESTT G E IP W A IR T  AKGEKFVMQE EFSRDGKALE
3 5 1  RFLQEYFDGN LKRYLKSEPI PETNEGPVKV W A E S F D D I V  N A E D K D V L IE
4 0 1  FYAPWCGHCK N LEPK Y K ELG  E K L S K D P N IV  IAK M DATAND V P S P Y E V K G F
4 5 1  PTIYFSPANK K LTPKKYEGG R E L N D L IS Y L  Q R E A T N P P I I  QEEKPKKKKK
5 0 1  AQEDL
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s7a: gi 8393322; Protein disulfide isomerase A3 precursor (Disulfide isomerase 
ER-60)
1  M R F S C L A L L P  G V A L L L A S A L  L A S A S D V L E L  T D E N F E S R V S  D TGSAGLMLV
5 1  EFFAPWCGHC KRLAPEYEAA A T R L K G I V P L  A K V D C TA N T N  T CNK YG VSGY
1 0 1  PTLKIFRDGE EAGAYDGPRT A D G IV S H L K K  QAGPASVPLR T E D E F K K F I S
1 5 1  D K D A S W G F F  RDLFSDGHSE F L K A A S N L R D  NYRFAHTNVE SLV K E Y DD N G
2 0 1  E G I T I F R P L H  L A N K F E D K IV  AYTEKKMTSG K I K K F I Q E S I  FG LCPHMTED
2 5 1  N K D L IQ G K D L  LTAYYDVDYE KNTKGSNYWR NRVMMVAKTF L DAG HKLNFA
3 0 1  V A S R K T F S H E  LSDFGLESTT G E IP W A IR T  AKGEKFVMQE E F S R D G K A L E
3 5 1  RFLQEYFDGN L K R Y L K S E P I  P E T N E G P V K V  W A E S F D D I V  N A E D K D V L I E
4 0 1  FYAPWCGHCK NLEPKYKELG EKLSKDPNIV IAKMDATAND VPSPYEVKGF
4 5 1  PTIYFSPANK KLTPKKYEGG R E L N D L I S Y L  Q REATNPPII QEEKPKKKKK
5 0 1  AQEDL
s20: gi 51036657; Prolyl 4-hydorxylase alpha-1 subunit
1  MIWGVLMMGI L L P Q C SA H P G  F F T S I G Q M T D  L I H N E K D L V T  S L K D Y I K A E E
5 1  DKLEQIKKWA E K L D R L T S T A  T K DPE G FVG H  PVNAFK LM KR L N TE W SE L EN
1 0 1  L IL K D M S D G F  I S N L T I Q R Q Y  FPNDEDQVGA A K A L F R L Q D T  Y N L D T N T I S K
1 5 1  GNLPGVKHKS FLTAEDCFEL GKVAYTEADY YHTELWMEQA LMQLEEGEMS
2 0 1  TV DK VSV LD Y  LSYAVYQQGD L D K A LLL TK K  LLELDPEHQR A N G N L V Y F E Y
2 5 1  IMSKEK DANK SA SG DQ SD Q K  T T P K K K G I A V  D Y L P E R Q K Y E  MLCRGEGIKM
3 0 1  TPR R Q K R LFC  RYHDGNRNPK FILAPAKQED EWDKPRII R F  H D I I S D A E I E '
3 5 1  I V K D L A K P R L  S R A T V H D P E T  G KLTTAQYRV SK S A W L S G Y E  D P W S R I N M R
4 0 1  IQ D L T G L D V S  T AEE LQ VANY GVGGQYEPHF D F A R K D E P D A  F R E L G T G N R I
4 5 1  ATWLFYMSDV S A G G A T V F P E  VGASVWPKKG T A VF W Y N LF A  SG E G D Y S T R H
5 0 1  AACPVLVGNK WVSNKWLHER G Q E F R R P C T L  S E L E
s8: gi 13592133; beta-actin
1  M D D D I A A L W  DNGSAMCKAG F A G D D A P R A V  F P S I V G R P R H  QGVMVGMGQK
5 1  DSY V G D E A Q S K R G I L T L K Y P  I E H G IV T N W D  DMEKIWHHTF YNELRVAPEE
1 0 1  HPVLLTEAPL NPKANREKMT Q I M F E T F N T P  A M Y V A IQ A V L  S L Y A S G R T T G
1 5 1  IVM DSGDGVT H T V P I Y E G Y A  L P H A I L R L D L  AGRDLTDYLM K I L T E R G Y S F
2 0 1  TTTAEREI V R  D IK E K L C Y V A  LDFEQ EM ATA A S S S S L E K S Y  ELPDGQVITI
2 5 1  G N E R F R C P E A  L F Q P S F L G M E  S C G I H E T T F N  S I M K C D V D I R  K D L Y A N T V L S
3 0 1  G G TTM YPG IA DR M Q K EITA L A P S T M K I K I I  A P P E R K Y S V W  I G G S I L A S L S
3 5 1  TFQQMWISKQ E Y D E S G P S I V  HRKCF
s8a: gi 13592133; beta-actin
1  M D D D I A A L W  DNGSAMCKAG FAGDDAPRAV F P S I V G R P R H  QGVMVGMGQK
5 1  D S Y V G D E A Q S K R G I L T L K Y P  I E H G IV T N W D  DMEKIWHHTF YNELRVAPEE
1 0 1  HPVLLTEAPL NPKANREKMT Q I M F E T F N T P  A M Y V A IQ A V L  S L Y A S G R T T G
1 5 1  IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF
2 0 1  TTTAEREI V R  D IK E K L C Y V A  LDFE Q E M ATA A S S S S L E K S Y  ELPDGQVITI
2 5 1  G N E R F R C P E A  L F Q P S F L G M E  S C G I H E T T F N  S I M K C D V D I R  KDLYANTVLS
3 0 1  GGTTMYPGIA D R M Q K EIT A L  A P S T M K I K I I  APPERKYSVW I G G S I L A S L S
3 5 1  TFQQMWISKQ E Y D E S G P S I V  HRKCF
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s9: gi 13592133; beta-actin
1 PRAVFPSIVG RSRHQGVMVG MGQKDSYVGD E A Q S K R G I L T  L K Y P I E H G I V
51  TNWDDMEKIW HHTFYNELRV APEEHPVLLT EAPLNPKANR E K M TQ IM FET
1 0 1  F N T P A M Y V A I Q A V L S L Y A S G  RTTGIVMDSG DGVTHTVPIY EGYALPHAIL
1 5 1  RLDLAGRDLT DYLMKILTER GYSFTTTAER E I V R D I K E K L  C Y V A LD F E Q E
2 0 1  M A T A A S S S S L  EKSYELPDGQ VITIGNERFR C P E A L F Q P S F  L G M E S C G IH E
2 5 1  TTFNSIMKCD VDIRKDLYAN TVLSGGTTMY PGIADRMQKE I T A L A P S T M K
3 0 1  IK IIA PPER K  Y S V W I G G S I L  ASLSTFQQ MW  I S K Q E Y D E S G  P S I V H R K C F
slO: gi 49868; putative beta-actin (aa 27-375)
1  P R A V F P S I V G  RSRHQGVMVG MGQKDSYVGD EAQSKRGILT L K Y P I E H G I V
5 1  TNWDDMEKIW HHTFYNELRV APEEHPVLLT EAPLNPKANR EKM TQ IM FET
1 0 1  F N T P A M Y V A I Q A V L S L Y A S G  RTTGIVMDSG DGVTHTVPIY EGYALPHAIL
1 5 1  RLDLAGRDLT DYLMKILTER GY SFTTTAER E I V R D I K E K L  C Y V A LD F E Q E
2 0 1  M A T A A S S S S L  EKSYELPDGQ VITIGNERFR C P E A L F Q P S F  L G M E S C G IH E
2 5 1  T T F N S I M K C D  VDIRKDLYAN TVLSGGTTMY PGIADRMQKE ITALAPSTMK
3 0 1  IK IIAPPER K  Y S V W I G G S I L  ASLSTFQQ M W  I S K Q E Y D E S G  P S I V H R K C F
sl8: gi 14389299; Vimentin
1 MSTRSVSSSS YRRMFGGSGT SSRPSSNRSY VTTSTRTYSL GSALRPSTSR
51  SLYSSSPGGA YVTRSSAVRL R S S M P G V R L L  QDSVDFSLAD AINTEFKNTR
1 0 1  TNEKVELQEL NDRFANYIDK VRFLEQQNKI LLAELEQLKG QGKSRLGDLY
1 5 1  EEEMRELRRQ VDQLTNDKAR VEVERDNLAE DIMRLREKLQ EEMLQREEAE
2 0 1  STLQSFRQDV DNASLARLDL ERKVESLQEE IAFLKKLHDE EIQELQAQIQ
2 5 1  EQHVQIDVDV SKPDLTAALR DVRQQYESVA AKNLQEAEEW YKSKFADLSE
3 0 1  AANRNNDALR QAKQESNEYR RQVQSLTCEV DALKGTNESL ERQMREMEEN
3 5 1  FALEAANYQD TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY
4 0 1  RKLLEGEESR ISL PL PN FSS LNLRETNLES LPLVDTHSKR TLLIKTVETR
4 5 1  DGQVINETSQ HHDDLE
sl8: gil 1560133; Tubulin alpha
1  M R E C I S I H V G  QAGVQIGNAC W E LY C L E H G I QPDG QMPSDK TIGGGDDSFN
51  TFFSETGAGK HVPRAVFVDL EPTVIDEVRT GTYRQLFHPE QLITGKEDAA
101  NN Y A RG H Y TI GKEIIDLVLD R IR K L A D Q C T  G L Q G F L V F H S  F G G G T G SG F T
1 5 1  SL L M E R L SV D  Y G K K S K L E F S  I Y P A P Q V S T A  W E P Y N S I L T  T H T T L E H S D C
2 0 1  A F M V D N E A IY  D I C R R N L D I E  R P T Y T N L N R L  IG Q IV S S IT A  SLRFDGALNV
2 5 1  DLTEFQTNLV PYPRIHFPLA TYAPVISAEK A Y H E Q L S V A E  I T N A C F E P A N
3 0 1  QMVKCDPRHG KYMACCLLYR G D W P K D V N A  A I A T I K T K R T  IQFVDWCPTG
3 5 1  FKVGINYQPP TWPGGDLAK VQRAVCMLSN TTAIAEAWAR LDHKFDLMYA
4 0 1  KRAFVHWYVG EGMEEGEFSE AREDMAALEK D Y E E V G V D S V  E Y E G E E E G E E
4 5 1  Y
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sl9: gi 14389299; Vimentin
1 M STRSVSSSS YRRMFGGSGT SSRPSSNRSY VTTSTRTYSL GSALRPSTSR
5 1  SLYSSSPGGA YVTRSSAVRL R S S M P G V R L L  QDSVDFSLAD AINTEFKNTR
1 0 1  TN E K V E L Q E L  N D R F A N Y ID K  V R F L E Q Q N K I  LLAELEQLKG QGKSRLGDLY
1 5 1  EEEMRELRRQ VDQLTNDKAR VEVERDNLAE DIMRLREKLQ EEMLQREEAE
2 0 1  S T L Q S F R Q D V  D N A S L A R L D L  ERKVESLQEE IAFLKKLHDE E I Q E L Q A Q I Q
2 5 1  E Q H V Q ID V D V  S K P D L T A A L R  DVRQQYESVA AKNLQEAEEW YKSKFADLSE
3 0 1  AANRNNDALR QAKQESNEYR R Q V Q S L T C E V  DALKGTNESL ERQMREMEEN
3 5 1  FA LE AANYQ D TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY
4 0 1  R K L L E G E E S R  ISL PL PN FSS LNLRETNLES LPLVDTHSKR T L L I K T V E T R
4 5 1  D G Q V I N E T S Q  HHDDLE
sl5: gi 6978809; Enolase-1, alpha
1 MSI L K I H A R E  IFDSRGNPTV EVDLYTAKGL FRAAVPSGAS TGIYEALELR
5 1  DNDKTRFMGK G V S K A V E H IN  K T I A P A L V S K  K L N W E Q E K I  DQLMIEMDGT
1 0 1  ENK SK F G A NA  I L G V S L A V C K  AGA V EK G V PL Y R H IA D L A G N  P E V I L P V P A F
1 5 1  N V IN G G S H A G  NKLAMQEFMI LPVGASSFRE A M RIG A E V Y H  N L K N V IK E K Y
2 0 1  GKDATNVGDE GGFAPNILEN K E A L E L L K S A  IA K A G Y T D Q V  V IG M D V A A S E
2 5 1  FYRAGKYDLD F K S P D D A S R Y  ITPDQLADLY K S F I K D Y P W  S I E D P F D Q D D
3 0 1  WDAWQKFTAT AGIQWGDDL TVTNPKRIAK A A G E K S C N C L  L L K V N Q I G S V
3 5 1  T E S L Q A C K L A  QSNGWGVMVS H R S G E T E D T F  I A D L W G L C T  G Q I K T G A P C R
4 0 1  S E R L A K Y N Q I  L R I E E E L G S K  A K F A G R S F R N  P L A K
sl6: gi 6978809; Enolase-1, alpha
1  M S I L K I H A R E  IFDSRGNPTV EVDLYTAKGL FRAAVPSGAS TGIYEALELR
5 1  DNDKTRFMGK G V S K A V E H I N  K T I A P A L V S K  K L N W E Q E K I  DQLMIEMDGT
1 0 1  E N K SK F G A N A  I L G V S L A V C K  AGAVEK GVPL Y R H IA D L A G N  P E V I L P V P A F
1 5 1  N V IN G G S H A G  NKLAMQEFMI LPVGASSFRE AMRIGAEVYH N L K N V I K E K Y
2 0 1  GKDATNVGDE GGFAPNILEN K E A L E L L K S A  IA K A G Y T D Q V  V IG M D V A A S E
2 5 1  FYRAGKYDLD FKSPDDASRY ITPDQLADLY K S F I K D Y P W  S I E D P F D Q D D
3 0 1  WDAWQKFTAT AGIQWGDDL TVTNPKRIAK A A G E K SC N C L  LLKVNQIGSV
3 5 1  TESLQACKLA QSNGWGVMVS H R S G E T E D T F  I A D L W G L C T  G Q IK T G A P C R
4 0 1  S E R L A K Y N Q I  L R I E E E L G S K  A K F A G R S F R N  P L A K
sl7: gi 6978809; Enolase-1, alpha
1  M S I L K I H A R E  I F D S R G N P T V  EVDLYTAKGL FRAAVPSGAS TGIYEALELR
5 1  DNDKTRFMGK G V S K A V E H IN  K T I A P A L V S K  K L N W E Q E K I  DQLMIEMDGT
1 0 1  E N K SK F G A N A  ILGVSLAVCK AGAVEK GVPL Y R H IA D L A G N  P E V I L P V P A F
1 5 1  N V IN G G S H A G  NKLAMQEFMI LPVGASSFRE AMRIGAEVYH N L K N V IK E K Y
2 0 1  GKDATNVGDE GGFAPNILEN K E A L E L L K S A  IA K A G Y T D Q V  V IG M D V A A S E
2 5 1  FYRAGKYDLD FKSPDDASRY ITPDQLADLY K S F I K D Y P W  S I E D P F D Q D D
3 0 1  WDAWQKFTAT AGIQWGDDL T V T N P K R IA K  A A G E K S C N C L  LLKVNQIGSV
3 5 1  TESLQACKLA QSNGWGVMVS H R S G E T E D T F  I A D L W G L C T  G Q I K T G A P C R
4 0 1  S E R L A K Y N Q I  L R I E E E L G S K  A K F A G R S F R N  P L A K
2 1 0
Appendix
s22: gi 26023949; EnoIase-2, gamma
1  M S IQ K IW A R E  ILDSRGNPTV EVDLHTAKGL FRAAVPSGAS TGIYEALELR
51  DGDKQRYLGK G V L K A V DH IN  S T I A P A L I S S  G L S W E Q E K L  DNLM LELDGT
1 0 1  ENK SK F G A NA  I L G V S L A V C K  AGAAEKDLPL Y R H IA Q L A G N  S D L I L P V P A F
1 5 1  N V IN G G S H A G  NKLAMQEFMI LPVGAESFRD AMRLGAEVYH T L K G V IK D K Y
2 0 1  GKDATNVGDE G G F A P N I L E N  S E A L E L V K E A  IDK AG YTEK M  VIGMDVAASE
2 5 1  FYRDGKYDLD FKSPADPSRC ITGDQLGALY QDFVRNYPW S I E D P F D Q D D
3 0 1  WAAWSKFTAN VGIQIVGDDL TVTNPKRIER A V E E K A C N C L  LLKVNQIGSV
3 5 1  TEAIQACKLA QENGWGVMVS H R S G E T E D T F  I A D L W G L C T  G Q I K T G A P C R
4 0 1  SER L AK YN Q L  MRIEEELGEE A R F A G H N F R N  P S V L
sl2: gi 730681; 40S ribosomal protein SA
1  MSGGLDVLQM K E E DV L K F LA  AGTH L G G TNL D F Q M E Q Y IY K  RK SD G IY IIN
51  LKRTWEKLLL AARAIVAIEN PADV SVISSR NTGQRAVLKF AAATGATPIA
101  GRFTPGTFTN QIQAAFREPR L L W T D P R A D  H Q P L T E A S Y V  N L P T I A L C N T
1 5 1  D S P L R Y V D I A  IPCNNKGAHS VGLMWWMLAR E V L R M R G T I S  REHPWEVMPD
2 0 1  L Y F Y R D P E E I  EKEEQAAAEK A V TK EE F Q G E  W T A P A P E F T A  AQPEV A D W SE
2 5 1  G V Q V P S V P I Q  QFPTEDW SAQ PA T E D W SA A P  TAQATEWVGA TTEWS
2 1 1
Appendix
sl4: gi 14286100; Plasma membrane calcium transporting ATP-ase (PMCA2)
There are 12 splice isoforms of this protein. The “XB” splice isoform was identified 
with MALDI-TOF and Swis Prot database search. The “XB”splice isoform does not 
contain the sequence 303-333 (highlighted in yellow) and is the only splice isoform that 
has Arg1142 (highlighted in black).
1  MGDMTNSDFY S K N Q R N E S S H  GGEFGCSMEE LRSLMELRGT EAW KIKETY
5 1  GDTESICRRL K T S P V E G L P G  T A PD LEK R K Q  IFG QNFIPPK  KPKTFLQLVW
1 0 1  E A L Q D V T L I I  L E I A A I I S L G  L S F Y H P P G E S  NEGCATAQGG A E D E G E A E A G
1 5 1  W I E G A A I L L S  V I C W L V T A F  NDW SKEKQFR G L Q S R I E Q E Q  K F T W R A G Q V
2 0 1  V Q I P V A E I W  G D I A Q IK Y G D  LLPADGLFIQ G N D L K I D E S S  L TG ES D Q V R K
2 5 1  SV D K D PM LL S GTHVMEGSGR M W T A V G V N S  Q T G I I F T L L G  A G GEEEEKKD
3 0 1  KKGVKKGDGL QLPAADGAAP ANAAGSANAS LVNGKMQDGS ADSSQSKAKQ
3 5 1  QDGAAAMEMQ P L K S AE G G D A  DDKKKANMHK KEKSVLQGKL TKLAVQIGKA
4 0 1  G L V M S A I T V I  I L V L Y F T V D T  FWNKKPWLT ECTPVYVQYF V K F F I I G V T V
4 5 1  L W A V P E G L P  L A V T I S L A Y S  VKKMMKDNNL VRH L DACETM  G N A T A I C S D K
5 0 1  TGTLTTNRMT W Q A Y V G D V H  Y K E I P D P S S I  N A K T L E L L V N  A I A I N S A Y T T
5 5 1  KILPPEKEGA LPRQVGNKTE C G L L G F V L D L  R Q D Y E P V R S Q  M PEEKLYKVY
6 0 1  T F N S V R K S M S  TVIKMPDESF R M Y S K G A S E I  V L K K C C K I L S  G A G E P R V F R P
6 5 1  RDRDEMVKKV IEP M A C D G L R  T I C V A Y R D F P  S S P E P D W D N E  N D I L N E L T C I
7 0 1  C W G I E D P V R  P E V P E A I R K C  QRAGITVRMV TGDNINTARA I A I K C G I I H P
7 5 1  G EDFLCLEG K  E F N R R IR N E K  G E I E Q E R I D K  IW P K L R V L A R  SSPTDKHTLV
8 0 1  KGIIDSTHTE Q R Q W A V T G D  GTNDGPALKK ADVGFAMGIA GTDVAKEASD
8 5 1  IIL T D D N FSS IVKAVMWGRN V Y D S I S K F L Q  F Q L T V N W A V  I V A F T G A C I T
9 0 1  QDSPLKAVQM LWVNLIMDTF A S L A L A T E P P  T E T L L L R K P Y  GRNKPLISRT
9 5 1  MMKNILGHAV Y Q L T L I F T L L  FV G E K M F Q ID  S G R N A P L H S P  P S E H Y T I I F N
1 0 0 1  TFVMMQLFNE I N A R K I H G E R  NVFDGIFRNP I F C T I V L G T F  A I Q I V I V Q F G
1 0 5 1  G K P F S C S P L Q  LDQWMWCIFI GLGELVWGQV I A T I P T S R L K  FL K E A G R L T Q
1 1 0 1  K E E I P E E E L N  E D V E E ID H A E  R E LR R G Q IL W  FRGLNRIQTQ I § W K A F R S S
1 1 5 1  L Y E G L E K P E S  R T S IH N F M A H  P E F R I E D S Q P  H I P L I D D T D L  E ED A A L K Q N S
1 2 0 1  S P P S S L N K N N  S A I D S G I N L T  T D T S K S A T S S  S P G S P I H S L E  T S L
s6: gi 21759130; RhoGDI-1
1  M AEQEPTAEQ L A Q IA A E N E E  D E H S V N Y K P P  AQKSIQEIQE LDKDDESLRK
5 1  YKEALLGRVA VSADPNVPNV I V T R L T L V C S  T A P G P L E L D L  T G D L E S F K K Q
1 0 1  SFVLKEGVEY R I K I S F R V N R  E I V S G M K Y I Q  HTYRKGVKID KTDYMVGSYG
1 5 1  PRAEEYEFLT PMEEAPKGML A R G S Y N I K S R  FTDDDKTDHL SWEWNLTIKK
2 0 1  EWKD
2 1 2
Appendix
sl3: gi 124902; Interferon regulatory factor 1 (IRF-1)
1 MPI TRMRMRP W LEMQINSNQ I P G L S W I N K E  EMIFQIPWKH AALHGW DINK
51  DACLFRSWAI HTGRYKAGEK EPDPKTWKAN FRCAMNSLPD I E E V K D Q S R N
1 01  KGSSAVRVYR MLPPLTKNQR K E R K S K S S R D  T K SK T K R K L C  G D S S P D T L S D
1 5 1  G L S S S T L P D D  H SS Y T A Q G Y L  GQDLDMDRDI T P A L S P C W S  SSLSEWHMQM
2 0 1  D I M P D S T T D L  Y N L Q V S P M P S  T S E A A T D E D E  E G K L P E D IM K  L F E Q SE W Q P T
2 5 1  HVDGKGYLLN E P G A Q L S T V Y  G D F S C K E E P E  I D S P G G D I E I  G IQ R V FT EM K
3 0 1  NMDPVMWMDT L L G N S T R P P S  I Q A I P C A P
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Appendix
C. M ALDI-TOF mass spectra
Representative MALDI-TOF mass spectra are shown for 2 proteins from each table (Table 3-1 and Table 5-1). 
Table 3-1, s l5  Tropomyosin 2
25001500 2000 3000 35001000
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Table 3-1, s5 Heat shock 70 kDa protein 5 (GRP78)
*»M‘ iU* ■'
3000 3500 401000 1500 25002000
Table 5-1, s7 ER-60 protease (GRP58)
Intens.
x 1 0 9 -
1.0 -
0 .8 -
0.6 -
0 .4 - 13 35
1 39 16 540 .2 -
m /z30002500200015001000
Table 5-1, sl6 Enolase-1
h t e n s
L i T  iuhAkiXHit. 1 . , .1 - , ^ j |
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